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ABSTRACT  
 
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder of the 
haemopoietic stem cell, defined by the Philadelphia chromosome (Ph) - the 
outcome of a balanced, reciprocal translocation between the long arms of 
chromosomes 9 and 22. The novel fusion oncogene generated on chromosome 
22 as a result of this translocation is called BCR-ABL. In the majority of patients, 
this oncogene transcribes a 210-kDa constitutively active protein tyrosine kinase, 
often referred to as p210BCR-ABL, which is necessary for the transformation of the 
disease. The introduction of the orally available, tyrosine kinase inhibitor (TKI) - 
imatinib mesylate (IM) - marked a major advance in CML treatment in terms of 
efficacy and tolerability and has now become the first line of therapy. IM acts by 
competing with ATP to block ABL-kinase activity, resulting in the selective 
apoptosis induction of BCR-ABL+ cells. However, despite the success of IM as 
standard therapy for CML, only a small proportion of patients obtain a complete 
molecular response, where they become negative for BCR-ABL transcripts by RT-
PCR. It is hypothesised that this minimal residual disease is the result of a 
primitive quiescent subpopulation of leukaemic cells, which may be the cause for 
relapse at a later date. Another major clinical concern is the observation of 
molecular resistance in IM-treated patients. Proposed mechanisms of resistance 
include BCR-ABL amplification, decreased intracellular IM concentrations caused 
by drug efflux proteins such as multi drug resistance-1 and the development of 
point mutations within the ABL-kinase domain. In an attempt to overcome IM-
resistance, a second generation of BCR-ABL inhibitors has been developed. 
Dasatinib (BMS-354825, Sprycel) is a TKI developed for the treatment of IM-
resistant or -intolerant patients with Ph+ leukaemias, which has a 325-fold greater 
potency than IM against cells expressing wild-type BCR-ABL, and is effective 
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against all IM-resistant BCR-ABL mutants tested in vitro, except T315I. Previously, 
we showed that dasatinib induced durable inhibition of BCR-ABL and impressive 
clearance of Ph+ cells, however, the primitive quiescent cell population did not 
appear to undergo apoptosis even after several days TKI exposure. Therefore, it 
was still not clear whether early CML progenitor cells depend on BCR-ABL for 
their growth and survival. In this study we have attempted to determine whether 
CML stem cells are dependent on BCR-ABL TK activity for their survival and/or 
proliferation using dasatinib treatment and aimed to characterise the cells which 
survived drug exposure. We found that 10% of the CML cells were able to survive 
the dasatinib treatment. We also showed that maximal BCR-ABL TK inhibition was 
achieved in the surviving CML cells, both in the bulk population of cells and the 
more problematic primitive stem cell population. Those cells which survived the 
dasatinib treatment were found to be primitive, residing mainly in the undivided cell 
fraction and the very early cell divisions. Since these BCR-ABL TK-inhibited, 
resistant cells were also able to grow when re-cultured in cytokines and form long- 
term culture-initiating cell (LTC-IC) colonies; these data suggested that ~10% of 
primitive CD34+ CML cells are not addicted to BCR-ABL TK activity for their 
survival. This also suggested that these primitive, resistant CML cells appeared to 
survive and proliferate by BCR-ABL-independent mechanisms. Therefore, the next 
experiments were then designed to investigate the cellular process of autophagy 
as a potential means of primitive CML cell survival. Analysis of the properties of 
CD34+ CML cells which remained viable following dasatinib treatment, revealed 
the existence of cytoplasmic autophagic structures determined by electron 
microscopy and significantly increased autophagosome-asociated LC3-II, 
particularly in the cells cultured without growth factors (GF)s. This suggested that 
autophagy is induced following GF deprivation of CML cells and is significantly 
increased within these cells, upon BCR-ABL inhibition following dasatinib 
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treatment. Furthermore, we also found that the inhibition of autophagy greatly 
potentiated the effect of TKI treatment on the reduction of primitive CML progenitor 
cells, in terms of the effective eradication of functionally defined colony forming 
cells and LTC-ICs. 
 
Overall, this thesis has shown for the first time that the most TKI-resistant primitive 
CML cells are likely to be independent of BCR-ABL TK activity for their 
proliferation and/or survival. Furthermore, we have shown that these resistant 
CML stem cells rely on the BCR-ABL independent autophagy process for survival 
in response to stressful conditions, such as, GF deprivation and TKI treatment. 
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1. INTRODUCTION 
 
1.1 Haemopoietic stem cells and normal haemopoiesis 
Haemopoiesis is the process of blood cell formation within an organism and 
results in the development and differentiation of haemopoietic stem cells (HSCs) 
(1, 2). In adult mammals, HSCs are predominantly found in the bone marrow 
(BM), with the majority being relatively short-lived within the circulation (3). In 
order to maintain the haemopoietic system, it is necessary for the BM to produce 
up to 1013 cells per day (4). Terminally differentiated cells are incapable of further 
growth themselves and therefore, to prevent the depletion of the BM stem cell 
pool, they must be replaced through the development and proliferation of HSCs.  
 
A key criterion which defines an HSC is the ability to replicate symmetrically, 
through the mitotic process of self-renewal. This results in the generation of 
progeny that are identical copies of the HSC and allows the BM cellularity to 
remain in a constant steady state.  Multipotency is a further criterion which defines 
an HSC, with a single cell being able to give rise to a number of differentiated cell 
types. In order to achieve this, the stem cell also replicates asymmetrically, 
producing one copy of itself and a second which is able to differentiate (5, 6). It is 
estimated that one stem cell is capable of producing approximately 106 mature 
blood cells after around twenty cell divisions.  
 
The haemopoietic system is often assessed using a transplantation assay, 
whereby the transplantation of a single HSC from the BM into a lethally irradiated 
animal can rescue the entire haemopoietic system (7-9). On the basis of these 
experiments using murine haemopoietic cells, transplanted HSCs can be further 
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classified into three distinct populations: long-term HSCs (LT-HSC) which are 
capable of producing all blood cell types indefinitely and generate progeny that 
demonstrate similar potentiality on secondary transplant; short-term HSCs (ST-
HSC) which reconstitute the myeloid and/or lymphoid compartments for a limited 
period of time; and multipotent progenitor (MPP) cells which have little or no 
detectable ability to self-renew (10, 11).  These MPP cells then commit either to 
the lymphoid or myeloid lineage by differentiating to common lymphoid progenitors 
(CLP) (12) or common myeloid progenitors (CMP) (13), which are able to give rise 
to cells which are functionally mature (Figure 1-1).  
 
At steady state, only a small proportion of HSCs reconstitute the haemopoietic 
system, as it is believed that HSCs cycle infrequently, with the majority of cells 
existing in a quiescent state, or G0 stage of cell cycle (14, 15). This infrequent 
proliferation is important for the maintenance of tissue homeostasis and allows 
time to repair any DNA damage which may arise from life-long HSC self-renewal 
(16).   
 
The fate of the HSC to self-renew, differentiate or remain quiescent is thought to 
be controlled by signals from their microenvironment, commonly known as the 
stem cell niche (17). The BM haemopoietic niche utilises signals from osteoblasts 
and mesenchymal stromal cells (18), to secrete factors like stromal cell-derived 
factor-1 (SDF-1) (CXCL12), which activate the CXCR4 receptor expressed on 
HSCs. This instructs circulating HSCs to home to and engraft in the BM (19) and 
thereby maintains HSC quiescence and potential for self-renewal (20-22). Loss of 
this mechanism would typically result in the stem cell leaving the niche to either 
divide, differentiate or apoptose (23). 
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Figure 1-1 The haemopoietic hierarchy model 
Only LT-HSC and ST-HSC have the capacity for self-renewal, which is lost 
once the cell has become an MPP. These give rise to the CLP and CMP, 
which undergo several proliferation and differentiation steps to give rise to 
mature, terminally differentiated progeny. [LT- long term, ST - short term, 
HSC- haemopoietic stem cell, CMP- common myeloid progenitor, CLP- 
common lymphoid progenitor, MPP- multi-potent progenitor] 
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The CD34 molecule is a 115-kDa type I transmembrane glycoprotein, which is 
strongly expressed on human HSCs and shows a progressive decline in 
expression as these cells undergo differentiation (24). Studies suggest that CD34 
may play a role in cell adhesion and signal transduction in HSC and progenitor 
cells, although despite its importance, its exact function and regulation are still not 
completely understood (25). Since its discovery, CD34 has become the most 
widely used marker to obtain enriched populations of human HSCs and 
progenitors for research or clinical use. However, the total CD34+ population is 
heterogeneous and it is thought that the frequency of the true HSC population is 
low (<0.5% in total BM and 1-10% of all CD34+ cells (26)). HSCs do not express a 
variety of surface markers which are associated with terminal differentiation. The 
lack of expression of these markers can, therefore, be used to distinguish the most 
primitive cells from differentiated cells within a total haemopoietic cell population. 
For example, the type II transmembrane glycoprotein, CD38, which was originally 
described as a lymphoid cell surface differentiation marker (27), is expressed at 
intermediate to high levels on >90% of CD34+ cells. These CD34+38+ cells are 
able to give rise to a transient repopulation of irradiated mice (28). By contrast, 
CD34+38- haemopoietic cells are capable of continuous, multi-lineage 
reconstitution following transplant into irradiated mice (29), indicating that true 
HSC exist only within this rare cell population. Therefore, a population of cells 
enriched for HSC can be identified by cell surface phenotype - CD34+lin-CD38- 
(30). Alternative strategies for HSC enrichment include positive selection of cells 
that express surface markers, such as CD133 (31, 32), in combination with CD34 
expression (Table 1-1).  
 
 
 
 30 
 
Cell type 
 
Phenotype 
 
 
 
HSC 
 
CD34+ Lin- 
CD38- CD33- 
HLA-DRlow 
c-Kit+ 
CD133+ 
CD90+ 
 
 
MPP and lineage-
committed progenitors 
 
 
CD34+ Lin+/- 
CD38+ CD33+ 
HLA-DRhigh 
 
 
Mature cell 
 
 
CD34- Lin+ 
 
Table 1-1 Lineage phenotypes of the human haemopoietic system 
 
 
Other than cell surface phenotype, primitive haemopoietic cells can be identified 
and purified based on their ability to efflux certain fluorescent dyes, such as 
Rhodamine-123 (Rho) and Hoechst 33342 (Hst). The majority of the HSCs in adult 
human and murine tissues are Rho-/lo (33) and this phenotype is attributed to the 
activity of the adenosine triphosphate-binding cassette (ABC) transporter, multi-
drug resistance-1 (MDR-1), expressed at the HSC surface (34).  
 
In 1996, Goodell et al. identified a new population of HSCs, by staining with Hst 
and visualising the dual wavelength by flow cytometry. These cells were able to 
efflux Hst and were designated as side population (SP) cells, because they form a 
cluster of events to the lower left side of a dual wavelength flow cytometric plot. 
The ability of SP cells to efflux Hst has been attributed to the high expression of 
the ABC transporter, breast cancer resistance protein (ABCG2) (35). The SP 
population was also thought to be enriched for stem or progenitor cells, as they 
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were subsequently shown to have a primitive phenotype and were capable of 
reconstituting lethally irradiated recipients (36).  
 
In order to isolate the most quiescent HSCs and distinguish between cells in G0 
and G1 phases of cell cycle, it is necessary to combine DNA- and RNA-labelling. 
Pyronin Y (PY) is an RNA-selective dye, which was first used in combination with 
Hst, by Shapiro in 1981, for two-parameter cell cycle assessment of intact cells 
(37). Using this technique, quiescent cells in G0 phase and out of cycle, can be 
detected as they have diploid DNA content and low RNA content, reflecting a low 
number of ribosomes. As the cells enter G1, they accumulate RNA and are able to 
uptake PY. As the cells progress through cell cycle to the S/G2 and M phase, they 
accumulate tetraploid DNA and appear double positive for both Hst and PY. 
 
Primitive haemopoietic cells are also relatively resistant to alkylating agents, such 
as the active derivatives of cyclophosphamide (38). This resistance is due to the 
expression of the enzyme aldehyde dehydrogenase (ALDH) on HSCs (39). The 
highest expression of ALDH has been found on the CD34+38- subset of human 
BM cells and therefore, fluorescent ALDH-substrates have also been used to 
identify and isolate HSCs by FACS (40).  
 
1.1.1 The leukaemic stem cell hypothesis 
The characterisation of HSCs has allowed parallels to be drawn between their 
identity and that of cancer cells, with human leukaemias frequently called stem cell 
diseases (41).  Early experiments by the group led by Philip Fialkow, where they 
used patterns of inactivation in X-linked genes, demonstrated that leukaemias 
such as chronic myeloid leukaemia (CML) (42) and acute myeloid leukaemia 
(AML) (43) are clonal disorders with origins in a multipotent stem cell (44). The 
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concept of a tumourigenic or leukaemic stem cell (LSC) was further explored in 
studies where only a small fraction of leukaemic cells was capable of extensive 
proliferation in vitro and in vivo. Park and colleagues demonstrated that only 1 in 
10000 to 1 in 100 murine myeloma cells were capable of forming colonies in vitro 
in clonal colony-forming assays (45). Furthermore, only 1-4% of the total number 
of leukaemic cells was able to form colonies within the spleen when transplanted 
in vivo (46).  
 
In 1997, adaptation of the existing quantitative assays for normal HSC 
repopulation in vivo, allowed the first direct evidence for the LSC hypothesis to be 
demonstrated in AML (47, 48). Bonnet and Dick demonstrated that only a small 
proportion of leukaemic blasts, which were referred to as ‘SCID leukaemia-
initiating cells’ (SL-IC) and possessed the immature phenotype, CD34+38-, were 
capable of causing human AML in non-obese diabetic/severe combined 
immunodeficient (NOD/SCID) mice. Additionally, these primitive cells were found 
to possess a high self-renewal capacity in serial transplantation experiments. 
Based on these findings, the authors proposed that AML forms a stem cell 
hierarchy that is similar to normal haemopoiesis. This concept suggests that many 
tumours may be maintained by a small population of LSCs which are capable of 
life-long self-renewal, differentiation and proliferation.  
 
Due to the phenotypic and functional similarities between the HSC and LSC, the 
authors also propose that the initial transforming events occur within a stem cell 
rather than a committed progenitor cell. HSCs already have the self-renewal 
pathways activated, therefore may require fewer mutations to maintain self-
renewal properties than more differentiated cells. Indeed, other studies support 
this model, whereby the transduction of the potent oncogene BCR-ABL, did not 
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confer similar self-renewal properties to committed progenitor cell populations 
(49). However, the idea that an LSC must arise from a normal stem cell is not 
universally accepted, with the alternative view suggesting that the LSC could be a 
more restricted or differentiated mature cell, which has transformed and 
reacquired the stem cell capability of self-renewal. Evidence for this was first 
demonstrated in murine models of leukaemia (50). Populations of murine 
progenitor cells, which lacked the capacity for self-renewal, were retrovirally 
transduced with either the MLL-ENL or MOZ-TIF2 human leukaemia oncogenes. 
This led to the reacquisition of self-renewal properties in these progenitor 
populations, as they were able to form colonies in serial methylcellulose-plating 
experiments in vitro. Similarly the transduced cells were also able to induce AML 
when transplanted into irradiated mice, which could then be transferred to 
secondary recipients. Furthermore, expression of the MLL-AF9 oncoprotein has 
also since been shown to initiate AML in isolated granulocyte-macrophage 
progenitor cells (51). More recently, Bonnet has herself demonstrated 
transplantation capacity for CD34+38+ AML cells in at least a proportion of AML 
samples (52), thus expanding the LSC compartment and beginning to separate 
LSC from HSC phenotypes (Figure 1-2). 
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Figure 1-2 Schematic models of leukaemic initiation and progression 
 
 (A) The initial transforming mutation disrupts the normal development of an 
HSC and gives rise to a self-renewing LSC, which is present in the stem cell 
compartment. (B) Conversely, the transforming mutation may occur in the 
downstream progeny. These cells have then reacquired the stem cell 
capability of self-renewal, to generate the LSCs. 
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1.2 CML 
Compelling evidence suggests that CML is one such malignancy which is driven 
by LSCs. CML is a clonal myeloproliferative disorder of primitive haemopoietic 
progenitor cells, which accounts for 15% of all adult leukaemias and has an 
incidence of 1-2 cases per 100,000 population (53). It is defined by the 
Philadelphia chromosome (Ph), which results from the reciprocal translocation 
between the 3’ end of the c-ABL (Abelson) gene from chromosome 9 and the 3’ 
end of the BCR (Breakpoint Cluster Region) gene on chromosome 22 
(t(9;22)(q34;q11)) (54). The novel fusion oncogene generated on chromosome 22 
as a result of this translocation is called BCR-ABL (breakpoint cluster region-
abelson) (55, 56) (Figure 1-3). In the majority of CML patients, this oncogene 
transcribes a 210-kDa constitutively active non-receptor tyrosine kinase (TK), 
often referred to as p210BCR-ABL, which is necessary for the transformation of the 
disease (57). 
 
 
 
 
 
 
 
 
Figure 1-3  The Ph chromosome  
The reciprocal translocation between chromosomes 9 and 22 results in the 
formation of the Ph chromosome. This is the shortened chromosome 22 and 
results in the production of the fusion gene product BCR-ABL. 
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CML is a clinically triphasic disorder, where the majority of patients present in 
chronic phase (CP), a stage which is characterised by an abnormal blood count, 
increased megakaryocytes in BM and splenomegaly (58). Diagnosis is confirmed 
by the detection of the Ph chromosome by BM cytogenetics and by measurement 
of BCR-ABL transcripts, in peripheral blood or BM, by highly sensitive quantitative 
reverse transcriptase-polymerase chain reaction (qRT-PCR) (59). If left untreated, 
the initial CP lasts for approximately 3-6 years, before progressing to accelerated 
phase (AP). As the disease develops, additional cytogenetic abnormalities arise 
and eventually terminate in blast crisis (BC). This is a period of overproduction of 
immature leukaemic blast cells within the BM compartment, where prognosis is 
generally poor (58). The most widely used criteria for AP and BC CML diagnosis 
are defined by the World Health Organisation (WHO) and are outlined below (60): 
 
AP CML  Diagnosis if one or more of the following is present: 
• Blasts 10 to 19% of peripheral blood white cells or BM cells 
• Peripheral blood basophils at least 20% 
• Persistent thrombocytopenia (100 x 109/L) unrelated to therapy, or 
persistent thrombocytosis (1000 x 109/L) unresponsive to therapy 
• Increasing spleen size and increasing WC count unresponsive to 
therapy 
• Cytogenetic evidence of clonal evolution 
 
BC CML  Diagnosis if one or more of the following is present: 
• Blasts 20% or more of peripheral blood white cells or BM cells 
• Extramedullary blast proliferation 
• Large foci or clusters of blasts in BM biopsy 
 
 
Table 1-2 Criteria for diagnosis of AP and BC CML 
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1.2.1 BCR-ABL structure and function 
The mammalian c-ABL gene is ubiquitously expressed and encodes a non-
receptor TK, with two 145-kDa isoforms arising from alternative splicing of the first 
exon (61). The amino-terminus of human c-ABL protein contains three SRC 
homology domains (SH1-SH3) that mediate TK (SH1), phospho-tyrosine protein-
binding (SH2) and kinase inhibitory (SH3) functions. The centre of the protein 
contains proline-rich sequences which can in turn interact with the SH3 domains of 
other adaptor-proteins, such as Crk. The carboxyl-terminus of c-ABL encodes a 
lysine-rich motif required for nuclear localisation, a DNA-binding domain and actin-
binding domains.  In c-ABL, the structural motifs which are thought to be 
necessary for cellular transformation are the SH1, SH2 and actin-binding domains 
(62-64). The c-ABL proto-oncoprotein is commonly distributed in both the nucleus 
where it is bound to chromatin and in the cytoplasm where it is bound to F-actin 
(65). Normal c-ABL protein is predominantly nuclear and appears to be involved in 
the regulation of cell cycle, suppression of cell growth, regulation of gene 
transcription and integrin signalling. In contrast, transforming c-ABL proteins are 
often localised in the cytoplasm, implying that the cytoplasmic fraction of c-ABL 
may normally be involved in the signalling cascades that induce mitogenesis (65). 
 
Like c-ABL, the 160-kDa BCR protein is ubiquitously expressed and localised 
within the cytoplasm, although its exact function is not clearly defined. The amino-
terminus of BCR contains a serine/threonine kinase domain, including at least 
three SH2 binding sites which can bind with substrates such as, BRCA1 (breast 
cancer 1)-associated protein (Bap)-1, a member of the 14-3-3 family of proteins 
(66).  A coiled-coil (C-C) domain (amino acids 1-63) at the amino-terminus of 
BCR-ABL allows dimer formation in vivo. The C-C structural motif, along with the 
tyrosine 177 (Y177) phosphorylation site, which is necessary for the binding of 
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growth-receptor-binding-2 (Grb-2) and subsequent activation of the Ras pathway, 
are thought to be necessary for the transforming function of BCR-ABL (67-69).  
The most important structural domains of BCR and c-ABL proteins are 
demonstrated in Figure 1-4. 
 
 
 
 
 
 
 
 
Figure 1-4 The important structural motifs of BCR and c-ABL proteins 
In BCR, the coiled-coil (C-C) (also known as the oligomerisation domain) 
resides at the amino (NH2) terminus. This is followed by a domain which is 
thought to facilitate binding to SRC-homology 2 (SH2)-domain-containing 
proteins. BCR also contains a serine/threonine (Ser/Thr) kinase domain, a 
tyrosine at position 177 (Y177), a Rho guanine-nucleotide-exchange factor 
(Rho-GEF) domain and a Rac GTPase activating protein (Rac-GAP) 
homology domain. In ABL, there are SH3, SH2 and SH1 tyrosine kinase (TK) 
domains at the amino terminus, several proline-rich domains (P) and a 
nuclear localisation signal (NLS). At the carboxy terminus (COOH) there are 
DNA- and actin-binding domains. 
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Three predominant products are formed depending on which breakpoint located 
within the BCR gene is fused with exon a2 of ABL. These different forms of BCR-
ABL are associated with three distinct forms of leukaemia. In the majority of CML 
cases, the breakpoint occurs within the major BCR (M-BCR), which spans exons 
b1-4. This results in the formation of fusion transcripts with b2a2 or b3a2 junctions, 
which encode the p210BCR-ABL oncoprotein. A second breakpoint is located 
upstream of M-BCR - minor BCR (m-BCR) - and encodes a 190-kDa protein, 
referred to as p190BCR-ABL. This commonly occurs in Ph+ acute B lymphoblastic 
leukaemia (ALL) (70), occasionally in AML (71) and in rare cases of CML (72). 
Lastly, a third downstream BCR (µ-BCR) encodes a 230-kDa protein (p230BCR-
ABL), which is found in chronic neutrophilic leukaemia and some cases of CML 
(73). 
 
The first evidence that BCR-ABL was responsible for the malignant transformation 
of HSCs in CML was provided by Daley et al., who demonstrated that mice 
transplanted with BM transduced with p210BCR-ABL, developed many features of 
CML (74). The importance of BCR-ABL was further demonstrated in transgenic 
mice in which the tetracycline-responsive element (tet-O) was used to induce 
BCR-ABL1 expression in HSCs. The BCR-ABL1-tet-O mice then developed a 
CML-like disease upon the withdrawal of tetracycline treatment (75). 
 
It is suggested that BCR-ABL gives rise to this malignant transformation through a 
number of mechanisms, namely, alteration of the BM microenvironment, anti-
apoptotic defences, constitutive activation of proliferation and survival pathways 
and growth factor (GF) independence.  
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1.2.2 BCR-ABL and alteration of the BM microenvironment  
In normal haemopoiesis, progenitor cell proliferation is negatively regulated by the 
microenvironment through adhesion of integrin receptors, such as the β1-integrin 
receptors, to BM stromal cells (76). The increased proliferation and abnormal 
circulation of primitive CML cells may, in part, be explained by perturbed adhesion 
between the BM microenvironment and the CML progenitors (77, 78). CML 
progenitors express a variant of the β1-integrin receptor that is not present on 
normal cells and evade this regulation through impaired adhesion. Following 
receptor-binding, integrins are capable of initiating normal signal transduction; 
therefore, it is possible that in CML cells, the signalling that usually inhibits 
proliferation is impaired. BCR-ABL may have a further impact on this altered 
signalling, as proteins that are also involved in signal transduction through β1-
integrins, such as paxillin, and phosphatidylinositol 3-kinase (PI3K) (79), are 
constitutively activated by BCR-ABL in cell lines transduced with the oncogene. 
Bhatia et al., have demonstrated that treatment with interferon alpha (IFNα), a 
therapeutic agent in CML, can restore β1-integrin mediated adhesion of CML 
progenitors to BM stroma and restore this anti-proliferative mechanism (80).  
 
SDF-1α-CXCR4 signalling positively regulates the homing of HSC to the BM (81). 
In primary blast CML cells, BCR-ABL has been shown to down-regulate CXCR4 
expression resulting in attenuated adhesion and migratory responses to SDF-1α, 
increasing the ability of these immature cells to escape from the marrow (82). 
Inhibition of BCR-ABL kinase activity, has been demonstrated to restore CXCR4 
expression in CML cells co-cultured with mesenchymal stem cells. This resulted in 
the migration of CML cells to the BM niche and an acquisition of stroma-mediated 
resistance of CML progenitor cells (21). These results suggest that the SDF-1α-
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CXCR4 interaction contributes to the resistance of CML cells against agents which 
inhibit BCR-ABL activity in the BM microenvironment. 
 
1.2.3 BCR-ABL and anti-apoptosis  
CML stem cells demonstrate elevated and continuous growth and expansion as 
compared to their normal counterparts, but do not exhibit greater proliferation 
potential (83). This indicates that the increased TK activity of BCR-ABL within 
CML progenitors may act to suppress the normal programmed cell death process, 
apoptosis. The “protection from apoptosis” hypothesis has been confirmed in 
transformed haemopoietic cell lines, whereby transfection with BCR-ABL 
upregulated the anti-apoptotic survival proteins, B-cell lymphoma (Bcl)-2 (84), 
myeloid cell leukaemia (mcl)-1 (85) and Bcl-XL (86).  
 
1.2.4 BCR-ABL and constitutive activation of proliferation and survival 
pathways 
A consequence of BCR-ABL is an increase in cellular proliferation. At first the 
“discordant maturation hypothesis” was proposed, where it was assumed that the 
most mature proliferating cells in CP CML caused the expansion of Ph+ cells. 
However, this was refuted by other investigations demonstrating that the myeloid 
expansion is a result of increased numbers of primitive CML progenitor cells (87).  
 
BCR-ABL is localised exclusively to the cytoplasm and is able to constitutively 
tyrosine phosphorylate a host of substrates. Importantly, due to 
autophosphorylation, there is increased phospho-tyrosine (p-Tyr) on the BCR-ABL 
oncoprotein itself. This then, generates many binding sites for the SH2 domains of 
other proteins. A number of target substrates of BCR-ABL have been reported as 
shown in Table 1-3. Substrates of BCR-ABL can be grouped into three broad 
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categories, depending on function: (1) adaptor molecules such as CrkL and 
p62Dok; (2) cell membrane and cytoskeleton related proteins such as talin and 
paxillin and (3) proteins with catalytic function such as Ras-GAP and 
phospholipase Cγ (PLCγ) (88). Tyrosine phosphorylation of these BCR-ABL 
substrates results in the constitutive activation of multiple cytoplasmic and nuclear 
signalling cascades, which are shared with cytokines known to regulate the 
proliferation, differentiation and survival of haemopoietic cells (Figure 1-5). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-5 BCR-ABL associated signalling cascades that contribute to 
cellular proliferation, differentiation and survival 
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Table 1-3 Examples of BCR-ABL PTK substrates 
 [Grb- growth-receptor-binding protein; Dok- docking protein; CrkL- Crk-like; 
GAP- GTPase-activating protein; PI3K- phosphatidylositol 3-kinase; STAT- 
signal transducer and activator of transcription; Fak- focal adhesion kinase; 
PLC- phospholipase C; Bap- BRCA1 (breast cancer 1)-associated protein.] 
Table adapted from Smith et al. 2003 (88). 
 
 
Substrate Function References 
Grb-2 Adapter molecule (69) 
P62Dok Adapter molecule (89) 
CrkL Adapter molecule (90) 
Crk Adapter molecule (91) 
Ras-GAP Ras-GTPase activation (92) 
Ras Signalling switch; 
cellular oncogene (93) 
Raf-1 Serine/threonine kinase (94) 
Cbl E3 ligase for 
ubiquitination (95) 
PI3 kinase 
(p85 subunit) Serine kinase (96) 
STAT1 and 5 Transcriptional 
activators (97, 98) 
Paxillin Cytoskeleton (99) 
Fak Cytoskeleton (100) 
Talin Cytoskeleton (101) 
PLCγ Phospholipase (102) 
Bap-1 14-3-3 adaptor protein (66) 
Vav Guanine-nucleotide-
exchange factor (103) 
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1.2.4.1 BCR-ABL and the Ras-Raf-MEK-ERK pathway 
Ras is a small guanine-nucleotide-binding protein (G-protein) that is active when 
bound to GTP, or inactive when GDP-bound. Ras is activated when GEFs 
catalyse the exchange of Ras-bound GDP for GTP. In contrast, GAPs inactivate 
Ras by catalysing its intrinsic GTPase activity.  
 
In normal cells, activation of Ras by haemopoietic GFs, such as IL-3, leads to the 
recruitment of the serine/threonine Raf-1 kinase to the cell membrane. Activated 
Raf-1 can then phosphorylate mitogen-activated protein kinase (MAPK) kinase 
(MEK) on both serine and threonine residues. MEK is then able to phosphorylate 
and activate extracellular signal-regulated kinase; ERK, which can, in turn, 
phosphorylate transcription factors, such as c-Jun and c-Fos and thereby direct 
gene regulation (93).  
 
It has also been demonstrated that elevated Ras activation occurs in CML cells 
(104). Autophosphorylation of Y177 on BCR-ABL provides a docking site for the 
adapter molecule Grb-2 (69). Activated Grb-2 can then bind the positive regulator, 
Son of sevenless (SOS; a GEF) and then stabilise Ras in the active form. Grb-2 
mutants that lack SH3 domains block the activation of Ras and suppress the 
transforming capability of BCR-ABL (105). Two other BCR-ABL adaptor 
molecules, Shc and CrkL, can also activate Ras (90, 106). The importance of Ras 
in CML cell growth was demonstrated in cell line models in which the introduction 
of a dominant-negative Ras into BCR-ABL-transfected cells inhibited malignant 
transformation (107). Further investigations have shown that, in BCR-ABL-
transformed haemopoietic cells, the constitutive activation of Ras is likely to lead 
to the activation of an anti-apoptotic pathway (108, 109). These data highlight an 
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important role for the Ras-Raf-MEK-ERK pathway in the pathogenesis of BCR-
ABL+ leukaemias. 
 
1.2.4.2 BCR-ABL and the JAK-STAT pathway 
The JAK-STAT pathway is activated by cytokines, such as IL-3, IFNα and 
granulocyte macrophage-colony stimulating factor (GM-CSF). Janus family of 
activated kinases (JAK1, JAK2, JAK3, Tyk2) are cytoplasmic protein TKs (PTKs) 
that mediate signalling downstream of cytokine receptors. Activated JAKs 
phosphorylate a family of downstream transcription factors called the STAT family 
members. STAT proteins then translocate to the nucleus and activate the 
transcription of specific genes necessary for the growth, survival and 
differentiation of haemopoietic cells. The JAK-STAT pathway is tightly regulated 
by the suppressors of cytokine signalling (SOCS) and cytokine-induced SH2-
containing (CIS) family of proteins (110). 
 
The constitutive activation of STATs is observed in BCR-ABL expressing cell lines 
and primary CML cells (111, 112) and the activation of STAT5 appears to 
contribute to malignant transformation (113). The effect of STAT5 activation in 
BCR-ABL+ cells appears to be predominantly anti-apoptotic, as the activation of 
STAT5 in CML cells contributes to upregulated expression of the anti-apoptotic 
family members, mcl-1 and Bcl-XL (114, 115). Although BCR-ABL is known to 
activate JAKs, there may also be a distinct BCR-ABL-mediated pathway for the 
phosphorylation of STAT5, as the introduction of dominant-negative JAK mutants 
in BCR-ABL transformed cells did not abrogate STAT5 phosphorylation (112). 
 
 46 
1.2.4.3 BCR-ABL and the PI3K pathway 
PI3K is a heterodimer consisting of an 85-kDa (p85) regulatory subunit containing 
one SH3 domain and two SH2 domains and a 110-kDa (p110) catalytic subunit 
(116). PI3K is found in cellular complexes with ligand-activated GF and oncogene 
PTKs (117).  These interactions are mediated by the SH2 and SH3 domains of 
p85 (118). The PI3K signalling pathway plays an important role in many biological 
processes, such as survival, proliferation, differentiation, mobility and metabolism 
in a number of cell types (119, 120).  
PI3K can bind to activated haemopoietic GF receptors via its SH2 and SH3 
domains and is recruited to the cell membrane following haemopoietic GF 
stimulation. Activated PI3K can produce PI-(4,5)-bisphosphate (PIP2) which may 
be converted to PI-(3,4,5)-triphosphate (PIP3), an important second messenger 
(121). PIP3 and other PI3K lipid products on the inner cell membrane generate 
binding sites for other proteins that contain pleckstrin homology domains. PI3K 
signalling is negatively regulated by phosphatases, such as, phosphatase and 
tensin homologue deleted on chromosome 10 (PTEN) which removes the 3-
phosphate from PIP3 (122). SH2-containing inositol-5-phosphatase (SHIP) - 
removes the 5-phosphate from PIP3 to generate PIP2, a second messenger which 
may have different signalling functions (Figure 1-6). 
 
 
 
Figure 1-6 Diagram of PI3K inositol lipid second messenger synthesis and 
degradation 
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that PI3K activity was regulated by BCR-ABL and required for the growth of CML 
cells, using antisense oligonucleotides against PI3K expression (84). Furthermore, 
a specific inhibitor of the p110 subunit of PI3K, wortmannin, was shown to inhibit 
the proliferation of BCR-ABL+ cells, but not normal haemopoietic cells (96). These 
findings are corroborated by the fact that BCR-ABL-transformed cells have 
increased PI3K class 1A activity and an accumulation of PIP3 (79). 
A YXXM motif is contained within the ABL sequence of BCR-ABL, which when 
phosphorylated corresponds to the optimal binding sequence for the SH2 domains 
of the p85 regulatory subunit of PI3K (123). However, the BCR-ABL-PI3K 
interaction does not appear to be direct as mutation of the YXXM motif does not 
attenuate PI3K activity. This finding indicates that PI3K activation occurs through 
associations with other tyrosine-phosphorylated proteins that are recruited to 
BCR-ABL (123).  
 
1.2.4.3.1 The adapter protein Gab2 
The majority of evidence indicates that the main pathway for PI3K activation in 
BCR-ABL+ cells occurs via the Y177 autophosphorylation site on the BCR portion 
of the fusion protein. The Y177 site is important for Grb2 binding via its SH2 and 
generates a docking site for Gab2 through its SH3 domain (124).  BCR-ABL can 
then phosphorylate Gab2 on tyrosines within its YXXM motif which, in turn, act as 
binding sites for the SH2 domains of PI3K regulatory subunits. Mutations within 
the Y177 site resulted in decreased transformation by BCR-ABL. Similarly, loss of 
Gab2 inhibited myeloid transformation both in vitro and in vivo (124).  
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1.2.4.3.2 The adapter protein CrkL 
A further possible Gab2-independent mechanism of PI3K activation involves the 
39-kDa protein CrkL. CrkL was originally identified by ten Hoeve et al. (125) and is 
one of the most prominent tyrosine-phosphorylated proteins detected in BCR-ABL-
transformed cells (90). CrkL belongs to the Crk family of adapter proteins which 
includes v-Crk and c-Crk. It is ubiquitously expressed and contains one SH2 
domain, an SH2’ domain (has no known function) and two SH3 domains (126).  It 
is thought to be involved in the regulation of cellular motility and integrin-mediated 
cell adhesion by association with other focal adhesion proteins such as paxillin 
(99). In CML, CrkL interacts and is phosphorylated on tyrosine 207 (127) directly 
by the BCR-ABL oncoprotein (90, 125, 128). Tyrosine phosphorylated CrkL then 
binds to c-CBL with its SH2 domain and forms a multimeric complex with PI3K, c-
ABL and BCR-ABL through its SH3 domain (95, 129).  The exact function of CrkL 
tyrosine phosphorylation in leukaemic cell signalling remains to be determined, 
however, it seems likely that CrkL binding to other tyrosine phosphorylated 
proteins, such as PI3K, leads to the activation of pathways that could contribute to 
leukaemic transformation. Due to the specificity of BCR-ABL signalling to CrkL 
activation and also the inherent instability of the BCR-ABL oncoprotein, detection 
of the activated form of CrkL (p-CrkL) has become a standard indirect method to 
assess BCR-ABL status, as illustrated by our own laboratory (130, 131) and 
others (132, 133).  
 
1.2.4.3.3 Akt - a major downstream signalling effector of PI3K 
Akt is a serine/threonine kinase (also known as protein kinase B) which is 
activated by PI3K and is the effector most closely associated with cellular 
transformation. Activated Akt has a number of different substrates which regulate 
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proliferation, metabolism and survival, as illustrated in Figure 1-7 and described 
below. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-7 Downstream substrates of PI3K/Akt phosphorylation 
Signalling via GF stimulation of cognate receptors or by BCR-ABL, results in 
the activation of PI3K and the subsequent recruitment of Akt. Activated Akt 
then phosphorylates many substrates to promote cell growth, proliferation 
and survival. See text for details. [TSC- tuberous sclerosis, mTOR- 
mammalian target of rapamycin, GSK3β- Glycogen synthase kinase 3β, 
FOXO- forkhead box, subgroup O, Bad- Bcl-2-associated death promoter, 
mdm2- murine double minute 2, 4EBP1-eukaryotic translation initiation 
factor 4E, eIF4E-eukaryotic initiation factor 4E] 
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1.2.4.3.3.1 Forkhead Box, Subgroup O  
The forkhead box, subgroup O (FoxO) family of transcription factors are a sub-
class of the Fox forkhead transcription factors that have a variety of roles in the 
regulation of proliferation, cellular metabolism and survival (134). The mammalian 
members of the FoxO transcription factors include FoxO1, FoxO3a, FoxO4 and 
FoxO6 and contain three evolutionarily conserved Akt phosphorylation sites within 
each of the FoxO proteins. Following GF stimulation, Akt phosphorylates FoxO 
transcription factors within the nucleus. This allows for the binding of the 14-3-3 
chaperone protein (135, 136), resulting in the efficient export and re-localisation of 
FoxO transcription factors to the cytoplasm. Cytoplasmic sequestration prevents 
the FoxO-dependent transcription of genes that may antagonise cell survival, such 
as Bim and Trail (137, 138) and also promote cell cycle arrest, such as the 
downregulation of cyclins D1 and D2 (139).  Recent investigations have 
demonstrated the importance of FoxO function in haematological malignancies. 
BCR-ABL transformation was shown to inhibit FoxO3a, via the constitutive 
activation of PI3K/Akt signalling and the subsequent cytoplasmic sequestration of 
Foxo3a (140). The expression of a constitutively active FoxO3a triple mutant in 
BCR-ABL+ cells resulted in the induction of apoptosis (140, 141). Furthermore, 
FoxO3a inhibition by BCR-ABL was also shown to affect the expression of the cell 
cycle regulatory gene, cyclin D2 (142). These data indicate that the inhibition of 
FoxO3a by BCR-ABL may represent a potentially important mechanism in CML 
tumourogenesis. 
 
1.2.4.3.3.2 Bcl-2-associated death promoter 
The Bcl-2-associated death promoter (Bad) protein is a pro-apoptotic member of 
the Bcl-2 gene family which is involved in initiating apoptosis. Non-phosphorylated 
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Bad exerts pro-apoptotic effects through binding to, and preventing the function of 
anti-apoptotic proteins such as Bcl-2 and Bcl-XL (143). Conversely, Bad 
phosphorylation by Akt (triggered by PIP3) causes the formation of the Bad-(14-3-
3) protein homodimer. This results in the sequestration of Bad in the cytoplasm 
and leaves Bcl-2 free to inhibit Bax-triggered apoptosis (144). In vitro studies have 
demonstrated that BCR-ABL can promote the phosphorylation and inactivation of 
Bad. However, within the same study, it was also noted that BCR-ABL-mediated 
phosphorylation of Bad was not essential for BCR-ABL-induced cell survival, as 
the cells continued to survive in the absence of Bad phosphorylation (145). This 
thereby suggests that the transforming ability of BCR-ABL is not due to one 
pathway, it is rather the activation of complex network of signalling cascades. 
 
1.2.4.3.3.3 Murine double minute 2 
Murine double minute 2 (Mdm2) is an E3 ubiquitin ligase which, when 
phosphorylated by Akt, acts as an important negative regulator of the tumour 
suppressor, p53 (146). Studies suggest that BCR-ABL may promote cell survival 
by p53 downregulation via increased expression of Mdm2 (147).  
 
1.2.4.3.3.4 Glycogen synthase kinase 3β 
Glycogen synthase kinase 3β  (GSK3β) is a serine/threonine kinase that is a 
downstream target of Akt and becomes inactivated following phosphorylation 
(148). Two downstream targets of GSK3β, include cyclin D1 and β-catenin. 
Activated GSK3β phosphorylates these proteins and targets them from 
proteasome-mediated degradation (149). Recent studies have demonstrated that 
HSCs which were deficient in β-catenin, demonstrated a reduction in long-term 
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self-renewal as measured by serial transplantation assays. Furthermore, BCR-
ABL-transduced cells deficient in β-catenin, failed to develop CML (150). These 
data highlight an important role for β-catenin in the maintenance of both normal 
and CML stem cells. However, a direct functional role for the inactivation of 
GSK3β downstream of PI3K/Akt in BCR-ABL transformed cells has yet to be 
determined. 
 
1.2.4.3.3.5 Tuberous Sclerosis-2 and the Mammalian Target of Rapamycin 
pathway 
The serine/threonine kinase, mammalian target of rapamycin (mTOR) functions as 
both a nutrient sensor and an important downstream substrate of PI3K/Akt 
signalling, following GF or oncoprotein stimulation (151). The activation of mTOR 
results in the regulation of processes, such as cell growth, cell-cycle progression, 
protein synthesis and autophagy (152, 153).  
 
mTOR can form at least two multi-protein complexes, mTORC1 and mTORC2 
(152). mTORC1 is a heterotrimeric protein kinase that consists of the mTOR 
catalytic subunit and two associated proteins - regulatory-associated protein of 
mTOR (raptor) and mLST8. mTORC1 has been demonstrated to be involved in 
cellular proliferation, autophagy and translation in response to nutrients. mTORC2 
also contains mTOR and mLST8 but, instead of raptor, it contains two other 
proteins - rapamycin-insensitive companion of mTOR (rictor) and mSin1. 
mTORC2 is less well understood than the first mTOR-containing complex, 
however studies suggest that it is involved in the PI3K/Akt pathway as it directly 
phosphorylates Akt (154). 
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The mTOR pathway has proven to be an attractive target for the drug treatment of 
several malignancies which display excessive PI3K/Akt signalling, including breast 
and ovarian cancers (155). Furthermore, rapamycin was observed to enhance the 
anti-leukaemic effects of IM on both IM-sensitive and -resistant CML cells both in 
vitro and in vivo (156, 157).    
 
The exact mechanism by which BCR-ABL activates mTOR in CML cells has yet to 
be defined but appears to be PI3K/Akt-dependent (156). PI3K/Akt-signalling 
regulates mTOR indirectly through activation of tuberous sclerosis complex 2 
(TSC2). TSC2 forms a heterodimer with TSC1 which acts as a brake on mTOR-
dependent signalling in the absence of GF/oncogene signals. When TSC2 is 
phosphorylated by activated Akt, the TSC1/TSC2 complex becomes inactive and 
its ability to inhibit the small G-protein Rheb is blocked. Rheb is then able to 
activate mTOR once released from this inhibition (158) (see Figure 1-7). 
 
The mTOR pathway controls cell growth through regulators of translation, such as, 
eukaryotic translation initiation factor 4E (4EBP1) and the p70 ribosomal protein 
S6 kinases 1 and 2 (S6K1 and S6K2) (159). Phosphorylation of 4EBP1 by mTOR 
blocks its ability to inhibit eukaryotic initiation factor 4E (eIF4E). The eIF4E protein 
is then released and is free to bind the 5’-cap structure of mRNAs to allow an 
increase in cap-dependent translation (159). The S6K activation of the S6 protein 
of 40S ribosomes promotes cell growth and proliferation by an unknown 
mechanism (160). 
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1.2.4.3.3.5.1 mTOR and autophagy  
As described previously, mTOR mediates the control of cellular growth. mTOR is 
active under favorable growth conditions, and promotes the initiation of  translation 
and nutrient import. However, during conditions of nutrient starvation, rapamycin 
treatment or mTOR depletion there is a dramatic downregulation of general 
protein synthesis and an activation of a process known as autophagy.  
 
The term autophagy is derived from the Greek, “auto” - oneself and “phagy” - to 
eat; and refers to a cellular catabolic degradation process. During autophagy, a 
cell’s own long-lived proteins and organelles are degraded through a lysosome-
dependent pathway and recycled to sustain metabolism (161).  Autophagy occurs 
at low basal levels in virtually all cells and has an important homeostatic function, 
to maintain organelle and protein turnover. It has a critical role during early 
mammalian development as mice lacking essential autophagy genes die within 
hours after birth. This is possibly due to their inability to adapt to the neonatal 
starvation period (162). Autophagy is also thought to have a critical role in 
response to conditions of cellular stress, such as nutrient deprivation, hypoxia and 
pathogen infection (163). 
 
Macroautophagy (herein referred to as autophagy) involves the delivery of cellular 
material sequestered inside double membrane vesicles to the lysosome in 
eukaryotic cells. In conditions of starvation or GF deprivation, a drop in 
intracellular nutients allows “protective” autophagy to occur. Initially, an isolation 
membrane (also called a phagophore) is formed (vesicle nucleation) and 
expanded (vesicle elongation). This structure sequesters the cytoplasmic material 
to be degraded, which may include mitochondria, endoplasmic reticulum, and 
ribosomes (Figure 1-8). The edges of the phagophore then fuse to form a double-
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membrane structure, known as the autophagosome. This is followed by a fusion of 
the outer membrane of the autophagosome with the lysosome, where the 
sequestered material, together with the inner membrane is degraded. Degradation 
of the sequestered material generates nucleotides, amino acids, and free fatty 
acids that may be recycled by the cell for protein synthesis and adenosine 
triphosphate (ATP) generation, thereby promoting cell survival (161).  
 
One of the main regulators of autophagy is mTOR, which is the key inhibitory 
signal that turns off autophagy in the presence of GFs or an abundance of 
nutrients. The binding of GFs to cell surface receptors activates class I PI3K/Akt 
signalling, leading to activation of mTOR. This results in the negative regulation of 
autophagosome formation and prevents the autophagy process from occuring 
(164). Autophagy may also be pharmacologically inhibited by targeting the fusion 
of autophagosomes with lysosomes, using inhibitors of the lysosomal H+ATPase 
proton pump, such as, bafilomycin A1 (BAF) or lysosomotropic alkalines, such as 
chloroquine (CQ) or 3-hydroxychloroquine (HCQ). Conversely, autophagy can be 
pharmacologically induced by targeting mTOR with rapamycin (163).  
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Figure 1-8 The autophagy pathway and its role in cellular adaptation in 
response to nutrient deprivation 
Autophagy is activated by a decrease in intracellular nutrients and involves 
the sequestration of cytoplasmic material by an isolation membrane to form 
the autophagosome. The autophagosome then fuses with a lysosome, to 
form an autolysosome, where the sequestered material is degraded. 
Degradation of this material by the autolysosome generates free fatty acids 
and amino acids that can be used by the cell to maintain mitochondrial ATP 
energy production and protein synthesis, thus promoting cell survival.  
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In yeast, approximately 30 genes (known as the Atg genes), which are essential 
for autophagy or autophagy-related processes, are located downstream of TOR 
kinase. Most of these genes have homologues in higher eukaryotes and encode 
proteins that act in different stages of autophagosome formation. The Atg proteins 
can be divided into 5 functional groups depending on function. They include a 
protein serine/threonine kinase complex that responds to upstream signals such 
as mTOR (Atg1, Atg13, Atg17); a lipid kinase signalling complex that mediates the 
formation of the isolation membrane (Atg6 (or beclin 1), Atg14, Vps34, and 
Vps15), ubiquitin-like conjugation pathways that allow vesicle expansion (the Atg8-
Atg-7 and Atg12-Atg7 systems), a recycling pathway that mediates the 
disassembly of Atg proteins from matured autophagosomes (Atg2, Atg9, Atg18) 
and vacuolar permeases that alow the efflux of amino acids from the degradative 
compartment (Atg22) (165).  
 
The identification of the genes and signals which regulate the autophagy process 
has also allowed the cellular manipulation and detection of autophagy.  
Classically, electron microscopy (EM) was used as the gold-standard to 
demonstrate autophagosomes in cells. However, more recently the 
autophagosome-associated protein microtubule-associated protein 1 light chain 3 
(LC3) (mammalian homologue of yeast Atg8) has been used as a marker of 
autophagy. When autophagy is not activated, LC3 is localised in the cytoplasm; 
however, upon the execution of autophagy, LC3 links up with the isolation 
membrane and remains associated with the autophagosome membrane. For this 
reason, transfection with the green fluorescent protein-linked LC3 (GFP-LC3) 
chimeric plasmid is useful for the detection of autophagosomes by fluorescence 
microscopy (166). LC3 has two forms: type I is cytosolic and type II is membrane-
bound. During autophagy, LC3-II increases by conversion from LC3-I. Therefore, 
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the increase of LC3-II can be detected by immunoblot analysis because LC3-I and 
LC3-II have different molecular weights (166). 
 
Increasing evidence suggests that autophagy is important in tumour development. 
In all eukaryotic organisms, autophagy promotes the survival of normal cells 
during nutrient starvation. Similarly, autophagy might promote the survival of 
rapidly growing cancer cells that have outgrown their vascular niche and face 
conditions of hypoxia or metabolic stress (167).  
 
It has also been shown that autophagy may also enhance the survival of cancer 
cells by targeting damaged mitochondria and other organelles for lysosomal 
degradation (168), thus, evading the oxidative stress response that can be 
triggered by activated cancer-causing genes or by anti-cancer treatments. Recent 
data suggests that CML cells undergo autophagy in response to TK inhibitor (TKI) 
treament (169, 170). Moreover, combination therapy with autophagy inhibitors, 
augmented the anti-leukaemic effects of both suberoylanilide hydroxamic acid 
(SAHA) (171) and dasatinib (to be discussed further later in this thesis) (172) on 
human primary CML cells in vitro. 
 
In the majority of circumstances, autophagy serves as an adaptation pathway to 
cellular stress that promotes cell survival. However, an apparent paradox is the 
fact that autophagy is also considered as a form of non-apoptotic cell death or 
“type II” cell death. Indeed, allelic loss of the essential autophagy gene beclin 1 is 
found with high frequency in human breast, prostate and ovarian cancers (173, 
174). Furthermore, inactivation of beclin1 leads to increased tumourigenesis in 
mice (175, 176). Therefore, whether autophagy protects against or causes 
disease is controversial and whether to turn autophagy on or off in a cancer cell 
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also remains a subject of much debate. This further highlights the need to clarify 
the mechanisms of autophagy and its inhibition in more detail. 
 
1.2.5 GF independence of BCR-ABL+ cells  
1.2.5.1 Interleukin-3 
Interleukin-3 (IL-3) is a 17-kDa cytokine which functions as a multipotent 
haemopoietic GF. Through activation of the IL-3 receptor, IL-3 induces activation 
of JAK-STAT, PI3K/Akt and Ras signalling pathways, to promote the proliferation, 
maturation, survival and probably self-renewal of pluripotent HSCs and cells of 
myeloid, erythroid and megakaryocytic lineages (177).  
 
1.2.5.2 Granulocyte-Colony Stimulating Factor 
Granulocyte-colony stimulating factor (G-CSF) is a 25-kDa secreted glycoprotein 
which also functions as a cytokine and was named for its specific induction of 
growth of haemopoietic progenitor cells in semi-solid cultures (178). The main 
biological effect of G-CSF is to cause an increase in proliferation and 
differentiation of cells in the neutrophil lineage, from HSCs to mature neutrophils, 
through the activation of JAK-STAT, PI3K/AKt and Ras signalling (179).   
Neutropenia is a significant side effect of many cytotoxic chemotherapy regimes 
used to treat cancer. Therefore, the actions of G-CSF meant that it was initially 
tested in clinic for its ability to prevent or reduce severe neutropenia (180). Other 
functional roles for G-CSF include the mobilisation of HSCs from the BM into the 
peripheral blood (181) and the possible regulation of immune responses (182). 
 
1.2.5.3 The autocrine production of IL-3 and G-CSF in CML cells 
Several studies suggest that the aberrant production of haemopoietic cytokines, 
such as IL-3 and G-CSF, could play a role in CML pathogenesis. Investigations 
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have shown that similar biochemical changes, which occur in normal cells 
following exposure to high concentrations of IL-3, can be demonstrated in both 
BCR-ABL-transformed cell lines and primary CML cells (183). Murine models have 
demonstrated that the transplantation of BM cells, retrovirally transduced or 
transgenically-engineered to produce IL-3, may induce the development of a 
myeloproliferative disorder (184-186). Further in vitro investigations have shown 
that retroviral introduction of p210BCR-ABL into cytokine-dependent cell lines induced 
GF-independent proliferation, in association with autocrine production of IL-3 and 
G-CSF (187-189). However, one group did note that IL-3 and GM-CSF were not 
required for the induction of a BCR-ABL-mediated CML-like disorder in mice, but 
may be required for disease maintenance (189).  Jiang et al. furthered this work by 
showing that primitive CD34+ cells, isolated from patients with CP CML, express 
aberrant RNA transcripts for IL-3 and G-CSF. This was associated with an 
autocrine production of IL-3 and G-CSF which resulted in increased STAT5 
phosphorylation and autonomous proliferation in cytokine-free cultures (190). 
Other groups have shown that normal progenitor cells die when cultured under the 
same conditions (83, 191). This evidence suggests that the autocrine GF loop is a 
further mechanism for selective CML cell proliferation and survival. 
 
1.2.6 Historical Treatment of CML 
The management of CML has changed significantly since the first treatment 
attempts with arsenic (Fowler’ solution) in 1856. Other early treatment strategies 
included benzene, radiotherapy and splenectomy which were used as palliative 
therapies and did not affect the overall survival of patients (192).   
 
In the 1950’s, the oral alkylating agent bulsulfan was introduced for the treatment 
of patients with CP CML. Bulsulfan was convenient to administer and was 
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relatively specific for the haemopoietic tissue. However, bulsulfan therapy was 
associated with severe side effects such as prolonged myelosuppression, 
idiosyncratic pulmonary reactions (“bulsulfan lung”) and BM fibrosis (193). 
 
In the 1970’s, bulsulfan therapy was largely replaced by hydroxyurea, a cell cycle-
specific inhibitor of DNA synthesis. It produces rapid but transient haematological 
control and is well tolerated with fewer adverse effects. Both bulsulfan and 
hydroxyurea produced complete haematologic responses in 50 to 80% of treated 
patients with CML and these responses could be maintained for several years. 
However, cytogenetic responses were rare and most patients progressed to the 
BC stage (194). Although these agents did provide some clinical benefit for 
patients with CML they did not significantly alter the natural history of the disease. 
 
Allogeneic stem cell transplantation (alloSCT) was introduced in the 1980’s, which 
for the first time, offered a curative potential for younger CML patients (<50-55 
years of age) with HLA-matched donors (195). Indeed, the complete elimination of 
the malignant clone in CML, defined by inability to detect BCR-ABL transcripts by 
qRT-PCR, is only possible with alloSCT (196). However, this procedure has a 
significant morbidity and mortality rate of between 20-40%, due to the associated 
graft-versus-host disease and frequent infections (58). Further, the majority of 
patients are not eligible for this therapy, due to age, the lack of a suitable donor 
and the associated high risk of mortality (197). 
 
The early 1980’s also saw the introduction of IFNα and began a new era for the 
treatment of CML. IFNα is given by subcutaneous injection and provides a 
significant survival advantage when compared to bulsulfan or hydroxyurea 
treatment (198). It is effective in reducing the leukocyte count and reversing the 
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clinical and laboratory features of CML. Additionally, it was observed that 5-15% of 
IFNα-treated patients achieved a significant reduction in Ph+ metaphases (199). 
Combination with cytosine arabinoside (AraC) further improved response rates, 
with the induction of a complete haematological response (CHR) of 66% and 
major cytogenetic response (MCR) of 41% with a survival rate of 85.7% within 
three years (200). Cytogenetic response is an important prognostic factor for 
improved survival. Definitions of response are given in Table 1-4. These early 
studies with IFNα demonstrated that cytogenetic responses could be achieved 
using drug treatment. Therefore, this became the overall therapeutic target for 
patients with CML 
 
 
Haematological 
response 
 
Cytogenetic 
response¥ 
Molecular 
response† 
Complete* 
Plt <450x109/L 
WC <10x109/L 
normal differential 
spleen not palpable 
Complete Ph+ 0% 
Partial Ph+ 1-35% 
Minor Ph+ 36-65% 
Minimal Ph+ 66-95% 
None Ph+ >95% 
Complete 
Undetectable 
Major <0.10% 
 
Table 1-4 CML disease response definitions 
[ *Plt- Peripheral blood platelet count, WC- white cell count with normal 
differential implying a lack of immature granulocytes and <5% basophils. 
¥Ph+ as % of total metaphases (at least 20) examined in the BM. †BCR-ABL 
to control gene ratio. Undetectable levels depend on the sensitivity of assay. 
A major response may also be defined as a 3 log reduction from baseline. 
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1.2.6.1 The development of an ABL TKI 
Studies investigating the structure of BCR-ABL and its importance in the malignant 
transformation of HSCs in CML provided the rationale for targeting BCR-ABL 
function therapeutically. This led to one of the most important advances in CML 
therapy to date - the development of imatinib mesylate (IM). 
 
In the early 1990’s, Anafi et al. first reported that the tyrphostins, AG568 and 
AG112 inhibited the TK activity of BCR-ABL in a BC-derived CML cell line, K562 
(201). Tyrphostins have competitive activity towards ATP and/or substrate. 
However, despite showing effective activity in vitro, these compounds were not 
developed for clinical use. A further early compound which demonstrated activity 
towards BCR-ABL was the benzoquinonoid ansamycin antibiotic, herbimycin A. 
Herbimycin A was shown to inhibit the growth of a number of p210BCR-ABL 
transformed cells, without affecting the growth of Ph- haemopoietic cell lines (202) 
and also prolonged the survival in a SCID mouse model of a disease akin to 
human Ph+ ALL (203). It was originally thought that herbimycin A inhibited the 
BCR-ABL kinase, however, it was later shown to promote the degradation of BCR-
ABL protein (204). Taken together, the data from investigations using these early 
compounds suggested that the development of a specific inhibitor towards BCR-
ABL would be an effective therapeutic agent in CML and other Ph+ leukaemias. 
 
1.2.7 The development of IM  
Scientists at Ciba Geigy (now Novartis) led the early development of IM by 
initiating a screen of a large number of ATP-competitive 2-phenylaminopyrimidine 
compounds for protein TK inhibitory activity. STI 571 (formerly CGP 57148B, now 
IM; GlivecTM or GleevecTM, Novartis Pharmaceuticals, Basel, Switzerland) 
emerged from the screen as the lead TKI for preclinical development (Figure 1-9).  
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Figure 1-9 Structure of IM 
 
IM was found to have potent inhibitory activity towards ABL, c-Kit and platelet-
derived GF receptor (PDGF-R). It exerts effect on BCR-ABL by competitive 
inhibition of ATP. It selectively binds to the NH2-terminal anchor region of the 
ATP-binding pocket or “activation loop” thereby preventing BCR-ABL 
autophosphorylation, TK activity and subsequent phosphorylation of downstream 
target substrates (205) (Figure 1-10). The activation loop controls the catalytic 
activity of the kinase by switching between the active and inactive states. 
Crystallographic studies show that IM binds to the ATP site only when the 
activation loop is closed, thereby stabilizing the inactive state and thus, preventing 
the conformational change to the active form of the oncoprotein (206). 
IM was found to inhibit ABL-kinase activity with 50% inhibitory concentration (IC50) 
values ranging between 0.1 and 0.35µM using in vitro kinase assays, in a range of 
cell lines expressing constitutively active ABL, such as viral ABL (v-ABL) (207), 
p210BCR-ABL (205), p185BCR-ABL (208, 209) and translocated ets leukaemia (TEL)-
ABL (208). Activity against the PDGFR and Kit were found to be in a similar range. 
Conversely, the IC50 values were at least 100-fold higher for a large number of 
other tyrosine and serine/threonine kinases, indicating that IM functions with a 
high level of selectivity (210). 
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Figure 1-10 Mechanism of action of IM 
BCR-ABL requires ATP binding for phosphorylation of substrates and 
subsequent activation of downstream pathways that promote cell survival, 
proliferation and regulation. IM can compete with ATP, binding to the 
inactive state of BCR-ABL, preventing the phosphorylation of substrates 
that would activate intracellular signals. 
 
In initial cellular studies, IM was shown to specifically inhibit the proliferation of 
myeloid cell lines expressing BCR-ABL or CML BC cell lines in vitro (205, 211, 
212). The inhibition of proliferation with cell death through apoptotic mechanisms 
was demonstrated to occur between 0.5 and 1µM of IM, whereas concentrations 
of up to 10µM IM did not affect the growth of BCR-ABL- cell lines (205, 211). 
Additional experiments showed that IM was equally potent in p185- and p210-
expressing cells (208, 209). Colony-formation assays were also performed, using 
mononuclear cells (MNC)s from CML patients and normal individuals, to assess 
the effects of IM on committed haemopoietic progenitors. In these studies, IM 
induced a 92-98% decrease in the number of BCR-ABL+ colonies formed with no 
or minimal inhibition of normal colony formation at concentrations up to 1µM (205, 
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211). These findings were then confirmed in stroma-dependent long-term cultures 
(213, 214). 
 
Animal studies demonstrated a dose-dependent inhibition of tumour growth in 
animals inoculated with BCR-ABL-transformed 32D cells and treated daily with IM, 
with inactivity against v-SRC-expressing tumours. However, using a once-per-day 
injection schedule of up to 50mg/kg, tumour growth was inhibited, but not 
eradicated (205). This modest in vivo activity could be explained by the murine 
pharmacokinetic profile of IM. It revealed a short drug half-life in mice, where a 
single dose of IM inhibited BCR-ABL kinase activity for only 2 to 5 hours. This was 
not seen in any other species - ie. rat, dog or human. In nude mice, a 3-times daily 
administration of IM resulted in continuous inhibition of BCR-ABL kinase activity. 
This led to an eradication of tumours in 87% of IM-treated mice (215). From this 
data, it was suggested that IM was able to target some, but not all leukaemic 
clones and therefore, it was likely that continuous exposure to IM would be 
required for optimal therapeutic effects. 
 
1.2.7.1 IM and Phase I Clinical Trials 
Phase I studies with IM began in June 1998 and were designed to establish the 
maximum tolerated dose. The study consisted of patients with CP CML who were 
refractory or resistant to therapy with IFNα (216). IM was given as a once daily 
oral therapy and was well tolerated. Side effects were generally mild and included 
occasional nausea, periorbital oedema, and muscle cramps. 98% of CP CML 
patients, who had failed IFNα therapy and were treated with IM at 300mg and 
above, achieved a CHR. Furthermore, only one of these patients had relapsed at 
one-year of follow-up. Pharmacokinetic studies showed that with a dose of 300mg, 
plasma levels of IM were equivalent to the effective in vitro concentration of 1µM. 
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Using the current standard dose for CP CML of 400mg IM, a peak plasma level of 
approximately 4.6µM and trough level of approximately 2.13µM could be 
achieved, with a half-life of 19.3 hours. These data indicated that the once-daily 
dosing schedule would be sufficient to cause continuous kinase inhibition.  
Following these promising results, the initial study was expanded to include 
patients with myeloid or lymphoid BC CML and relapsed or refractory Ph+ ALL 
patients (217). With doses at or exceeding 300mg per day, 21 of 38 (55%) myeloid 
BC patients responded, with 11% achieveing a CHR. In patients with lymphoid BC 
or ALL, 70% responded, including 20% who had complete responses. However, 
all but one patient with lymphoid BC or ALL had relapsed within weeks to months. 
 
1.2.7.2 IM and Phase II Clinical Trials 
The successful data from the Phase I trial led to the commencement of Phase II 
studies, which began in late 1999 using IM as a single agent for all stages of CML. 
In CP patients who had failed IFNα therapy, 95% achieved a CHR and 60% a 
MCR, which was defined as a reduction to less than 35% Ph+ metaphases. Only 
13% of these patients had relapsed at the median follow-up of 29 months (218). 
However, although the response rates in AP and BC CML patients were also quite 
high, the relapses were much more common, with the majority of BC patients 
relapsing during the first year of therapy (219, 220). Overall, these clinical trials 
confirmed the promising results of the phase I studies. This led to Food and Drug 
Administration (FDA) approval of IM for the treatment of CML in advanced phase 
and after failure of IFNα therapy. 
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1.2.7.3 IM and Phase III Clinical Trials - A Randomised Comparison of IM with 
IFNα Plus Ara-C 
The next clinical trial was a phase III study of newly diagnosed CP CML patients 
which compared IM treatment with the standard therapy of IFNα plus Ara-C. This 
was named the International Randomized Study of Interferon and STI571 (IRIS) 
study and was initiated in June 2000. The trial managed to reach its goal of 
recruiting more than 1000 patients in a 7-month period (221). At the median 
follow-up of 18 months, patients who had been randomised to IM therapy 
responded significantly better than the patients treated with IFNα plus Ara-C in all 
measured parameters, as shown in Table 1-5.  
 
 IM (% responding at 
400mg/day) (n=553) 
IFNα plus Ara-C 
(n=553) 
CHR 97 69 
MCR 87 35 
CCR 76 14 
Intolerence 3 31 
Progressive disease 3 8.5 
 
Table 1-5 Phase III results of IM versus IFNα plus Ara-C for newly diagnosed 
CP patients with CML - taken from (221). 
Results are with a median follow-up of 18 months. [CHR- complete 
hematologic response; MCR- major cytogenetic response; CCR- complete 
cytogenetic response; intolerance leading to discontinuation of first-line 
therapy; progressive disease, progressing to AP or BC. All of these 
differences are highly significant, with p < 0.001.] 
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The apparent superiority of IM treatment, led to the results being disclosed early 
and most of the patients were crossed over into the IM arm.   
 
Five year follow-up studies have shown more impressive results for IM. In the 
most recent update of the IRIS study, the estimated overall survival for newly 
diagnosed CP CML patients, who received IM as an initial therapy was 89%. The 
best observed rate of CHR (normal white count and loss of symptoms) was 97% 
and the CCR (no Ph+ metaphases) rate was 87%. Furthermore, an estimated 93% 
of IM-treated patients remained free from disease progression to AP or BC phase 
CML (222). 
 
1.2.8 Molecular persistence 
The monitoring of residual disease in CML patients is generally performed by  
qRT-PCR for BCR-ABL. It was observed that in the Phase III trial, for complete 
cytogenetic responders, the risk of disease progression was inversely correlated 
with the reduction of BCR-ABL transcripts as compared with pre-treatment levels 
(223). However, despite the fact that the majority of patients randomised to the IM 
arm achieved a CCR, most of these patients still had detectable leukaemia. Only a 
small proportion (4%) of patients obtained a complete molecular response (CMR), 
where they became negative for BCR-ABL transcripts by qRT-PCR. Therefore, for 
the majority of IM-treated patients, there is persistence of the leukaemic clone and 
most have relapsed if treatment was discontinued. It is hypothesised that this 
minimal residual disease (MRD) is a result of a primitive “quiescent” subpopulation 
of leukaemic cells (224), which may be the cause for relapse at a later date. 
Holyoake et al. were the first to isolate such primitive, quiescent cells - which were 
found to account for around 0.5% of the CD34+ compartment - from CML cells 
using two different approaches (224, 225). The authors first obtained viable G0 
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and G1/S/G2/M fractions by fluorescence-activated cell sorting (FACS), using Hst 
and PY staining, with quiescence being confirmed by the subsequent analysis of 
Ki67 and cyclin D expression. In GF-supplemented serum-free cultures, this non-
proliferating population could also be isolated by first labelling CD34+ CML 
progenitor cells with carboxyfluorescein diacetate succinimidyl ester (CFSE), in 
order to track cell division at high resolution by FACS. The group found that these 
quiescent cells were Ph+ and expressed high levels of CD34, but lacked 
expression of lineage markers, CD38, CD45RA or CD71.  They also had in vitro 
progenitor activity as demonstrated by colony-forming cell (CFC) and long-term 
culture-initiating cell (LTC-IC) assays and were capable of engrafting NOD/SCID 
mice (224). Significantly, these studies also demonstrated that quiescence is a 
temporary phenomenon, whereby the G0 cells can re-enter the cell cycle, via a 
mechanism associated with the upregulation of IL-3 expression (225). Therefore, 
the existence of a transiently quiescent leukaemic clone may account for the fact 
that IM is unable to completely eradicate CML and also provides a feasible 
explanation for patients often relapsing at a later date.  
 
In vitro studies have also demonstrated that these BCR-ABL+ quiescent cells 
appear to be inherently resistant to IM therapy, at concentrations up to 10 times 
higher than those achievable in vivo, whereas the more mature, proliferating cells 
remain sensitive (226, 227). Bhatia and colleagues also found that CD34+ cells 
taken from IM-treated patients, who had achieved CCR, were able to form 
colonies in both CFC and LTC-IC assays (228). Jorgensen et al. identified a 
second subset of primitive cells within a total CML cell population. These cells 
were found to undergo cell cycle arrest and accumulate in the G0/G1 phase in the 
presence of anti-proliferative agents, including IM (229). It was also demonstrated 
that these cells could be encouraged into cell cycle with sequential pulsed therapy. 
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Overall, these data suggest that IM is able to control the disease, through 
inhibition of stem cell proliferation, but is unable to eliminate the quiescent 
malignant clone. This has also since been postulated by a mathematical model 
which has demonstrated that during IM treatment, the clearance of BCR-ABL 
transcripts follows a biphasic decline. The initial phase is characterised by a rapid 
clearance of transcripts, whereas the second phase shows a slower rate of 
clearance. This model predicts that this biphasic decline is likely due to the 
differential susceptibility of a total CML population to IM treatment. The more 
mature differentiated cells are readily cleared by the drug, whereas the G0 CML 
cells escape IM-induced apoptosis, simply by virtue of their quiescent state (230).  
 
1.2.9 Molecular resistance 
Another major clinical concern is the observation of molecular resistance in IM-
treated patients. This is generally observed in CML patients at the advanced stage 
of disease, with an estimated 4-year resistance rate of 20% in later CP and 70% to 
90% in AP/BC phases (220, 222), although, it has also been seen in CP CML 
patients. IM resistance can be described either as primary (“refractoriness”), 
defined as a failure to achieve CHR at 3 months, a cytogenetic response at 6 
months or a MCR at 12 months; or secondary (“acquired”), defined as loss of 
established IM response or progression to AP or BC (231). It has also been 
speculated that there are 2 broad categories of IM resistance: BCR-ABL-
independent and BCR-ABL-dependent.  
 
1.2.9.1 BCR-ABL-independent mechanisms of resistance 
BCR-ABL-independence suggests that the leukaemia cells are no longer reliant on 
BCR-ABL to drive proliferation; but have acquired additional oncogenic mutations 
and mechanisms, which are responsible for their growth and survival. Donato et 
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al. demonstrated that compensatory SRC activation within a CML cell may play a 
role in CML progression to BP and BCR-ABL independent IM resistance (232, 
233). It was found that patients who have progressed whilst being treated with IM 
had an elevated SRC kinase activity, while the BCR-ABL transcripts and protein 
were reduced. Furthermore, it has also been shown that the SRC family kinase 
(SFK), LYN, is persistently activated in patients who have failed IM therapy and 
who harbour no BCR-ABL mutations (234). These data have led to the 
development of new agents that target the SRC kinase and inhibit other non-ATP 
binding sites (to be discussed further later). The induction of autocrine GF 
secretion is another potential mechanism for IM resistance. Adaptive autocrine 
secretion of GM-CSF was shown to mediate BCR-ABL-independent TKI 
resistance via activation of the anti-apoptotic JAK2-STAT5 pathway. This GM-
CSF-induced resistance could then be overcome by the inhibition of JAK2 (235). A 
further possibility is that IM resistant cells are inherently refractory to TKI treatment 
and resistance reflects intrinsic properties of CML stem cells, to sustain survival in 
the presence of drug treatment. Thus, BCR-ABL is no longer a relevant target for 
IM in these cells and any specific BCR-ABL inhibitor would be ineffective in this 
situation.  
 
1.2.9.2 BCR-ABL-dependent mechanisms of resistance 
Conversely, resistance in Ph+ leukaemias may be dependent on BCR-ABL. 
Proposed mechanisms of resistance include BCR-ABL amplification- where 
multiple copies of BCR-ABL gene can be detected in the interphase nuclei in 
patients who relapse after initially responding to IM, resulting in overexpression of 
the BCR-ABL oncoprotein (236-238). However, BCR-ABL dependent IM 
resistance is most often attributed to the development of point mutations within the 
ABL-kinase domain, which are found in more than 50% patients with acquired 
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resistance (132, 238-240). In 2001, Gorre and colleagues described the 
development of BCR-ABL mutations in 11 patients with BC phase CML or Ph+ ALL 
who relapsed on IM therapy (238). BCR-ABL gene amplification was only detected 
in three patients. Following sequencing of the ATP-binding pocket and the 
activation loop of the kinase domain, an identical cytosine to thymidine mutation at 
ABL nucleotide 944 in 6 of 9 assessable patients was identified. This mutation 
resulted in a single amino-acid change at position 315, is designated T315I. 
Threonine 315 (also known as the “gatekeeper” residue) is located at the binding 
site of ABL and forms a crucial hydrogen bond interaction with IM (241). The 
T315I mutation disrupts this bond interaction which, along with the bulkier 
isoleucine side chain, sterically inhibits IM binding. This results in complete 
insensitivity to IM therapy at clinically achievable doses (238). The T315I mutant 
remains the most clinically significant as it linked to poor prognosis in CML 
patients (242). To date, more than 100 kinase domain mutations have been 
described in vivo and from in vitro screens (240, 241, 243, 244), each conferring a 
different transforming potential and level of resistance relative to wild-type BCR-
ABL. These include mutations within the ATP binding site (P-loop), activation loop 
(A-loop) or the caboxy terminus. Some mutations only confer a moderate degree 
of resistance; however, the mutations within the P-loop are often associated with a 
poorer outcome (239). This is probably due to the restriction of IM-binding due to 
mutations altering and destabilising the conformation of the ATP-binding site 
(240). However, it is also worth noting that the presence of BCR-ABL mutations 
does not always explain resistance in IM-treated patients (245).  
 
It has been noted that the concentration of drug within a target cell is a further 
important treatment consideration; therefore, the active efflux of chemotherapeutic 
drugs from target cells could be a mechanism of drug resistance. The ABC 
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transporter (ABCB1 (or MDR-1)) is a cell-surface transmembrane protein that 
mediates multi-drug resistance in a variety of malignancies through the regulation 
of chemotherapeutic agent efflux. Cells from BC CML patients have demonstrated 
a higher expression of ABCB1 compared with those from CP patients and has 
been linked to the development of IM resistance (237). Several groups have also 
shown that IM is a substrate for ABCB1 (246, 247). However, the role of ABCB1 in 
CML remains unclear as in vitro studies have shown that overexpression of 
ABCB1 in K562 cells does not confer resistance to IM (248). Furthermore, 
inhibition of ABCB1 did not enhance the therapeutic effect of IM against BCR-ABL 
activity in primitive CML cells (249). Another related ABC transporter, ABCG2, is 
also present on HSCs and has been suggested as another candidate for 
regulating intracellular IM availability. However, Jordanides and colleagues 
demonstrated that IM is an inhibitor of, but not a substrate for ABCG2 and 
therefore does not modulate the intracellular IM concentrations within CML stem 
cells (250).  
 
1.2.10 Second generation TKIs  
In an attempt to overcome IM-resistance, a second generation of BCR-ABL 
inhibitors have been developed. These include the ATP-competitive compounds, 
nilotinib, bosutinib and dasatinib. 
 
1.2.10.1 Nilotinib (AMN107, TasignaTM) 
Nilotinib (Tasigna™; AMN107, Novartis, Basel, Switzerland) is an orally 
administered second-generation TKI which inhibits ABL-kinase, PDGFR, Kit and 
ephrin receptor kinase and is currently approved by the FDA for the treatment of 
CP CML or AP CML (Figure 1-11). Nilotinib is an analogue of IM, which disrupts 
the ATP-phosphate-binding pocket, binding exclusively to the inactive 
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conformation of the ABL-kinase domain. Nilotinib has additional alterations in its 
structure that allow higher binding affinity and in IM-sensitive cell lines, 
demonstrates 43- to 60-fold greater potency than IM. In IM-resistant cell lines, 
nilotinib demonstrates at least 20-fold more potency than IM. Indeed, nilotinib 
inhibited 32 of 33 IM-resistant mutant cell lines in vitro, except for cells containing 
the T315I mutation (251, 252), and also prolonged survival in mice injected with 
cells expressing both wild-type and IM-resistant BCR-ABL mutants (253). 
                     
                                 
Figure 1-11 Structure of nilotinib 
 
Phase I studies determined the appropriate dosing of nilotinib and established its 
clinical safety and efficacy in patients with CML or Ph+ B-ALL who were resistant 
or intolerant to IM. Promising response rates were observed in patients with CP 
disease, with a CHR achieved in 92% (11 of 12). Responses in advanced stage 
disease were lower, with 72 (33 of 46) and 48% (22 of 46) of patients with AP 
disease achieving haematological and cytogenetic responses, respectively. 
Among patients with BP disease, 39% (13 of 33) achieved a haematological 
response and 27% (9 of 33) achieved a cytogenetic response (254). 
Subsequent clinical evaluation has since confirmed the safety and efficacy of 
nilotinib treatment. In Phase II studies, IM-resistant or -intolerant CP CML patients, 
who were treated with 400 mg nilotinib twice daily, demonstrated MCR and CCR 
rates of 48 and 31% at 6 months, respectively. The estimated overall survival rate 
at 12 months was 95% (255). Within the group of patients whose baseline BCR-
ABL mutation status was available, IM-resistant patients with no BCR-ABL 
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mutations showed similar MCR rates as patients with mutated BCR-ABL - 51 
versus 42%, respectively. Furthermore, consistent with the in vitro data, 4 out of 4 
patients with the T315I mutation showed no response to IM treatment (255). 
Further in vitro studies have shown that nilotinib has anti-proliferative effects on 
CD34+ CML cells, but does not eradicate the most primitive cells within the stem 
cell compartment (256). Therefore, whether nilotinib like IM, contributes to the 
disease persistence phenomenon still remains to be seen. 
 
SFKs comprise of nine structurally homologous cytoplasmic non-receptor TKs 
(SRC, FYN, YES, BLK, YRK, FGR, HCK, LCK and LYN) which regulate signalling 
pathways involved in cell growth, differentiation and survival (257). As stated 
previously, studies have shown that the overexpression of SFK, such as LYN, 
plays a role in the proliferation and survival of CML cells, and in some cases, IM 
resistance (233). Further, experiments with SRC-dominant-negative mutants 
suggest that SFKs are involved in the proliferation of BCR-ABL+ cell lines 
(258),(259). Therefore, the simultaneous inhibition of BCR-ABL and SRC kinase 
makes a further attractive option for CML therapy. 
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1.2.10.2 Bosutinib (SKI-606) 
Bosutinib (SKI-606, Wyeth, Madison, NJ) is an orally available 4-anilino-3-
quinolinecarbonitrile derivative (Figure 1-12) that is a potent dual inhibitor of the 
SF and ABL TK activity with an IC50 of 1.2 and 1nM, respectively.  
 
                     
 Figure 1-12 Structure of bosutinib 
 
Bosutinib showed in vitro activity against all IM-resistant mutants, except T315I, 
and caused regression of large K562 xenografts in nude mice (260). Unlike both 
IM and nilotinib, bosutinib does not significantly inhibit PDGFR and Kit activity, 
which may result in a safer toxicity profile in vivo. Indeed, bosutinib demonstrated 
favourable toleribility in Phase I and II trials with patients who are resistant or 
intolerant to IM. Responses up to CCR were achieved in patients who harboured 
various BCR-ABL mutants, however, no patient with the T315I mutation 
responded (261). Recent in vitro studies suggest that bosutinib does not 
demonstrate increased ability to eliminate primitive CML progenitors by apoptosis, 
as compared to IM (262), however due to its toleribility; bosutinib may be a good 
option for patients who have failed therapy with IM or any other second generation 
TKI. 
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1.2.10.3 Dasatinib (BMS-354825; Sprycel®) 
Dasatinib (BMS-354825; Sprycel, Bristol-Myers Squibb, Princeton, NJ) is a 
second-generation TKI for the treatment of IM-resistant or -intolerant patients with 
Ph+ leukaemias, that was approved by the FDA in 2006 (263) (Figure 1-13). 
                   
                  Figure 1-13 Structure of dasatinib 
 
Like bosutinib, dasatinib is also a potent oral inhibitor of SFKs and BCR-ABL, and 
has added activity against Kit, PDGFR and Ephrin receptor TKs (264). Dasatinib 
has a 325-fold greater potency than IM against cells expressing wild-type BCR-
ABL, with an IC50 of less than 1nM, and is effective against all IM-resistant BCR-
ABL mutants tested in vitro, except T315I (252). Dasatinib binds to the ATP-
binding site in a similar position to IM, but is also able to bind both the active and 
inactive conformation of ABL-kinase (265). This less stringent conformation 
requirement for ABL-kinase inhibition may be a further way of overcoming IM 
resistance.  
 
The clinical efficacy of dasatinib was demonstrated in a series of Phase II studies 
called the SRC/ABL Tyrosine Kinase Inhibition Activity Research Trials (START). 
The START-C trial was a Phase II multicentre study for the assessment of 
dasatinib treatment of patients with CP CML who were resistant or intolerant to IM 
(266). At the median follow-up of 24 months, data was available from 387 patients 
(288 IM-resistant and 99 IM-intolerant). In 91% of the patients, a CHR was 
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achieved, with 62% obtaining a MCR. Responses were observed across all BCR-
ABL mutations, irrespective of the location (with the exception of T315I), thus 
demonstrating that dasatinib has activity across the subgroups, including those 
patients with P-loop mutations (266). At the 24-month follow-up, progression-free 
and survival rates were determined as 80 and 94%, respectively. Impressive 
responses have even been noted in myeloid and lymphoid BC CML with a CCR 
rate of more than 20% (267, 268). However, despite these promising in vivo 
results, recent in vitro data showed that although dasatinib demonstrated 
increased efficacy over IM against earlier progenitor populations, it did not target 
the quiescent stem cell population (131). Therefore, dasatinib treatment alone may 
not have the ability to completely eradicate the disease. 
 
1.2.11 Oncogene Addiction 
The term ‘oncogene addiction’ was first coined by IB Weinstein (269-271) to 
describe the phenomenon by which some cancers acquire dependency on one or 
a few genes for the maintenance of the malignant phenotype and cell survival. 
Evidence for this concept has now been obtained from a number of systems such 
as, transgenic mice, where switching off the overexpressed “dependent” oncogene 
leads to growth inhibition, apoptosis and/or tumour regression. The dependence 
on a single oncogene for survival has been observed in murine models for a 
number of different cancers including, lung tumours induced by the K-ras 
oncogene (272), melanoma induced by the H-ras oncogene (273), T-cell and AML 
induced by c-myc (274) and acute B-cell leukaemia induced by BCR-ABL (275). 
Similarly, mechanistic studies using human cancer cell lines have also illustrated 
the oncogene addiction phenomenon. The inhibition of HER2 (276), cyclin D1 
(277), K-ras (278) and β-catenin (279) expression using antisense DNA or RNA 
interference systems attenuated the growth various human cancer cell lines. The 
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most convincing evidence for the apparent dependency on oncogenes for tumour 
cell survival comes from examples of patients treated with molecularly-targeted 
drugs. The targeting of BCR-ABL by TKI has shown remarkable therapeutic 
efficacy.  TKI treatment has been demonstrated to efficiently kill a subset of cells 
expressing the oncogene, particularly in early CP CML (223).  However, despite 
the impressive clearance of the majority of Ph+ cells by IM and dasatinib, the 
primitive CD34+38- cell population does not appear to undergo apoptosis even 
after several days TKI exposure (131). Therefore, it is still not clear whether early 
CML progenitor cells depend on BCR-ABL for their survival. 
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2. MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Small molecule inhibitors 
IM was provided as a white powder under a Materials Transfer Agreement from 
Novartis Pharma (Basel, Switzerland). It was dissolved in sterile H2O and stored 
as a 100mM stock solution at 4°C. Dasatinib was pro vided as a white powder 
under a Materials Transfer Agreement from Bristol-Myers Squibb (Princeton, NJ, 
USA). It was dissolved in dimethyl sulfoxide (DMSO) to give a stock concentration 
of 20mM and stored in multiple aliquots at -20°C pr ior to use. All small molecule 
inhibitors were made up fresh and diluted to the appropriate concentration with 
PBS prior to use.   
 
 
2.1.2 Tissue culture supplies (including CD34+ selection) 
Abbot Diagnostics 
Maidenhead, UK LS1 BCR-ABL Dual Colour FISH probe 
Baxter Healthcare 
Nottingham, UK Sterile water 
Becton Dickinson 
Plymouth, UK Luer lock syringes 
Bio-Rad 
Hercules, CA, USA Triton-X-100 
Chugai Pharma 
London, UK Recombinant human G-CSF 
Greiner bio one 
Gloucestershire, UK 
25 and 75cm3 tissue culture flasks 
96-well plates 
FACS tubes 
Pipette tips 
Hendley 
Essex, UK Multispot microscope slides 
Invitrogen 
Paisley, UK 
2-Mercaptoethanol 
Colcemid 
Foetal calf serum (FCS) 
L-glutamine 200mM (100x) 
Phosphate buffered saline (PBS) 
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Penicillin-streptomycin solution 
(5000U/mL) 
RPMI 1640 medium 
Miltenyi Biotec 
Bisley, UK 
CliniMACS CD34 reagent 
CliniMACS PBS/EDTA buffer 
CliniMACS tubing set 
Nalge Nunc International 
Roskilde, Denmark 
35mm non-adherent tissue culture 
dishes 
75cm3 non-adherent tissue culture 
flasks 
Cryotubes 
Cryofreezer container 
Vacubottles 
Sartorius 
Hannover, Germany 
Minisart 0.2µM sterile filters 
Minisart 0.45µM sterile filters 
Scottish National Blood 
Transfusion Service 
Glasgow, UK 
20% human albumin solution (ALBA) 
4.5% ALBA 
Sigma-Aldrich 
Dorset, UK 
Bovine serum albumin (BSA) 
Carbonate-bicarbonate buffer 
DMSO 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
E-64d protease inhibitor (1mg/mL) 
Ficoll/histopaque solution (1.077g/mL) 
G418 disulphite salt solution 
Hank’s buffered salt solution – calcium 
and magnesium free (HBSS-CMF) 
Hydrochloric acid (HCl) 
Hygromycin B 
Isocove’s Modified Dulbecco’s Medium 
(IMDM) 
Magnesium chloride (MgCl2) 
Pepstatin A protease inhibitor (1mg/mL) 
Poly-L-lysine 
Potassium chloride (KCl) 
Sodium azide 
Trisodium citrate 
Trypan blue 
Trypsin-EDTA 
Stem Cell Technologies 
British Columbia, Canada 
Bovine pancreatic deoxyribonuclease 
(DNAse I) 1mg/mL 
Bovine serum albumin/insulin 
/transferrin (BIT) serum substitute 
Flt-3 ligand 
Hydrocortisone 21-hemisuccinate 
IL-3 
IL-6 
MethocultTM 
MyelocultTM 
Stem cell factor (SCF) 
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Sterlin Ltd 
Hounslow, UK 
Iwaki Type I Collagen-coated 6-well 
plates 
Pastettes 
5mL, 10mL and 25mL disposable 
pipettes 
15 and 50mL sterile plastic falcon tubes 
90mm Petri dishes 
Thermo Fisher Scientific 
Loughborough, UK 
Immulon II HB 96-well flat bottomed 
plates 
Acetic acid 
Methanol 
Weber Scientific International, 
West Sussex, UK Hawksley Neubauer counting chamber 
 
 
2.1.3 Flow cytometry reagents 
BD Biosciences, 
Oxford, UK 
Anti-human IgG FITC isotype control 
Anti-human IgG PE isotype control 
Anti-human IgG APC isotype control 
FACS flow 
FACS clean 
Mouse anti-human-active caspase-3-PE 
antibody  
Mouse anti-human-Ki67-FITC antibody  
Mouse anti-human-annexin-V-FITC 
antibody 
Mouse anti-human-CD34-APC 
Mouse anti-human-CD38-FITC 
Viaprobe- 7 aminoactinomycin D  
(7-AAD) 
Caltag Laboratories 
Silverstone, UK Fix and Perm
®
 A and B 
Cell Signaling 
(New England Biolabs),  
Hitchin, UK 
 
Rabbit anti-human-p-CrkL antibody  
Rabbit anti-human-p-STAT5 antibody 
 
Molecular probes 
Eugene, OR, USA CFSE 
Sigma-Aldrich 
Dorset, UK 
Anti-rabbit IgG-FITC conjugate 
Anti-rabbit IgG-PE conjugate 
Formaldehyde solution 
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2.1.4  Molecular biology supplies 
Abcam, Cambridge, UK Anti-rabbit IgG 
Amersham Pharmacia Biotech Ltd 
Buckinghamshire, UK 
 
Rainbow  marker (RPN756) 
 
Applied Biosystems, 
Foster City, CA, USA 
High capacity cDNA archive kit 
Taqman gene expression assays- cyclin 
D1 and glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) 
qPCR mastermix plus 
Bio-Rad 
Hercules, CA, USA 
 
4-15% Tris-HCl gradient gels 
Laemmli sample buffer 
Immun-star ECL reagents 
Nitrocellulose membrane 
Tris/Glycine/SDS running buffer 
Tris/Glycine transfer buffer 
Tween-20 
Triton-X-100 
Cell Signaling  
(New England Biolabs), 
Hitchin, UK  
Anti-rabbit IgG horseradish peroxidase 
(HRP)-linked secondary antibody 
Rabbit anti-human-p-CrkL antibody  
Rabbit anti-human-LC3b antibody  
Rabbit anti-human-GAPDH antibody 
Rabbit anti-human-p-S6K antibody  
Rabbit anti-human-FoxO3a antibody  
Chemicon International 
Temecula, CA, USA 
Re-blot™ Plus Strong Antibody 
Stripping Solution 
Eurogentec Ltd 
Southampton, UK 
BCR-ABL p210 detection: 
ENF501 (FORWARD PRIMER): 
TCCGCTGACCATCAAYAAGGA 
ENF561 (REVERSE PRIMER): 
CACTCAGACCCTGAGGCTCAA 
ENP541 (PROBE): 
FAM-
CCCTTCAGCGGCCAGTAGCATCTGA-
TAMRA 
Fisher Scientific 
Loughborough, UK Methanol 
Invitrogen (Molecular Probes) 
Paisley, UK Anti-rabbit-Alexa Fluor 488 
Perbio 
Northumberland, UK BCA kit 
Qiagen, 
Crawley, UK RNeasy mini kit  
Roche, 
Burgess Hill, UK PCR grade water 
Sigma-Aldrich 
Dorset, UK 
Ethylenediaminetetraacetic acid (EDTA) 
Ficoll/histopaque solution  
36.5% Formaldehyde solution 
NP-40 
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Protease inhibitor cocktail 
Sodium chloride 
Tris (hydroxymethyl)aminomethane 
hydrochloride (Tris-HCl) 
Tris base 
Osmium tetroxide 
Uranyl acetate 
25% gluteraldehyde solution 
Sodium cacodylate 
SPI Supplies 
Loughborough, UK 300-mesh formvar-coated grids 
Taab Laboratories Equipment Ltd, 
Aldermaston, UK Taab epoxy resin 
Upstate (Millipore) 
Watford, UK Anti-phosphotyrosine (4G10) antibody 
Vector Laboratories Inc 
Burlingame, CA, USA 
VECTASHIELD® mounting medium with 
DAPI 
 
 
2.2 Preparation of media and solutions 
2.2.1 Tissue culture media 
2.2.1.1 RPMI++  
RPMI 1640 500mL 
FCS 50mL  
L-glutamine 5mL 
Penicillin/Streptomycin solution 5mL 
 
 
 
2.2.1.2 Serum free medium (SFM)  
 
BIT 25mL 
2-Mercaptoethanol 250µL  
L-glutamine 1.25mL 
Penicillin/Streptomycin solution 1.25mL 
IMDM 97.25mL 
 
• Made up in a Vacubottle and filter sterilised 
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2.2.1.3 SFM supplemented with GF cocktail (SFM+5GF) 
 
SFM 50mL 
IL-3 (50µg/mL) 20µL  
IL-6 (50µg/mL) 20µL 
G-CSF (50µg/mL) 20µL 
Flt-3 ligand (50µg/mL) 100µL 
SCF (50µg/mL) 100µL 
 
• Filter sterilised through 0.22µM filter 
 
 
 
2.2.1.4 RPMI for maintenance of stromal cell line M2-10B4 for LTC-IC 
 
RPMI 1640 500mL 
FCS 50mL 
L-glutamine 10mL 
Penicillin/streptomycin solution 10mL 
 
 
 
2.2.1.5 DMEM for maintenance of stromal cell line Sl/Sl for LTC-IC 
DMEM 500mL 
FCS 75mL 
L-glutamine 10mL 
Penicillin/streptomycin solution 10mL 
 
 
2.2.1.6 Myelocult 
Myelocult™ 100mL 
Hydrocortisone hemisuccinate 
(1x10-4M) 1mL 
 
 
 
2.2.2  Tissue culture solutions 
2.2.2.1 PBS/2% FCS 
 
PBS 490mL 
FCS 10mL 
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2.2.2.2 PBS/20% FCS 
 
PBS 80mL 
FCS 20mL 
 
 
 
2.2.2.3 ‘DAMP’ solution for thawing cryopreserved CD34+  
or unmanipulated cell (MNC) aliquots from -150°C 
 
DNAse II solution (1mg/mL) 1 vial 
Magnesium chloride (400x; 1M) 625µL 
Trisodium citrate (0.155M) 26.5mL 
20% ALBA 12.5mL 
PBS (magnesium/calcium free) To 250mL 
 
 
2.2.2.4 20% DMSO/4.5% ALBA 
DMSO 20mL 
4.5% ALBA 80mL 
 
 
 
2.2.2.5 IMDM/2% FCS 
 
IMDM 98mL 
FCS 2mL 
 
 
 
2.2.3  Flow cytometry solutions 
 
2.2.3.1 PBS/0.4% formaldehyde 
 
PBS 48mL 
10% formaldehyde solution 2mL 
 
 
 
2.2.3.2 PBS/0.2% Triton-X-100 
PBS 50mL 
Triton-X-100 100µL 
 
 
 
 
 
 88 
2.2.3.3 Annexin/viaprobe buffer 
 
Annexin/viaprobe buffer (10X) 1mL 
Distilled water 9mL 
 
 
 
2.2.3.4 Fix perm wash – PBS/1% BSA 
 
BSA 10g 
PBS To 1L 
 
 
2.2.4  Molecular biology solutions 
2.2.4.1 Lysis buffer for protein lysates (RIPA)  
 
dH2O 7.75mL 
1.5M NaCl 1mL 
1M Tris-HCl 0.5mL 
150mM EDTA 333µL 
NP-40 50µL 
10% (w/v) Sodium deoxycholate  250µL 
 
• Immediately prior to use, 100mL of protease  
inhibitor cocktail was added  
 
 
 
2.2.4.2 Running buffer 
 
10x TGS buffer 100mL 
PBS 900mL 
 
 
 
2.2.4.3 Transfer buffer 
 
10x TG buffer 100mL 
PBS 700mL 
Methanol 200mL 
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2.2.4.4 Tris-buffered saline (TBS) (1x) 
 
Sodium chloride 8g 
Potassium chloride 0.2g 
Tris base 3g 
dH2O To 1L 
 
• Adjusted to pH 7.4 with 1M HCl 
 
 
 
2.2.4.5 Wash buffer (TBS-Tween; TBS-T) 
TBS 1000mL 
Tween 100µL 
 
 
 
2.2.4.6 Blocking buffer  
TBS 100mL 
BSA 5g 
 
 
 
2.2.4.7 3.65% Formaldehyde (Immunofluorescence) 
PBS 10mL 
36.5% Formaldehyde solution 1mL 
 
 
2.2.4.8 0.5% Triton-X-100 (Immunofluorescence) 
PBS 50mL 
Triton-X-100 250µL 
 
 
 
2.2.4.9 0.1M Sodium cacodylate (pH 7.4) 
dH20 100mL 
Sodium cacodylate 2.14mg 
 
• Buffer to pH 7.4 with 0.2M HCl 
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2.2.4.10 Fixing solution for EM 
25% gluteraldehyde solution 1mL 
0.1M Sodium cacodylate (pH 7.4) 9mL 
 
 
2.2.4.11 Post-fixation solution for EM 
Osmium tetroxide 0.1g 
0.1M Sodium cacodylate (pH 7.4) 10mL 
 
 
 
2.2.4.12 5% uranyl acetate 
dH20 10mL 
Uranyl acetate 0.5g 
 
 
 
2.2.4.13 2% uranyl acetate 
dH20 10mL 
Uranyl acetate 0.2g 
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2.3 Methods 
2.3.1 Cell culture 
2.3.1.1 Culture of cell lines 
The BC CML cell lines K562, LAMA84 and BV173 (BCR-ABL+) and the AML cell 
line HL60 (BCR-ABL-), which were all available “in-house”, were grown in 
suspension culture in RPMI++ medium in tissue culture flasks. Ba/F3 cells (murine 
IL-3 dependent pro-B cells) which stably expressed either wild-type p210 or BCR-
ABL with kinase domain mutations (M351T and T315I) were donated as a kind gift 
from Professor Junia Melo and also maintained in RPMI++. M2-10B4 and Sl/Sl 
murine fibroblast cell lines were cultured in RPMI (see Section 2.2.1.4) and DMEM 
(see Section 2.2.1.5), respectively. 
 
All cell lines were maintained at 10ml in 25cm3 tissue culture flasks, counted and 
passaged every two days with warm fresh media, to maintain a density of between 
1x105-1x106. 
 
2.3.1.2 Cell counting and cell viability assessment 
Cell counts and assessment of viability were performed using a counting chamber. 
Cells were counted with trypan blue exclusion. Trypan blue dye was first diluted 
1:10 with PBS and 90µL was added to 10µL of cell suspension to give a 1:10 
dilution of cells. Approximately 10µL of the mixture was transferred to a 
haemocytometer and a minimum of 100 viable cells were counted. Cells that have 
damaged membranes are porous and absorb the trypan blue dye, appearing dark-
blue under the microscope, whereas the cells with an intact membrane do not 
absorb the dye. Hence, the unstained cells were counted and the remaining 
stained dead cells were deemed non-viable. 
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2.3.1.3 Cryopreservation of cells 
Between 4x106-2x107 CD34+ selected CP CML cells, 1x108 unselected (MNC) CP 
CML cells and 5x106-1x107 cell line cells were cryopreserved at -150°C until  use. 
To each cell suspension, an equal volume of 20% DMSO in 4.5% ALBA was 
added to give a final concentration of 10% DMSO. The cryotubes were transferred 
to a cryofreezer container and first cooled at -80°C to provide a controlled 
temperature reduction and then transferred to a -150°C freezer for long-term 
storage. 
 
2.3.1.4 Collection of human primary cell samples 
All samples were collected with the approval from the Local Research and Ethics 
Committee and with written informed patient consent from patients at diagnosis of 
CP CML. Cells were collected by leukapheresis prior to any drug treatment. Each 
sample was determined to be Ph+ by D-FISH and BCR-ABL+ by PCR. Further 
samples were also obtained from patients, with normal BM undergoing autologous 
stem cell collection for either non-Hodgkin’s lymphoma or multiple myeloma, who 
had been mobilised with G-CSF following chemotherapy and had excess CD34+ 
cells remaining after those required for clinical use had been processed.  
 
2.3.1.5 Purification of the MNC fraction from whole blood cell samples 
Either 6mL of ficoll/histopaque solution was added to a 15mL falcon tube, or 20mL 
of ficoll/histopaque solution was added to a 50mL falcon tube (depending on the 
volume of blood sample) and brought to room temperature. The whole blood 
sample was first diluted (1:2) with PBS, carefully layered drop-wise onto the 
ficoll/histopaque solution, until it reached the top of the centrifuge tube and 
centrifuged at 1500rpm for 20 minutes at room temperature. Following 
centrifugation, the opaque interface containing the MNCs was carefully aspirated 
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with a pastette. The interface was then transferred into a sterile centrifuge tube 
with a pastette and washed twice with sterile PBS (centrifuge at 1000rpm for 5 
minutes). The resultant MNCs were either used fresh or cryopreserved according 
to Section 2.3.1.3 until required. 
 
2.3.1.6 Selection of CD34+ cells from MNC samples 
Enrichment for CD34+ cells was achieved using the sterile CliniMACS system 
(Miltenyi Biotec, Bisley, UK), which positively selects for CD34+ cells according to 
the manufacturers’ instructions. Briefly, total MNCs were incubated with a specific 
anti-CD34 monoclonal antibody (Miltenyi Biotec) to which super-paramagnetic 
MACS beads (~50nM in diameter) had been conjugated. The cell sample was 
then passed through a high-gradient magnetic separation column, where the 
target CD34+ cells were retained in the column and the unlabelled CD34- cells 
flushed through and discarded. The bound CD34+ cells were then eluted after 
removal from the magnetic field, collected and an aliquot was removed for flow 
cytometry assessment of CD34 purity, which confirmed that all samples were 
>95% CD34+ post-selection (Figure 2-1). All samples were for stored at the 
indicated concentrations (see Section 2.3.1.3) in cryotubes at -150°C, until 
required for use.  
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Figure 2-1 Example of cellular CD34 purity following CliniMACS selection 
The left panel shows the percentage of CD34+ cells, within a total MNC 
population, prior to the selection. The right panel shows the purified cells 
following CD34 selection.  
 
2.3.1.7 Recovering frozen cells 
CML cells were removed from -150°C and immediately thawed at 37°C in a water 
bath until the ice crystals had melted. Using a pastette, the cells were added to a 
15ml sterile tube and recovered by slowly adding 10ml of thawing solution (DAMP) 
drop-wise over a 20 minute period. This step was performed at room temperature 
to enhance the activity of the DNAse II, with constant agitation to prevent clumping 
of the cells. The cells were centrifuged at 1000rpm for 10 minutes, the supernatant 
was poured away and the pellet loosened by flicking the tube. The pellet was then 
washed twice in DAMP and centrifuged, then resuspended in SFM for counting 
and cell viability. The CML cells were then plated in 25cm3 tissue culture flasks at 
~2x106/mL. 
 
1% 99.8%
FS
C
CD34-APC
FS
C
 95 
Cell lines were thawed in a 37°C water bath and rec overed slowly as above but in 
RPMI++. The cells were then washed twice more with RPMI++ and resuspended in 
10ml of RPMI++, then plated in 25cm3 tissue culture flasks.  
NB. The exception to this was with M2-10B4 and Sl/Sl murine fibroblast cell lines, 
which were thawed and cultured in RPMI (see Section 2.2.1.4) and DMEM (see 
Section 2.2.1.5), respectively. 
 
2.3.1.8 Selection of CD34+38- cells from total CD34+ samples 
Total CD34+ cells (2x107) were centrifuged (1000rpm, 5 minutes) and 
resuspended in 100µl PBS/2% FCS. Aliquots of cells (2x104 cells per tube) were 
removed for appropriate isotype controls which were used to correctly set the 
detectors, so that the negative isotype population was placed in the first log 
decade for each flow cytometry channel. CD34 APC and CD38 FITC positive 
controls (5µL of antibody per tube) were also set up. The remaining test cells were 
stained with 15µL of both CD34 APC and CD38 FITC antibodies and all samples 
were incubated for 20 minutes at room temperature in the dark. Following 
incubation, samples were washed twice with PBS/2% FCS (1000rpm, 5min). The 
controls were resuspended in 100µL PBS/2% FCS and the test cells were 
resuspended in 2mL PBS/2% FCS. All samples were sterile filtered through a 
0.22µM filter before sorting. The controls were then run first and the compensation 
adjusted. The CD34+38- cells were then sorted using a Becton Dickinson 
FACSAria.  
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2.4 Cellular techniques 
2.4.1 CFSE staining 
In 1994, Lyons and Parish introduced a technique for tracking the cell division of 
lymphocytes by flow cytometry, using the serial dilution of a fluorescein-based dye 
- CFSE (280). CFSE is a lipophilic molecule which passively enters cells, where it 
is converted to a reactive dye by non-specific intracellular esterases. Once inside 
a cell, it binds irreversibly to the free amines of cytoplasmic proteins, resulting in 
stable long-term retention. The dye is then equally partitioned between two 
daughter cells during mitosis, so fluorescence intensity is halved with every cell 
division. This property allows both the identification of cell progeny and the 
division-tracking of individual cells that have undergone up to ten sequential 
division cycles. Li et al. have demonstrated, using a mixture of CFSE-stained 
human and unstained rat cells in an in vitro co-culture, that no dye leaks from the 
stained cells and that the fluorescence intensity of the undivided cells remains 
constant (281). This therefore, confirms the reliability of this technique for the 
identification of undivided cells. Figure 2-2A shows the intensity of CFSE halving 
with each cell division and Figure 2-2B demonstrates the subsequent FACS 
histogram identifying the ‘peaks’, which each represent a cell division.  
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Figure 2-2 Tracking a cell with CFSE stain 
(A) A schematic diagram of the brightness of the CFSE stain in a cell halving 
in the daughter cells with each division. (B) A histogram of a FACS plot 
showing the classic ‘peaks’ pattern with the undivided cells showing the 
highest fluorescence and the intensity halving with each division. A single 
peak can be gated to determine the percentage of cells in the total 
population that have undergone the equivalent number of divisions. [UD: 
undivided] 
 
Following successful recovery of cells and resuspension in PBS/2% FCS, an 
aliquot (~10%) of the CD34+ cells was removed and set up in culture in SFM+5GF 
as an unstained control. A stock solution of 5mM CFSE (in DMSO) was diluted at 
1 in 10 dilution with PBS/2% FCS and 10µL added to 5mL of the remaining cells to 
give a final concentration of 1µM. The cells were then incubated in a water bath at 
37°C for exactly 10 minutes, after which the cells were removed and the CFSE 
was quenched by adding 10x volume of ice-cold PBS/20% FCS. The cells were 
UD12345
DIV1 DIV2UD
A B
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then centrifuged for 10 minutes at 1000rpm, the supernatant was discarded and 
the cells washed in fresh PBS/2% FCS. The cells were cultured overnight in 10mL 
SFM+5GF in non-adherent (75cm3) tissue culture flasks (1-2x107 CD34+ 
cells/flasks) at 37°C, 5% CO 2. 
 
After CFSE staining and overnight incubation, the CFSE-stained cells were 
removed from the tissue culture flask and placed in a sterile tube. The flask was 
then washed out with PBS/2% FCS and this was also added to the tube. The cells 
were then centrifuged at 1000rpm for 10 minutes and washed again in PBS/2% 
FCS. Following this, the CFSE+ cells were resuspended in PBS/2% FCS and the 
cell count and viability was determined. An aliquot of cells (~2x104) was removed 
for flow cytometry to assess the position of the undivided (CFSEmax; CD34+) cell 
population prior to culture in different treatment conditions. For every experiment, 
a colcemid control was set up using CFSE+ cells to determine the position of the 
CFSEmax peak after culture. One µL of the colcemid stock (100µg/mL) was 
added per mL of the tissue culture medium to give a final concentration of 
100ng/mL. The cells unstained for CFSE were used to alter the voltage settings 
and optimally compensate for spectral overlap. 
 
2.4.2 Culture of CD34+ cells 
Following either recovery from -150°C or CFSE stain ing, cells were cultured in 
SFM or SFM+5GF (as indicated in the text) in 35mm suspension dishes at an 
initial cell concentration of ~5x105/mL for 1 to 12 days at 37°C, 5% CO 2. Drugs 
were added to each experiment as appropriate to the described conditions. The 
cells were harvested at indicated time-points, washed in PBS/2% FCS and 
aliquots were removed for performing a cell count and FACS analysis. In Chapter 
4, the cells were harvested every 4 days and at the end of the final cycle of each 
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experiment (day 12), as well as performing a cell count and FACS analysis, an 
aliquot of cells was prepared for FISH to determine if the cells remaining after 
culture were BCR-ABL+. Furthermore aliquots of cells were also taken for protein 
lysate and RNA preparation (methods described in Sections 2.6.1 and 2.8.1 
respectively). 
 
2.4.3 LTC-IC 
Primitive haemopoietic cells, with proliferative potential, can be maintained in 
culture for extended periods of time, typically several months. These culture 
conditions have been called long-term bone marrow culture (LTBMC) (282). 
Briefly, LTBMC requires the formation of a supportive stromal layer which supplies 
the necessary microenvironment to allow the primitive haemopoietic cells to 
proliferate over time. An application of LTBMC is an assay that measures the 
number of LTC-IC (283, 284). In this assay, the cells of interest are overlayed on 
pre-established, irradiated stromal layers. After 5 weeks culture the contents of 
each plate are set up in a committed progenitor assay for a further two weeks. At 
the end of this, the number of colonies formed is counted and this allows the 
frequency of LTC-IC to be determined. Figure 2-3 shows a schematic diagram for 
the method used in the LTC-IC assay. 
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Figure 2-3 Schematic diagram for the assessment of LTC-IC 
Test cells are overlayed on a supportive stromal cell monolayer and cultured 
for 5 weeks before being added to a commited progenitor assay (CFC). The 
number of colonies counted at the end of the assay correlates with the 
number of LTC-IC within the test cell sample.  
 
Two genetically-modified murine fibroblast cell lines, M2-10B4 and Sl/Sl fibroblasts 
(both kindly provided by the Terry Fox Laboratories, Vancouver, BC, Canada) 
were used to provide the stromal support necessary for the LTC-IC. The M2-10B4 
cells have been genetically modified to express G-CSF and IL-3, and Sl/Sl 
fibroblasts have been genetically modified to express SCF and IL-3. After thawing, 
these cell lines were maintained in culture at 37°C , 5% CO2. The cells were 
trypsinised and passaged when the monolayer was semi-confluent to allow 
propagation of sufficient cells for LTC-IC. To minimise the proliferation of 
untransduced wild-type cells, the cultures were fed on alternate weeks with 
hygromycin B (final concentration 62.5µg/mL for M2-10B4 and 125µg/mL for Sl/Sl 
SI/SI
Irradiated and mixedM2-10B4
Stromal
monolayer
Test cells5wk 
cultureCFC
Assessment
Of colonies
14 days
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fibroblasts) and G418 (final concentration 400µg/mL for M2-10B4 and 800µg/mL 
for Sl/Sl fibroblasts). 
 
Before the stromal layers were seeded with the test cells, it was necessary to 
irradiate the stromal cells to render them incapable of proliferation. Prior to 
irradiation, the stromal cells were trypsinised and counted. A total of 1.5x105 M2-
10B4 and 1.5x105 SI/SI fibroblasts were required for each test well. The stromal 
cell layers were then irradiated at 80Gy. Following this, the M2-10B4 and SI/SI 
fibroblasts were mixed and resuspended in MyelocultTM supplemented with 
hydrocortisone, to give a final cell concentration of 3x105/mL. Two millilitres of this 
stromal cell suspension was then aliquoted into the required number of wells of a 
Type I Collagen coated 6-well plate (to facilitate stromal adherence). The plates 
were then incubated at 37°C, 5% CO 2. After the stromal cells had been incubated 
for 24 hours, the test cells (CD34+ cells treated under different drug conditions as 
described in Section 2.4.2) were inoculated onto the stromal monolayers. 
Following drug treatment, the remaining CML cells were washed in PBS/2% FCS 
and then resuspended in 300µL of SFM. Duplicate LTC-IC wells were set up with 
150µL of treated CD34+ cell suspension. The cells were then incubated for a total 
of 5 weeks at 37°C, 5% CO 2. Every week, 1mL of MyelocultTM medium was 
removed from each well and 1mL of fresh MyelocultTM was added and this 
constituted a half medium change.  
 
At the end of 5 weeks culture, the LTC-IC were harvested and set up in committed 
progenitor CFC assays. For each LTC-IC culture well, the culture supernatant 
(containing non-adherent cells) was pipetted into a sterile 15mL centrifuge tube 
(harvest tube). Two millilitres of HBSS-CMF was added to remove any serum-
containing MyelocultTM medium and the plate swirled gently before the HBSS-CMF 
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was transferred to the harvest tube. One millilitre of trypsin-EDTA was then added 
to each well and swirled gently at intervals until all the adherent cells had 
detached (up to 5 minutes). Detachment was facilitated by repeatedly pipetting the 
trypsin-EDTA over the surface of each well, helping to generate a single cell 
suspension. The supernatant was transferred to the harvest tube. Immediately, 
2mL of IMDM/2% FCS was added to the LTC-IC well, swirled gently and 
transferred to the harvest tube. A further 2mL of HBSS-CMF was added to the well 
and swirled gently before being transferred to the harvest tube. The harvest tubes 
were then centrifuged at 1000rpm for 10 minutes. Following this, the supernatant 
was gently poured off and the cells resuspended in the remaining supernatant. 
The volume of the remaining cell suspension was noted and a cell count 
performed. 
 
2.4.3.1 CFC assay 
Duplicate committed progenitor cell assays were set up for each cell volume of 
each treatment condition at two different cell concentrations - 2.5x104/mL and 
5x104/mL. The appropriate volume of cell suspension for duplicate wells was 
added to 2mL of MethocultTM methylcellulose medium for committed progenitor 
cell assays. The cell suspension and MethocultTM medium were thoroughly mixed 
and 1mL of this mixture was added to a 35mm tissue culture dish. The dish was 
then gently swirled, so that the bottom of the dish was completely coated, and 
then incubated for 14 days at 37°C, 5% CO 2. At the end of this time, the number of 
viable colonies was counted in each dish and this allowed a comparison of the 
LTC-IC present in the different treatment conditions.  
 
In experiments where CFC assays were performed alone (without LTC-IC), 
exactly the same methodology (described directly above) was carried out. 
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2.4.4 Dual-colour fluorescence in situ hybridisation    
CML cells, pre- and post-culture, and colonies from LTC-IC experiments were 
assessed for the presence of BCR-ABL by dual-colour fluorescence in situ 
hybridisation (D-FISH). Aliquots of at least 5000 cells were transferred to a 1.5mL 
eppendorf, washed in PBS/2% FCS and re-suspended in 500µL pre-warmed 
(37°C) hypotonic solution (0.075M potassium chlorid e). Samples were then 
incubated at room temperature for 20 minutes. One hundred microlitres of freshly 
made fixative (methanol:acetic acid [3:1]) was added to the cells and the samples 
were incubated for a further 5 minutes at room temperature. The cells were then 
centrifuged at 5000rpm for 5 minutes; the supernatant removed and a further 
500µL fixative added, the cells incubated for a further 5 minutes and then 
centrifuged for 5 minutes. This step was repeated a further twice. The cell pellet 
was finally resuspended in 50µL of fixative and then stored at -20°C prior to fur ther 
preparation for D-FISH. 
  
Aliquots of 20µL of cell solution were spotted onto multi-spot microscope slides 
previously coated with poly-L-lysine and air-dried overnight. The prepared slides 
were wrapped in parafilm and stored at -20°C until D-FISH was performed with the 
LS1 BCR-ABL Dual Colour, Dual Fusion translocation probe according to the 
manufacturer’s instructions. Interphase nuclei were evaluated using a Leica 
fluorescence microscope with a triple band pass filter for DAPI, Spectrum Orange 
and Spectrum Green. All D-FISH slides were prepared and scored by Mrs Elaine 
Allan. 
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2.5 Flow Cytometry 
Flow Cytometry also known as FACS is a quantitative technique that permits the 
visualisation and sorting of cells by multiple parameters according to their 
fluorescence. A flow cytometer can also measure the size of a cell using forward-
angle light scatter (FSC) and the granularity of a cell using side-angle light scatter 
(SSC). Therefore, in comparison to spectrophotometry, flow cytometry allows the 
measurement of fluorescence per cell, hence allowing accurate analysis of single 
cells. All the flow cytometric analyses were carried out on a Becton Dickinson 
FACSCanto.  
 
2.5.1 Intracellular antibody staining 
First, 5x104 -1x105 cells were resuspended in 100µL of fixing reagent (reagent A) 
from the Fix & Perm® Cell Permeabilisation kit and incubated for 15 minutes. The 
cells were then washed with PBS, the supernatant completely removed using a 
graduated pipette and the cell pellet resuspended in 50µL permeabilising reagent 
(reagent B) from the Fix & Perm® Cell Permeabilisation kit. To this the appropriate 
volume of intracellular antibody was added (anti-active-caspase-PE; 1:10 dilution) 
and the cells incubated for 45 minutes at room temperature in the dark. Finally the 
cells were washed twice in PBS (1200rpm for 5 minutes) prior to FACS analysis. 
 
2.5.2 Assessment of phospho-proteins by flow cytometry 
There is no specific antibody that is able to detect the activity of BCR-ABL. 
However, it is known that one of the prominent downstream substrates 
constitutively phosphorylated by the BCR-ABL oncoprotein is the 39-kDa adaptor 
protein CrkL. It has previously been shown that CrkL phosphorylation is inhibited 
in a concentration dependent manner when CML cells are treated with IM, 
correlating with BCR-ABL phosphorylation (130). 
 105 
The rabbit anti-human phospho-CrkL (p-CrkL) antibody used for this assay 
detected endogenous levels of CrkL only when it was phosphorylated at tyrosine 
207 - the BCR-ABL phosphorylation site. Measuring the difference in the 
geometric mean fluorescence intensity (MFI) of p-CrkL peaks between drug-
treated samples and untreated controls, determined the effect of the treatments on 
the inhibition of BCR-ABL. Samples for analysis of p-CrkL levels were prepared by 
permeabilisation and staining using the Fix & Perm® Cell permeabilisation kit as 
above (Section 2.5.1), but with minor modifications. Following fixation with 100µl 
fixing reagent, the cells were resuspended in 25µl of permeabilising reagent with 
2.5µl of the p-CrkL antibody for 40 minutes. The cells were washed twice and 
resuspended in 100µl fix perm wash with 2µl of the secondary anti-rabbit IgG FITC 
conjugate (1: 50 dilution), or 10µl of the secondary anti-rabbit IgG PE conjugate (1: 
10 dilution) and incubated at room temperature in the dark for 30 minutes. 
Different secondary antibodies were added depending on the requirements for 
multi-parametric FACS. For example, in non CFSE-stained cells, anti-rabbit IgG 
FITC conjugated secondary antibody was used, whereas in CFSE+ cells, anti-
rabbit IgG PE conjugated secondary antibody was used. Following incubation, the 
cells were then washed twice and then analysed immediately by flow cytometry. 
 
The amount of p-CrkL in an untreated CML sample was assessed as the 
geometric MFI of the cell sample minus the geometric MFI of the isotype control. 
The p-CrkL status of the drug-treated samples was expressed as a percentage of 
the untreated control (100%). 
 
Assessment of phospho-STAT5 (p-STAT5) was carried out in exactly the same 
way, except the p-CrkL primary antibody was replaced by the p-STAT5 antibody at 
the same concentration 
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2.5.3 High resolution cell cycle analysis 
Differing culture and treatment conditions may alter progression of cells through 
the cell cycle. Therefore, it was important to determine the effects of the different 
treatment conditions on progression of CML cells through the cell cycle.  
Ki67 is an antigen present in the nuclei of cells which are in the active phases of 
cell cycle - G1, S/G2 and M - and is not expressed in G0 cells. The precise function 
of Ki67 still remains unclear, however, since it is only present in proliferating cells 
(normal and malignant) (285); it has become a widely accepted marker for cellular 
proliferation. 7AAD is a fluorescent compound with a strong affinity for DNA, which 
has been used in chromosome analysis, cell cycle studies and, most commonly, to 
quantify apoptosis. Using the Ki67 stain in conjunction with an intercalating DNA 
stain such as 7AAD, allows for a high resolution of cell cycle analysis, as it 
distinguishes between the different phases of cycling cells (286). G0 cells can be 
identified as they have low DNA content and are negative for Ki67. Cells in G1 
phase have the same DNA content; however, begin to express low amounts of 
Ki67. Both DNA content and Ki67 expression increase within cells from S and G2 
phases and staining is maximal in mitosis. Since LSCs exist within G0 phase of 
cell cycle, this staining technique has also proven invaluable for the discovery and 
isolation of primitive, quiescent malignant cells in CML (224). 
 
Approximately  3x105 cells were washed in PBS (1200rpm for 5 minutes), the 
supernatant discarded and then resuspended in 500µL of PBS/0.4% formaldehyde 
for fixing and incubated for 30 minutes on ice. Following this, 500µL of PBS/0.2% 
Triton-X-100 was added to permeablise the cells, which were then incubated 
overnight at 4°C. The following morning, the cells were washed once in PBS and 
then resuspended in 1mL PBS. The cell suspension was then divided equally 
between two FACS tubes (500µL each) and either 20µL of Ki67-FITC labelled 
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antibody or 20µL of FITC isotype control was added to the tubes. The cells were 
then vortexed and incubated for 40 minutes at room temperature in the dark. After 
one further wash, the cells were resuspended in 1mL PBS and 5µL of 7AAD 
(1µg/mL) was added and then incubated for at least 6 hours, but preferably 
overnight, at 4°C prior to FACS analysis. Before FA CS analysis, the cells were 
washed once in PBS. To separate the cells from debris, the cell population was 
gated on using FSC versus FL3. The gated population was then analysed in FL1 
versus FL3 and this allowed the relative percentages of cells at each stage of the 
cell cycle. 
 
2.5.4 FACS for CFSE experiments 
CFSE stained cells were surface stained as described in Section 2.4.1. Flow 
cytometry analysis of CFSE-stained cells was performed at baseline to determine 
the position of the undivided peak and confirm uniform staining of the cell 
population (which allowed resolution of the peaks at subsequent analyses), and 
again at the time-points stated for each set of experiments. Isotype controls were 
used to correctly set the detectors, so that the negative isotype population was 
placed in the first log decade for each flow cytometry channel. A CFSE positive 
control was then run and the compensation adjusted. Because CFSE is a very 
bright fluorescent stain which has substantial spectral overlap into other FACS 
channels, considerable levels of compensation were required. 
 
2.5.4.1 Calculation of the undivided (CFSEmax) cell population 
To determine the anti-proliferative effect of different treatment conditions and 
assess the size of the non-proliferating primitive progenitor population, the 
percentage recovery of viable CML cells in the undivided population remaining 
after culture was assessed. At each analysis time-point, the number of viable cells 
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harvested from each culture condition was recorded, as was the percentage of 
CML cells found in the undivided fraction (CFSEmax). Percentage recovery of 
input cells in the undivided peak could then be calculated by dividing the absolute 
number of CFSEmax CML cells by the total number of input CML cells and 
multiplying by 100%. This allowed direct comparison of different treatment 
conditions on the non-proliferating primitive progenitor population. 
 
2.5.5 Assessment of apoptosis and necrosis 
For analysis of cell death, cells were incubated with 5µL annexin-V-FITC and 10µL 
viaprobe in 100µL annexin buffer for 15 minutes in the dark. The cells were then 
topped with 300µL annexin buffer and read by flow cytometry within the hour to 
identify necrotic (viaprobe detected in FL-3) and apoptotic (annexin-V detected in 
FL1) cells. 
 
2.6 Western blotting 
The Western blot, alternatively known as the protein immunoblot, is an analytical 
technique used to detect specific proteins in a given cell sample. A specific protein 
can be identified after fractionation on either one or two dimensional gels, by 
exposing all proteins present to a specific antibody coupled to an easily detectable 
enzyme such as HRP, a radioactive isotope or fluorescent dye. This is done after 
the proteins separated on the gel have been transferred or ‘blotted’ onto a 
membrane - typically nitrocellulose paper or polyvinylidene fluoride (PVDF) as this 
is more robust than the gel. 
 
2.6.1 Preparation of protein lysate 
The RIPA lysis buffer was prepared immediately prior to use. Equal cell numbers 
from different treatment conditions were washed twice with ice cold PBS (1200rpm 
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for 5 minutes). The cells were then transferred to a 1.5mL eppendorf and washed 
again in ice cold PBS (3000rpm for 5 minutes in a bench-top micro-centrifuge). 
The lysis buffer was added to the cells (50µL per 1-3x105 cells), mixed by pipetting 
up and down and incubated for 15 minutes on ice. Following this incubation, the 
cells were gently vortexed and then spun at 14,000rpm for 10 minutes at 4°C to 
clarify the supernatant which was then saved as a protein lysate and stored at       
-20°C until use. 
 
2.6.2 Protein quantification 
Protein quantification was performed using the bicinchoninic acid (BCA) method 
for colorimetric detection and quantification of total protein according to the 
manufacturers’ instructions. This method utilises the reduction of Cu2+ to Cu1+ by 
protein in an alkaline medium (the biuret reaction with the colorimetric detection of 
the cuprous cation (Cu1+) using a reagent containing BCA (287). The purple 
reaction product of this assay is formed by chelation of one cuprous ion with two 
molecules of BCA. The water-soluble complex exhibits a strong absorbance at 
562nm that is nearly linear over a broad range of protein concentrations (20-
2000µg/mL) 
 
First the BSA standards were prepared. BSA was dissolved in 0.9% saline to give 
a concentration of 2mg/mL. Serial dilutions of this stock were then made to 
produce a concentration gradient for the controls. The following concentrations of 
BSA control were prepared: 1500; 1000; 750; 500; 250; 125; 50; 25; 5µg/mL and a 
blank (dH2O). The controls were then stored at -20°C for use on multiple 
occasions. To prepare the assay, 25µL of each control was pipetted onto the well 
of a 96-well plate in duplicate. Protein lysate (5µl) was added to 20µL of PBS in 
duplicate test wells. BCA solutions A and B were mixed in a 50:1 ratio (A:B) and 
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200µL of the BCA mixture was added to each well. The 96-well plate was then 
incubated at 37°C for 30 minutes and the plate was read using an enzyme-linked 
immunosorbent assay (ELISA) plate reader according to the manufacturers’ 
instructions. This allowed accurate protein quantification so that equal amounts of 
protein could be compared in Western blotting. 
 
2.6.3 Sodium dodecyl sulphate-polyacrylamide-gel electrophoresis  
Sodium dodecyl suphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a 
denaturing separation method commonly used to analyse protein samples, which 
uses a highly cross-linked gel as the inert matrix through which the proteins 
migrate. The proteins are in solution that includes SDS, a negatively charged 
detergent, which binds to hydrophobic regions of the protein molecules, causing 
them to unfold into long polypeptide chains and become freely soluble in the 
solution. A reducing agent such as β-mercaptoethanol is also added to break any 
disulphide bonds present in the proteins, so that all the constituent polypeptides 
can be analysed separately. Each protein molecule binds many of the negatively 
charged detergent molecules, which masks the protein’s inherent positive charge. 
An electric current is then applied, resulting in migration of the protein towards the 
positive electrode. The direction, distance, and speed of migration are dependent 
on the size and shape of the polypeptides and the pore-size of the gel matrix; with 
smaller polypeptides travelling more rapidly through the gel. Common gel 
materials are agarose (a polysaccharide) and acrylamide (a 3-carbon amide which 
is polymerized to form long chains with cross-links between the chains). The pore 
size of the gel is influenced by the percentage of gel material used and, in the 
case of acrylamide, the amount of cross-linking.  
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To perform SDS-PAGE, equal volumes of protein lysate and Laemmli 2x sample 
buffer were mixed together in a 1.5mL eppendorf and then heated to 95°C for 5 
minutes. The samples were then loaded onto a 4-15% gradient gel. Ten 
microlitres of rainbow ladder marker was loaded onto a lane of the gel to allow 
determination of protein size. The gel was electrophoresed in a 1xTGS running 
buffer for 90 minutes at 120V using the Bio-rad Mini-PROTEANTM electrophoresis 
system. 
 
2.6.4 Transfer to nitrocellulose membrane 
The protein bands were then transferred from the gel to the nitrocellulose 
membrane. Sponges, blotting paper and nitrocellulose membrane were first 
soaked in transfer buffer and the transfer sandwich was prepared as shown in 
Figure 2-4. 
 
 
 
 
 
 
 
Figure 2-4 Preparation of transfer sandwich for wet transfer of protein from 
gel to nitrocellulose membrane 
 
The sandwich then underwent electrophoresis for 1 hour at room temperature at 
80V. 
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2.6.5 Immunolabelling 
After transfer, the nitrocellulose membrane was briefly washed in TBS-T and 
blocked in blocking buffer, with shaking at room temperature for 1-2 hours. 
Following this, the blocking buffer was discarded and the membrane incubated 
with the primary antibody solution (p-CrkL, LC3B, GAPDH; p-S6K; 1:1000 dilution 
in blocking buffer) overnight at 4°C with gentle ag itation. The following morning, 
the nitrocellulose membrane was washed twice (15 minutes per wash) in TBS-T 
and then incubated with anti-rabbit HRP-conjugated secondary antibody (1:3000 
dilution) in blocking solution for 1 hour at room temperature with gentle agitation. 
The membrane was then washed twice (15 minutes per wash) in TBS-T and then 
developed with the Immun-star ECL reagents A and B (first diluted 1:2) and 
developed directly using a Biorad Molecular Imager ChemiDoc XRS+ System. 
 
2.6.6 Stripping and reblotting 
The Re-Blot Plus Strong stripping solution was diluted 1:10 with distilled water. 
The nitrocellulose membrane was then incubated in the stripping solution for 10-
15 minutes and then washed twice (5 minutes per wash) in TBS-T. The membrane 
was then re-blocked for 1 hour, prior to being incubated with another antibody. 
This allowed the re-blotting of the membrane 3-4 times. 
 
2.7 ELISA for the measurement of p-Tyr 
Whole cell protein lysates were prepared from 105-106 cells according to Section 
2.6.1. Lysates were diluted in carbonate-bicarbonate coating buffer, added to each 
well of an Immulon II HB 96-well flat bottom ELISA plate in triplicate (5µg protein in 
100µl carbonate-bicarbonate buffer/well) and plates were then incubated at 4°C, 
with shaking, overnight. Following incubation, plates were washed with TBS-T four 
times, surfaces were blocked with 100µl of blocking buffer (except those wells 
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reserved for chromagen blanks) and plates incubated for 1 hour at room 
temperature with shaking. Plates were then washed as previously and incubated 
with 100µl per well of 1:1000 4G10 anti-p-Tyr antibody or 1:500 anti-GAPDH in 
blocking buffer for 2 hours at room temperature on a shaker.  Plates were washed 
with TBS-T four times and incubated with 100µl per well of 1:1000 anti-mouse 
IgG-HRP secondary antibody (anti-P-Tyr samples) or 1:1000 anti-rabbit IgG-HRP 
secondary antibody (anti-GAPDH samples) for 1 hour at room temperature on a 
shaker. Plates were then washed four times with TBS-T, 100µl of chromagen 
substrate (tetramethylbenzidine) was added to each well and plates incubated for 
20 minutes in the dark. The reaction was stopped by adding 50µl of 2N HCl and 
plates were then read at 460nm absorbance on an ELISA plate reader. 
 
Negative control wells were included in the assay (lysate only and antibody only) 
and these values were subtracted as background, where indicated, from each 
relevant test well. 
 
2.8 mRNA transcript measurement and mutation analysis 
2.8.1 RNA synthesis 
Total RNA was isolated from pellets using the RNeasy Mini Kit according to the 
manufacturer’s instructions. The resulting RNA was quantitated using a nanodrop 
spectrophotometer Nd-1000 (Labtech International, East Sussex, UK). An 
absorbance at 260nm quantified nucleic acid and the ratio of 260/280 determined 
purity (pure RNA ratio is 2.0). 
 
2.8.2 cDNA synthesis 
RNA was synthesised to cDNA by the High Capacity cDNA Archive kit according 
to the manufacturer’s instructions. 
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2.8.3 qRT-PCR using Taqman 
The TaqMan probe principle relies on the 5´-3´ nuclease activity of Taq 
polymerase to cleave a dual-labelled probe during hybridization to the 
complementary target sequence. As in other qRT-PCR methods, the resulting 
fluorescence signal permits quantitative measurements of the accumulation of the 
product during the exponential stages of the PCR; however, the TaqMan probe 
significantly increases the specificity of the detection. TaqMan probes consist of a 
reporter fluorophore covalently attached to the 5’-end of the oligonucleotide probe 
and a quencher at the 3’-end (Figure 2-5). The quencher molecule quenches the 
fluorescence emitted by the reporter fluorophore via Fluorescence Resonance 
Energy Transfer  (FRET), when excited by the thermal cycler’s light source. As 
long as the reporter and the quencher are in proximity, quenching inhibits any 
fluorescence signals. The probes anneal within a DNA region amplified by a 
specific set of primers. As the Taq polymerase extends the primer and synthesises 
the nascent strand, the 5' to 3' exonuclease activity of the polymerase degrades 
the probe that has annealed to the template. Degradation of the probe releases 
the fluorophore from it and breaks the close proximity to the quencher, thus 
relieving the quenching effect and allowing fluorescence of the reporter 
fluorophore. Hence, fluorescence detected in the RT-PCR thermal cycler is 
directly proportional to the fluorophore released and the amount of DNA template 
present in the PCR. 
 
The mRNA levels of cyclin D1 and the endogenous reference gene GAPDH were 
measured using the ABI PRISM 7900HT sequence detector (Applied Biosystems 
(ABI), Warrington, U.K.). The cyclin D1 PCR products were detected using a 
probe containing a 6-carboxyfluorescein (FAM) reporter and tetramethylrhodamine 
(TAMRA) quencher. For the GAPDH reaction VIC replaced FAM. The cyclin D1 
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and GAPDH mRNA levels were measured using the pre-developed Taqman Gene 
Expression Assays (primer and probe mix). For each reaction, 2.5µl of cDNA was 
used as template and added to 6.25µl q-PCR Mastermix Plus, 0.62µl of relevant 
Taqman Gene Expression Assay and made to a total volume of 12.5µl with PCR-
grade water. Each reaction was carried out in triplicate. Samples were run on the 
ABI PRISM 7900 with the following reaction conditions: 50°C for 2 minutes, 95 °C 
for 10 minutes followed by 40 cycles of 95°C for 15  seconds and 60°C for 1 
minute. The levels of cyclin D1 were calculated using the validated 2-∆∆CT method 
to calculate the relative expression. 
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Figure 2-5 Schematic diagram on the mechanism of Taqman qRT-PCR 
(A) While the probe is attached or unattached to the template DNA and 
before the polymerase acts, the quencher (Q-fluorophore) reduces the 
fluorescence from the reporter (R-fluorophore). (B) Following denaturation, 
both the TaqMan® probe and the primers anneal to the specific target DNA, 
allowing Taq polymerase to create a complementary strand. (C) Taq 
polymerase then adds nucleotides and removes the Taqman® probe from 
the template DNA. This separates the quencher from the reporter, and allows 
the reporter to emit its energy which is then quantified using a computer.  
 
 
 
 
 
 
QR
QR
Q
R
TAQ
Denature
Anneal
Extend
(A)
(B)
(C)
 117 
2.8.4 RT-PCR and BCR-ABL kinase domain mutation analyses  
Quantitative RT-PCR to amplify BCR-ABL fusion transcript was performed 
according to Standardised EAC (European Against Cancer) protocols previously 
described (288). The final results are expressed as BCR-ABL/ABL ratios in 
percent according to the international scale (244). The mutation was detected by 
direct sequencing (on both strands) according to the methods described by 
Branford et al. (239) with some modification (289). BCR-ABL transcript 
measurement and mutation analysis was performed by Dr Sandrine Hayette, 
Hôpital Lyon, Lyon, France. 
 
2.9 Immunofluorescence 
2.9.1 Fixing cell samples onto multi-spot slides 
Cells were washed in PBS/2% FCS and pellet resuspended in PBS. Twenty 
thousand cells were added to each relevant well of a poly-L-lysine-coated multi-
spot slide and cell samples were added in duplicate. Samples were allowed to 
adhere to the slides for 90 minutes at room temperature.  Following this, the 
excess PBS was gently removed and 30µL of the 3.65% formaldehyde solution 
was added per well, in order to fix the cells. The slides were then incubated for 20 
minutes at room temperature and then washed twice, 5 minutes each in PBS. The 
slides were then either antibody-stained straight away or stored at 4°C in a 
humidified chamber (with enough PBS to cover the cells on the slides) until 
required for immunofluorescence (IF) analysis. 
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2.9.2 Intracellular antibody-staining for IF  
All slides were first air-dryed until no moisture remained and 30µL of the 0.5% 
Triton-X-100 solution was added per well, in order to permeablise the cells. The 
slides were then incubated for 10 minutes at room temperature and then washed 
twice, 5 minutes each in PBS. Following this the slides were dried and each spot 
was blocked with 30µL blocking buffer for 1 hour at room temperature. The 
blocking buffer was then gently soaked away with a tissue and antibody (LC3B or 
FoxO3a) at a concentration of 0.5µg/mL in blocking buffer was added to each 
relevant well. Thirty microlitres of anti-rabbit IgG (Abcam) (0.5µg/mL in blocking 
buffer) was added to the two wells reserved for isotype control. The slides were 
then incubated for 90 minutes at room temperature. Following incubation, the 
slides were washed 4 times with PBS (5 minutes per wash). The slides were then 
incubated with anti-rabbit-Alexa Fluor 488 secondary antibody (1µg/mL in blocking 
buffer; 30 µL per spot) for 1 hour at room temperature. Following incubation, the 
slides were washed 4 times with PBS (5 minutes per wash) and then air-dryed 
until no moisture remained. Two drops of VECTASHIELD® mounting medium with 
DAPI were added to the centre of each slide and a coverslip was placed on the 
top. The coverslip was carefully pushed down, so that the mounting medium 
spread over each well of the slide and was then sealed with nail varnish. The 
slides were stored at 4°C until analysis.  
 
All slides were analysed using a Zeiss Imager M1 microscope at 100x 
magnification using oil immersion and Axiovision software.  
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2.10 EM 
CML cells (2x105-1x106) were pelleted in a 1.5mL eppendorf (1000rpm; 5 mins) 
immediately prior to fixation. One millilitre of fixing solution for EM (Section 
2.2.4.10) was added, without resuspending pellet and the samples were left to 
incubate for 1 hour. The fixing solution was then carefully removed, without 
disturbing the pellet, and replaced with 1mL 0.1M sodium cacodylate solution, as a 
rinse. The cells were then post-fixed with 1mL post-fixation solution for EM 
(Section 2.2.4.11) for 1 hour. After 3 changes in distilled water (10 minutes each), 
specimens were stained with 1mL 5% uranyl acetate, and embedded in Taab 
epoxy resin. Sections (100nm) were stained with aqueous 2% uranyl acetate for 
10 minutes and viewed on 300-mesh formvar-coated grids by zero-loss imaging 
on a LEO 912 AB energy filtering transmission electron microscope (Olympus).  
 
All EM procedures were performed by Dr David Dinsdale from the microscopy 
facility at the University of Leicester, Leicester, UK. 
  
2.11 Statistics 
The results are shown as the mean ± standard error values unless otherwise 
stated. All statistical analyses were performed using the Student’s T-test on the 
Graph Pad prism software package. A level of p<0.05 was deemed significant. 
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3. RESULTS (I) Optimisation of methods to assess BCR-
ABL activity in Ph+ cell lines and primary CML cells 
 
There is now an expanding set of scenarios in which the ability to accurately 
assess degrees of BCR-ABL inhibition by TKIs, either in the laboratory or in 
patient samples, would be extremely valuable. With the development of second 
generation TKIs, including dasatinib (264), nilotinib (251) and bosutinib (260), 
clinicians would like to be able to predict response for individual patients at 
diagnosis, or at the time of a proposed change in therapy, in order to select the 
agent with the best chance of success. Great progress has been made in this 
application by the group of Tim Hughes (290). Here, the group have demonstrated 
that the IC50 of IM, determined by Western blotting for the level of inhibition of 
phosphorylation of CrkL, on peripheral blood from individual patients, was highly 
predictive of molecular response to IM therapy.  
 
Since its introduction, a minority of patients have developed resistance to IM. For 
the individual patient with IM-resistant disease, methods to select the TKI likely to 
produce maximal BCR-ABL inhibition would be beneficial. Schultheis et al. (291) 
have developed a FACS-based assay that demonstrated differences in total p-Tyr 
inhibition by IM between CD34+ cells from cytogenetic responders and non-
responders to IM treatment. Our own group have since developed another rapid 
method for the detection of p-CrkL in CML cell lines, cell lines with known BCR-
ABL mutations and human primary CML cells, at the single cell level by flow 
cytometry (130). This method also appeared to be predictive of response to IM 
therapy. Figure 3-1 shows the p-CrkL profiles of two patients’ CML CD34+ cells 
cultured in the presence and absence of 5µM IM for 16 hours. Panel A 
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demonstrates the p-CrkL profile of a CML patient who did not respond optimally to 
IM treatment (i.e. did not achieve any degree of cytogenetic response by 6 
months). It was observed that the IM-treated CD34+ CML cells showed no 
reduction in p-CrkL, consistent with the presence of IM-resistant cells. Panel B 
shows a representative p-CrkL profile of a CML patient who responded well to IM 
treatment (i.e. CHR by 4 weeks and CCR by 6 months). Following IM treatment, 
there was only 7% phosphorylation of CrkL in IM-treated CD34+ CML cells, 
relative to no drug control (100%), indicating that most of the cells were sensitive 
to IM. 
 
 
 
 
 
 
 
Figure 3-1 The effect of IM treatment on BCR-ABL activity within CD34+ CML 
cells as measured by flow cytometry 
CD34+ CML cells were cultured ± 5µM IM for 16 hours, before p-CrkL levels 
were determined by FACS and compared to the levels obtained from normal 
CD34+ cells at baseline. Panels A and B demonstrate the p-CrkL profile from 
a ‘non-responder’ and ‘responder’ to IM, respectively.   
 
To fully understand the mechanism(s) of resistance in CML stem cells it is 
essential to be able to measure inhibition of BCR-ABL activity at the stem cell level 
and using very small cell samples. The phosphorylation of proteins in signal 
transduction is traditionally studied by means of techniques such as ELISA, which 
Non-responder Responder
A B
p-CrkL
Normal CD34+
CML CD34+ untreated
CML CD34+ + IM
Isotype control
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reliably provide information regarding homogeneous or purified cell populations. 
Hence, to further investigate the potential methods for the measurement of BCR-
ABL activity, the following studies were designed for the: 
 
1. Development of a novel ELISA method for the detection of BCR-ABL 
activity in CML cells 
2. Comparison of the ELISA method with established techniques for the 
measurement of BCR-ABL activity in CML cells 
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3.1 Development of a novel ELISA method for the measurement 
of BCR-ABL activity in CML cells 
 
3.1.1 Comparison of plastics for use in a novel ELISA assay for the 
determination of BCR-ABL activity in CML cells 
To further explore alternative methods for assessment of BCR-ABL, a novel 
ELISA method was developed. Initially, 96-well plates from two different 
companies (Greiner bio-one and Thermo Fisher Scientific) were tested for their 
suitability for the ELISA method. For Western blot, 10µg of protein is generally 
added per lane and the blot probed with a 1:1000 dilution of relevant antibody. 
Therefore, for this preliminary ELISA, each well of an ELISA plate was first coated 
with 10µg of K562 protein lysate and a 1:1000 dilution of p-Tyr antibody in 5% 
BSA/TBST was added to each relevant test well. Absorbance was then read at 
460nm using an ELISA plate reader. Figure 3-2 shows that the ELISA plate from 
Greiner bio-one gave the best discrimination in absorbance between the test wells 
(lysate + Ab) and background (no lysate + Ab and lysate - Ab), with a significant 
difference between the two different plates (p= 0.032). Therefore, the 96-well 
ELISA plates from Greiner bio-one were used for all subsequent experiments.  
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Figure 3-2 Comparison of plastics for use in a novel ELISA assay for the 
determination of BCR-ABL activity in CML cells 
ELISA plates from indicated companies were coated with 10µg of protein 
lysate from K562 cells and p-Tyr antibody was added to each relevant test 
well in triplicate (p=0.032). Negative controls were included- lysate without 
antibody and no lysate with antibody. Absorbance was read at 460nm. [Ab: 
antibody] 
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3.1.2 Optimisation of blocking solution for use in a novel ELISA method 
Next, different buffers were tested to determine the optimal blocking solution for 
the p-Tyr antibody for use in the novel ELISA method.  Each well of the ELISA 
plates were first coated with 10µg of protein lysate from K562 cells and blocked in 
either 5% BSA/TBST or 5% MILK/TBST, with a 1:1000 dilution of p-Tyr antibody in 
either 5% BSA/TBST or 5% MILK/TBST added to each relevant test well in 
triplicate. Figure 3-3 demonstrates that the 5% BSA/TBST blocking buffer gave the 
greatest discrimination in absorbance between the test wells and background, with 
a significant difference observed between the two buffers (p=0.037). Therefore, 
the 5% BSA/TBST blocking buffer was used in the ELISA for all subsequent 
experiments. 
 
 
 
 
 
 
 
 
Figure 3-3 Optimisation of blocking solution for use in a novel ELISA 
method 
ELISA plates were coated with 10µg of protein lysate from K562 cells and 
blocked in either 5% BSA/TBST or 5% MILK/TBST, with a 1:1000 dilution of 
p-Tyr antibody in either 5% BSA/TBST or 5% MILK/TBST added to each 
relevant test well in triplicate (p=0.037). Negative controls were included- 
lysate without antibody and no lysate with antibody.  
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3.1.3 Antibody and protein concentration titration for optimal use in a novel 
ELISA method 
Since cellular material is limited when working with primitive populations of primary 
CML cells, it is important to be as efficient with the protein lysate as possible. 
Furthermore, since antibodies are relatively expensive it is also essential that they 
are not wasted unnecessarily. Therefore an ELISA was performed using different 
concentrations of protein lysate and probed with different concentrations of the p-
Tyr antibody. ELISA plates were first coated with either 1µg (A), 5µg (B) or 10µg 
(C) of K562 protein lysate, before the indicated concentrations of p-Tyr were 
added to the plate in triplicate (Figure 3-4). Both 5 and 10µg of K562 protein lysate 
were found to give significantly increased absorbance levels as compared to 1µg 
of lysate (p= 0.0007 and 0.0011 for 1:2000 dilution; p= 0.0005 and 0.0029 for 
1:1000 dilution; p= 0.0023 and 0.0053 for 1:500 dilution and p= 0.0009 and 0.0005 
for 1:250 dilution for 1µg versus 5µg and 10µg of K562 protein lysate, 
respectively). Each of the antibody concentrations consistently gave absorbance 
levels of over 2.0 units using both 5 (B) and 10µg (C) of protein lysate. Therefore, 
it was decided that 5µg of protein lysate per well, using the lowest antibody 
concentrations would be sufficient to give effective p-Tyr absorbance readings. 
However, since K562 cells express multiple copies of BCR-ABL and hence, have 
much higher TK activity than human primary CML cells, it was thought best to err 
on the side of caution in terms of the amount of p-Tyr antibody used. 
Therefore, in order to give the best results, whilst also being as economical as 
possible with both the amount of protein and antibody used, it was decided that 
the optimal conditions for the ELISA were a 1:1000 dilution of p-Tyr antibody, 
using 5µg of protein lysate. 
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Figure 3-4 Antibody and protein concentration titration for optimal use in a 
novel ELISA method 
ELISA plates were first coated with either 1µg (A), 5µg (B) or 10µg (C) of 
K562 protein lysate, before the indicated concentrations of p-Tyr were added 
to the plate in triplicate. Negative controls were included- lysate without 
antibody and no lysate with antibody. Absorbance was read at 460nm. 
 
 
 
 
 
 
 
 
1:2000 1:1000 1:500 1:250
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Concentration of antibody
Ab
so
rb
an
ce
 
(46
0n
m
)
1:2000 1:1000 1:500 1:250
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Concentration of antibody
A
bs
o
rb
an
ce
 
(46
0n
m
)
1:2000 1:1000 1:500 1:250
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
K562: Lysate - Ab
K562: No lysate + Ab
K562: Lysate + Ab
Concentration of antibody
A
bs
o
rb
an
ce
 
(46
0n
m
)
A B
C
 128 
3.1.4 Comparison of antibodies for optimal use in a novel ELISA method 
As the measurement of total tyrosine phosphorylation is not entirely specific to 
BCR-ABL, other antibodies were also tested in the ELISA method. Anti-p-ABL and 
anti-p-CrkL were compared to the anti-p-Tyr antibody, for the measurement of 
BCR-ABL activity within the Ph+ cell line, K562, in 3 replicate experiments. As 
shown in Figure 3-5, the anti-p-Tyr antibody gave the best discrimination in 
absorbance between Ph+ cells against background (p= 0.015 and 0.016 for p-Tyr 
versus p-CrkL and p-Abl, respectively). Therefore, this antibody was used in the 
ELISA for all subsequent experiments. 
 
 
 
 
 
 
 
 
 
Figure 3-5 Comparison of antibodies for optimal use in a novel ELISA 
method 
Activity was measured in K562 cells by ELISA using the indicated 
antibodies, in triplicate (p= 0.015 and 0.016 for p-Tyr versus p-CrkL and p-
Abl, respectively).  
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3.1.5 Confirmation of effective protein-coating in a novel ELISA method 
In order to confirm good reproducibility of protein coating, several ELISAs were 
initially performed using anti-GAPDH antibody. Figure 3-6 demonstrates that the 
results were very consistent, with an average reading of 1.59 absorbance units 
(460nm) (n=6) (range: 1.5253 - 1.6439; coefficient of variation: 5.24%) per 5µg of 
protein per well from K562 cells and an average reading of 1.57 absorbance units 
(460nm) (n=6) (range: 1.455 - 1.674; coefficient of variation: 5.54%) per 5µg of 
protein per well from HL60 cells. No significant difference was observed between 
the two cell lines (p=0.595). This, therefore, confirmed good protein-coating 
efficacy and to save on cell samples, the following ELISAs were conducted using 
the anti-p-Tyr antibody only. 
 
 
 
 
 
 
 
 
 
Figure 3-6 Confirmation of effective protein-coating in a novel ELISA method 
GAPDH levels were measured in K562 and HL60 cells by ELISA in 6 
replicates.  
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3.1.6 Assessment of p-Tyr in BCR-ABL positive and negative cell lines using 
a novel ELISA method 
The ELISA was further tested using other Ph+ BC CML cell lines, LAMA84 and 
BV173, in comparison with K562 cells and also the Ph- cell line, HL60 (Figure 3-7). 
The results were very consistent between the Ph+ cell lines. The anti-p-Tyr 
antibody produced absorbance readings of >3 absorbance units (460nm) for all 
Ph+ cell lines, whereas the reading was around 0.5 absorbance units (460nm) for 
the Ph- cell line, HL60. Further negative controls which consisted of lysate without 
antibody and antibody without lysate, consistently gave readings of <0.5 
absorbance units (460nm). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7 Assessment of p-Tyr in BCR-ABL positive and negative cell lines 
using a novel ELISA method 
Total p-Tyr status was measured by ELISA for each of the cell lines, in 
triplicate.  
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3.1.7 The effect on total p-Tyr levels upon drug treatment of K562 and HL60 
cell lines measured by ELISA 
The ELISA’s ability to detect changes in p-Tyr levels in CML cells following TKI 
treatment was next investigated. K562 and HL60 cells were first treated for 16 
hours with either IM or dasatinib and p-Tyr was measured by ELISA. Figure 3-8 
shows that in response to increasing concentrations of TKI, the absorbance 
readings decreased in K562 cells, reaching the background level of HL60 cells 
with 5µM IM and 150nM dasatinib treatment (p=0.000794 for no drug versus 1µM 
IM; p=0.000646 for no drug versus 2.5µM IM; p=0.000218 for no drug versus 5µM 
IM; p=0.000381 for no drug versus 10nM dasatinib and p=0.000274 for no drug 
versus 150nM dasatinib). As expected, neither IM nor dasatinib reduced the 
absorbance for HL60 cells (p=0.612664 for no drug versus 1µM IM; p=0.097389 
for no drug versus 2.5µM IM; p=0.658101 for no drug versus 5µM IM; p=0.255663 
for no drug versus 10nM dasatinib; and p=0.290042 for no drug versus 150nM 
dasatinib). 
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Figure 3-8 The effect on total p-Tyr levels upon drug treatment of K562 and 
HL60 cell lines measured by ELISA 
K562 and HL60 cells were treated ± increasing concentrations of IM (1, 2.5 
and 5µM) and dasatinib (10 and 150nM) for 16 hours (n=3). No significant 
differences were observed between no drug and each condition in HL60 
cells, whereas significant differences were observed between no drug and 
each condition in K562 cells, (p=0.612664 and 0.000794 for 1µM IM; 
p=0.097389 and 0.000646 for 2.5µM IM; p=0.658101 and 0.000218 for 5µM IM; 
p=0.255663 and 0.000381 for 10nM dasatinib; p=0.290042 and p=0.000274 for 
150nM dasatinib) for HL60 and K562 cells, respectively. 
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3.1.8 Effect of increasing concentrations of IM and dasatinib on Ba/F3 cell 
lines containing BCR-ABL mutations 
The ELISA was further tested by assessing the response of cells with known BCR-
ABL mutations to TKI treatment (Figure 3-9). Ba/F3 cells transduced with either 
BCR-ABL-p210 wild-type, M351T or T315I were exposed to IM (A) or dasatinib (B) 
for 16 hours. Following this, p-Tyr levels were assessed by ELISA. As expected, 
dasatinib was found to be more potent than IM, inducing 100% inhibition of p-Tyr 
in cells transduced with wild-type p210 at 150nm, as compared to 80% maximal 
inhibition with IM at 5µM. Consistent with the literature (292), dasatinib also 
inhibited the M351T mutation as effectively as the wild-type p210 at each 
concentration of drug. The specific type of mutation is a key factor in the level of 
resistance conferred to IM (293). The M351T mutation confers only moderate 
resistance to IM, which implies that dose escalation may be able to recapture a 
cellular response. This is indeed reflected in Figure 3-9A, where the level of p-Tyr 
inhibition reaches that of wild-type p210 at the highest concentration of IM. The 
T315I mutation was fully resistant to both agents as expected.  
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Figure 3-9 Effect of increasing concentrations of IM and dasatinib on Ba/F3 
cell lines containing BCR-ABL mutations 
Ba/F3-BCR-ABL p210, M351T, and T315I were cultured ± increasing 
concentrations of IM and dasatinib for 16 hours (n=3). Total p-Tyr levels 
were then determined by ELISA, in triplicate. The above figures demonstrate 
that the level of p-Tyr detected correlated with each Ba/F3-BCR-ABL 
mutant’s degree of IM (A) or dasatinib (B) resistance. 
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3.1.9 Assessment of p-Tyr in primary CML CD34+ and mature cells by ELISA 
Finally, the ELISA’s suitability for measuring BCR-ABL activity in both mature and 
primitive primary human CML samples was investigated. Primary CML CD34+ 
(n=3) and MNC samples (n=6) were found to have increased levels of p-Tyr at 
baseline, as compared to Ph- samples from both CD34+ (n=3) (p=0.012) and MNC 
(n=3) (p=0.0007) cell fractions (Figure 3-10).  
 
 
 
 
 
 
 
 
 
 
Figure 3-10 Assessment of p-Tyr in primary CML CD34+ and mature cells by 
ELISA 
Total p-Tyr status was measured by ELISA in CD34+ (n=3) and MNC (n=6) 
CML cells and compared to non CML cell samples from both fractions (n=3). 
Levels of p-Tyr were found to be significantly increased in the CML cell 
samples as compared to the Ph- cell samples (p=0.012 for CML versus non 
CML CD34+ cells and p=0.0007 for CML versus non CML MNC cells).  
 
Overall, these data confirm the novel ELISA’s ability to assess total p-Tyr levels in 
Ph+ cell lines, cells with known BCR-ABL mutations and both mature and primitive 
primary human CML cells. 
+
CM
L C
D3
4
+
No
n 
CM
L C
D3
4
CM
L M
NC
No
n 
CM
L M
NC
0.0
0.5
1.0
1.5
A
bs
o
rb
an
ce
 
(46
0n
m
)
 136 
3.2 Comparison of the novel ELISA method with established 
techniques for the measurement of BCR-ABL activity in CML 
cells 
 
Western blot is a well established and reliable method which has previously been 
shown to reproducibly measure p-CrkL. However, it is time-consuming and 
laborious which makes the testing of large sample numbers difficult. Furthermore, 
it requires a relatively large number of cells, which is often unrealistic when 
working with a small pool of primitive CML cells. More recently, flow cytometric 
methods have been developed to detect p-Tyr (291) and p-CrkL (130) levels in 
small numbers of primary CML cells. Although this technique requires few cells 
and is rapid, even within our own group we have found it to be less reproducible 
between individuals than Western blot. In order to determine how the novel ELISA 
method compared with the more established techniques, further investigations 
were carried out.  
 
3.2.1 Equivalence between Western blot, flow cytometry and ELISA methods 
as a means of detecting BCR-ABL activity in K562 cells 
K562 cells were first treated with IM (0, 1, 5µM) for 48 hours, before p-CrkL was 
measured by Western blot and FACS and p-Tyr was detected by ELISA. When 
phosphorylation levels from 3 independent experiments were compared, the 
methods appeared equivalent, with no significant differences observed between 
the 3 techniques (p=0.87 and 0.15 for Western versus flow cytometry; p=0.19 and 
0.24 for Western versus ELISA and p=0.2 and 0.13 for ELISA versus flow 
cytometry) for 1 and 5µM IM treatment, respectively (Figure 3-11).  
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Figure 3-11 Equivalence between Western blot, flow cytometry and ELISA 
methods as a means of detecting BCR-ABL activity in K562 cells 
K562 cells were treated with IM (0, 1, 5µM) for 48 hours. Reduction of p-CrkL 
was then detected by Western blot and flow cytometry and total p-Tyr was 
measured by ELISA. No significant differences were observed between the 3 
methods (p=0.87 and 0.15 for Western versus flow cytometry; p=0.19 and 
0.24 for Western versus ELISA and p=0.2 and 0.13 for ELISA versus flow 
cytometry) for 1 and 5µM IM treatment, respectively. 
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3.2.2 Comparison of flow cytometry and ELISA methods used to measure 
the effect of IM treatment on Ba/F3 cell lines containing BCR-ABL mutations 
The ELISA was further investigated by assessing the response of Ba/F3 cells 
transduced with either BCR-ABL-p210 wild-type, M351T or T315I, to 16 hours 
treatment with 5µM IM, and the results were compared with data obtained from the 
p-CrkL flow cytometry method (Figure 3-12).  Inhibition of p-Tyr was maximal in 
BCR-ABL-p210 wild-type (80% reduction as compared to no drug control (100%)) 
and each mutant was inhibited according to their degree of low and high IM-
resistance. Furthermore, the techniques appeared equivalent with no significant 
differences observed between the 2 methods (p=0.55 for BCR-ABL-p210 wild-
type; p=0.08 for M351T and p=0.06 for T315I). 
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Figure 3-12 Comparison of flow cytometry and ELISA methods used to 
measure the effect of IM treatment on Ba/F3 cell lines containing BCR-ABL 
mutations 
Ba/F3-BCR-ABL p210, M351T and T315I were cultured ± 5µM IM for 16 hours. 
Total p-Tyr levels were then determined by ELISA, and compared to p-CrkL 
levels measured by flow cytometry. Percentage phosphorylation was 
calculated based on the relevant no drug control (100%). The level of p-Tyr 
detected correlated with each Ba/F3-BCR-ABL mutant’s degree of IM 
resistance, with no significant differences detected between the methods 
(p=0.55 for wild-type p210; p=0.08 for M351T and p=0.06 for T315I). 
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3.2.3 Equivalence between ELISA and flow cytometry methods as a means 
of detecting BCR-ABL activity in CML CD34+ cells 
It was noted that the comparison made between p-Tyr and p-CrkL levels is not 
strictly accurate and that the assessment of total tyrosine phosphorylation assayed 
by ELISA and flow cytometry, would allow a better evaluation of the ELISA 
method. Therefore, primary CML CD34+ cells (n=4, >90% Ph+), were treated ± 
5µM IM before p-Tyr levels were measured by both ELISA and flow cytometry. 
Incomplete inhibition of p-Tyr was achieved following IM treatment (around 70% 
inhibition as compared to no drug control (100%)), with no significant difference 
observed between the ELISA and flow cytometric methods (p=0.54) (Figure 3-13). 
This level of BCR-ABL inhibition in response to IM is consistent with data 
previously published (131). 
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Figure 3-13 Equivalence between ELISA and flow cytometry methods as a 
means of detecting BCR-ABL activity in CML CD34+ cells 
CML CD34+ cells (n=4) were treated ± 5µM IM for 16 hours and samples were 
taken for p-Tyr measurement by ELISA and flow cytometry. The IM-treated 
CD34+ cells showed a 70% reduction in BCR-ABL activity as compared to no 
drug control (100%). No significant differences were observed between the 
methods (p=0.54).  
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3.3 Summary 
The advantages and disadvantages of the techniques to assess the activity of 
BCR-ABL that have been described in this chapter and in the literature (130, 131, 
290, 291, 294-297) are described in brief in Table 3-1. Although Western blot has 
been shown to be a reliable and reproducible technique for the assessment of p-
CrkL, it requires >100 times the number of cells needed for flow cytometry.  This is 
often not feasible when attempting to characterise a rare population of CML stem 
cells. The main advantages of the p-Tyr ELISA are that it is reproducible between 
individuals and also allows the assay of many samples at once, so could be 
adapted for high throughput applications. However, large cell numbers are also 
required, as one sample performed in triplicate would require a total of 15µg of 
protein lysate. The experiments performed in this chapter were performed without 
verification of sample protein-coating. However, to be more exact, a loading 
control, such as GAPDH should be included for each sample, taking the total 
amount of protein required up to 30µg. This is more than is necessary for a 
Western blot and an unrealistic amount when it comes to working with very 
primitive CML cells. When analysing small numbers of immature CML cells the 
only reasonable option is flow cytometry. It also provides an accurate assessment 
of a viable cell population, as any dead cells or debris can be gated out prior to 
analysis, which would be impossible with either Western blot or ELISA. 
Furthermore, multi-parameter flow cytometry offers the valuable advantage of 
characterising certain cell surface and intracellular markers, to identify cellular 
subpopulations in response to a stimulus or drug treatment. This is a key factor 
when attempting to identify CML stem cells, track their survival and proliferation, 
and also assess BCR-ABL activity in response to TKI treatment. 
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In summary, for the single measurement of BCR-ABL activity, it would be 
advisable to use anti-p-CrkL antibody in Western blot in all situations where 
sufficient cells are available and the number of samples to be tested is low. When 
a large quantity of samples requires to be tested, then ELISA for p-Tyr can be 
used. Where cell numbers are limited and a number of parameters require to be 
tested simultaneously, flow cytometry should be used. However, wherever 
possible key results should be confirmed using a limited number of Western blots 
to reassure the investigator that their interpretation of results obtained by flow 
cytometry and ELISA are consistent with the gold standard.    
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Western 
blot 
(BCR-ABL) 
(295-297) 
 
 
Western 
blot 
(p-CrkL) 
(130, 131, 
290, 294) 
Flow 
cytometry 
(p-Tyr) (291) 
Flow 
cytometry 
(p-CrkL) 
(130, 131) 
ELISA   
(p-Tyr) 
 
Required 
number of 
cells 
 
105 – 106 
 (≥10µg/ 
well) 
105 – 106 
 (≥10µg/ 
well) 
103 – 105 103 – 105 10
5 
– 106 
(5µg/well) 
 
Ease of 
throughput 
 
+ + ++ ++ +++ 
 
Time 
required 
 
≥ 2 days ≥ 2 days 2-4 hours 2-4 hours 1 day 
 
Reproducib 
-ility 
 
+++ +++ ++ ++ +++ 
 
Suitability 
for cell lines 
 
+++ +++ +++ +++ +++ 
 
Suitability 
for mature 
primary 
cells 
 
X +++ +++ +++ +++ 
 
Suitability 
for CD34+ 
primary 
cells 
 
+++ +++ +++ +++ +++ 
 
Suitability 
for multi-
parametric 
analysis 
 
X X +++ +++ X 
 
Table 3-1  Summary of methods to assess BCR-ABL activity in Ph+ cell lines 
and primary CML cells  
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4. RESULTS (II) Is BCR-ABL relevant for the survival of 
cancer stem cells in CML? 
 
 
The importance of BCR-ABL for the malignant transformation of CML has led to 
the development of TKIs, such as IM. Despite IM’s initial therapeutic success, only 
a small proportion of patients obtain a CMR, where they become negative for 
BCR-ABL transcripts by RT-PCR. It is hypothesised that this MRD is the result of 
a primitive subpopulation of LSCs, which may cause relapse at a later date. 
Another major clinical concern is the observation of molecular resistance in IM-
treated patients. There are 2 broad categories of IM resistance: BCR-ABL-
independent and BCR-ABL-dependent. In most cases of acquired resistance to 
IM, BCR-ABL-dependence is found. Postulated mechanisms include BCR-ABL 
amplification with over-expression and decreased intracellular IM concentrations 
caused by reduced drug-uptake and increased drug-efflux through drug 
transporters (298).  However, BCR-ABL dependent IM resistance is most often 
attributed to the development of point mutations within the ABL-kinase domain 
(240),(299).  A further possibility is that IM resistant stem cells are simply 
refractory to TKI treatment due to poorly understood properties that allow them to 
survive drug exposure. For example, we and others (131, 298, 300) have 
demonstrated that CML stem cells over-express BCR-ABL, which may be 
sufficient to render them IM resistant.  
 
BCR-ABL-independence suggests that resistance is a result of stem cell-related or 
intrinsic mechanisms whereby the leukaemia cells either do not require BCR-ABL 
for survival and the maintenance of a quiescent state; or are no longer reliant on 
BCR-ABL to drive proliferation. These cells may employ additional mechanisms 
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which are responsible for their growth and survival. Although examples of this type 
of resistance have been demonstrated in more advanced phase CML (301, 302), 
this has not yet been proven for the CP CML stem cell population.  
 
In an attempt to understand the mechanisms of IM resistance in CML, the primary 
aim of this chapter is to determine whether CML stem cells are dependent on 
BCR-ABL kinase activity for their survival. Hence, the following experiments were 
designed for the: 
 
1. Optimisation of culture conditions to maximise targeting of BCR-ABL kinase 
activity within CP CML cells. 
2. Characterisation of primitive CML cells following kinase inhibition of BCR-
ABL 
3. Analysis of functionality of the CML cells remaining following prolonged 
BCR-ABL kinase inhibition 
 
If the CML stem cells are proven to be dependent on BCR-ABL kinase activity for 
survival then efforts to enhance intracellular concentration and binding of potent 
TKIs selective for BCR-ABL should lead to improved responses/cures for patients. 
If CML stem cell survival is proven to be independent of BCR-ABL kinase activity 
then alternative approaches to develop CML stem cell therapies would be 
required. 
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4.1 Optimisation of culture conditions to maximise targeting of 
BCR-ABL kinase activity within CP CML cells 
 
4.1.1 Comparison of GF culture conditions in TKI-treated CML cells 
In order to determine the optimal culture conditions for maximal BCR-ABL 
inhibition, preliminary experiments were carried out. CML stem cells produce 
autocrine cytokines at low levels and are able to survive in culture in the absence 
of added GFs (190), however, these cells may also respond to supplemental 
cytokines. There has therefore been concern that the addition of cytokines at high 
concentration to these cultures may support the survival of CML stem cells during 
exposure to TKIs (303),(235). Thus, an experiment was performed to compare the 
effects of TKI treatment on CML CD34+ cells, cultured in SFM with and without 
added GF support. Figure 4-1 shows total cell numbers, determined by trypan blue 
dye exclusion, following treatment ± either 2µM IM or 150nM dasatinib and 
cultured ± 5GF for 3 days (n=3). As predicted, untreated CML CD34+ cells were 
able to survive and proliferate in the absence of GFs. However, this condition 
resulted in significantly reduced cell numbers as compared to untreated cells 
cultured with GFs (p=0.05). Treatment with either IM or dasatinib in the presence 
of GFs resulted in a significantly decreased cell number as compared to the 
corresponding untreated control (p=0.05 for no drug +GF versus IM +GF and 
p=0.04 for no drug +GF versus dasatinib +GF). Interestingly, TKI treatment in the 
presence of GFs also gave the same effect as removing the GF support from 
untreated control cells, with no significant difference observed between the 
conditions (p=0.70 for no drug versus IM and p=0.94 for no drug versus dasatinib). 
This demonstrates the protective effect that cytokines may have over TKI 
treatment of CML cells. Due to the compelling evidence that autocrine stimulation 
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via cytokines such as, G-CSF, IL-3 and GM-CSF could be of importance for the 
regulation of the growth and survival of CML cells (187, 190); it is perhaps not 
surprising that the exogenous GF support mediated such resistance against the 
TKI treatment of these CML cells. The greatest effect was observed with TKI 
treatment minus GFs, with a significantly decreased cell number as compared to 
TKI treatment plus GFs (p=0.03 for IM -GF versus IM +GF; p=0.04 for IM -GF 
versus dasatinib +GF; p=0.02 for dasatinib -GF versus IM +GF and p=0.03 for 
dasatinib -GF versus dasatinib +GF). There was no significant difference in cell 
number observed between IM- and dasatinib-treated cells cultured without GFs 
(p=0.774). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1 Comparison of GF culture conditions in TKI-treated CML cells 
CML CD34+ cells (n=3) were treated ± either 2µM IM or 150nM dasatinib and 
cultured in SFM ± a 5GF cocktail for 3 days. Viable cell counts were 
determined by trypan blue dye exclusion. 
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4.1.2 Comparison of TKI treatments and exposure times in primary CML 
cells 
In order to compare the effects of different TKI treatments, studies were performed 
whereby CD34+ CML cells were cultured in SFM without exogenous GF support 
and treated for 1, 2, 3, 4, 24 and 72 hours with increasing concentrations of either 
IM, nilotinib or dasatinib. At each treatment time-point, the cells were washed 
twice with PBS to remove any trace of drug and put back into culture with fresh 
medium. A viable cell count was then performed by trypan blue dye exclusion at 
the 72 hour time-point. Figure 4-2 demonstrates the percentage of viable CML 
cells remaining following the treatment timecourse with IM (A), nilotinib (B) or 
dasatinib (C). The percentage of viable cells was significantly increased, following 
exposure for the shortest treatment time (1 hour), as compared to the longest 
treatment time (72 hours), using the lowest concentration of IM (1µM) (p=0.009). 
However, no significant difference in cell number was observed as the 
concentration was increased (p=0.11 for 5µM IM; p=0.18 for 10µM IM and p=0.5 
for 20µM IM). Furthermore, no significant difference in viable cell number was 
observed between the 1 and 20µM concentrations of IM at both the shortest and 
longest treatment time-point (p=0.07 and 0.14) for 1 and 72 hours, respectively 
(Figure 4-2A).  
No significant differences in viable cell number were observed between the 
shortest (1 hour) and longest (72 hours) treatment times using both the lowest and 
highest concentration of nilotinib (p=0.47 and p=0.436) (Figure 4-2B) and 
dasatinib (p=0.06 and 0.1475) (Figure 4-2C) for the lowest and highest 
concentrations of drug, respectively. Similarly, no significant difference in viable 
cell number was detected between 10 and 1000nM dasatinib treatment (p=0.1255 
 150 
and 0.081) and 1 and 20µM nilotinib treatment (p=0.27 and p=0.23) at both the 
shortest and longest treatment time-point, respectively.  
Figure 4-2D demonstrates a comparison of each TKI treatment at clinically 
achievable concentrations. Although no significant differences in cell number were 
observed between each condition by the 72 hour time-point (p=0.31 for IM versus 
nilotinib; p=0.074 for IM versus dasatinib and p=0.19 for nilotinib versus dasatinib), 
there was a trend towards a greater reduction in viable cells following 150nM 
dasatinib treatment. 
 
In general, these data show that transient exposure with relatively low 
concentrations of TKI is as effective as continuous treatment with increased 
concentrations of TKI, which are clinically unachievable. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 151 
A  
 
 
 
 
 
 
 
B  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 24 72
0
25
50
75
100
No drug
1µM IM
5µM IM
10µM IM
20µM IM
Treatment times (hours)
%
 
v
ia
bl
e 
ce
lls
1 2 3 4 24 72
0
25
50
75
100
No drug
1µM nilotinib
5µM nilotinib
10µM nilotinib
20µM nilotinib
Treatment times (hours)
%
 
v
ia
bl
e 
ce
lls
 152 
C  
 
 
 
 
 
 
 
D  
 
 
 
 
 
 
 
 
Figure 4-2 Comparison of TKI treatments and exposure times in primary 
CML cells 
CD34+ CML cells (n=3) were treated with increasing concentrations of IM (A), 
nilotinib (B) and dasatinib (C) for the indicated treatment times. Following 
each time-point, the cells were washed with PBS and put back into culture 
with fresh media. Viable cell counts were performed by trypan blue dye 
exclusion at the 72 hour time-point and compared to no drug control cells 
(100%). A comparison of each TKI treatment at a clinically achievable dose 
is shown in Panel D.  
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4.1.3 Effect of TKI treatment on apoptosis induction within CD34+ CML cells  
In order to determine which TKI had the greatest effect on CML cells, further 
characterisation was carried out. First, CML CD34+ cells were cultured without 
GFs and treated ± either 5µM IM or 150nM dasatinib for 48 hours. Apoptosis was 
then determined by annexin-V and viaprobe staining as measured by flow 
cytometry (n=3). Figure 4-3 demonstrates the relative fold change in the 
percentage of early and late apoptotic cells (i.e. the cells which stained positive for 
both annexin-V and viaprobe) for each condition, as compared to no drug control. 
IM treatment significantly increased the number of apoptotic cells as compared to 
no drug control (p=0.05). Dasatinib treatment significantly increased the number of 
apoptotic cells as compared to both no drug control and IM treatment (p=0.02 and 
p=0.05, respectively).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3 Effect of TKI treatment on apoptosis induction within CD34+ CML 
cells 
CML CD34+ cells were cultured for 48 hours in SFM without GFs and treated 
± either 5µM IM or 150nM dasatinib (n=3). Apoptosis was determined at this 
time-point by annexin-V and viaprobe staining measured by flow cytometry. 
Each condition was then compared relative to a no drug control. 
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4.1.4 Effect of TKI treatment on p-CrkL levels within CML cells 
To compare the effects of TKI treatment on BCR-ABL activity within CML cells,    
p-CrkL was measured. CD34+ CML cells were cultured in SFM and treated ± an 
IC90 concentration of TKI (5µM IM and 150nM dasatinib) for a total of 72 hours. 
The levels of p-CrkL were then measured by Western blot of whole cell protein 
lysates, prepared at 16 hours in order to measure the immediate effects of TKI 
inhibition of BCR-ABL and then at 72 hours to measure the effects of TKI on cells 
which survive the initial drug treatment. Pan-actin was included as a protein 
loading control. Figure 4-4 demonstrates that IM treatment resulted in a reduction 
of p-CrkL, as compared to no drug control after 16 hours of treatment, suggesting 
that the majority of cells were IM-sensitive. However, despite re-exposure to IM 12 
hours before the 72 hour time-point, those cells that survived treatment showed no 
reduction in p-CrkL, consistent with enrichment, following cell death, of an IM-
resistant population. Dasatinib treatment inhibited p-CrkL both at the early time-
point and also, unlike IM, at the later time-point. 
 
 
Overall, these data show that the greatest effect of TKI on CML cells is seen in 
culture conditions without added GF support. Further, that dasatinib is superior to 
IM, in terms of inducing apoptosis (which should lead to a reduction in CML cell 
numbers) and provides the greatest inhibition of BCR-ABL. Therefore, dasatinib 
treatment without added GFs was the culture condition used for all subsequent 
experiments. 
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Figure 4-4 Effect of TKI treatment on p-CrkL levels within CML cells 
Whole cell protein lysates were prepared from CD34+ CML cells treated ± 
either 5µM IM or 150nM dasatinib for a total of 72 hours. The levels of p-CrkL 
were assessed in each sample at the 16 and 72 hour time-point by Western 
blot. Pan-actin levels were also measured as a protein loading control. 
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4.2 Characterisation of primitive CML cells following kinase 
inhibition of BCR-ABL  
 
4.2.1 Assessment of CML cell viability following treatment with dasatinib 
The studies described in Figure 4-1 demonstrate that up to 6 days dasatinib 
treatment does not completely eradicate CML CD34+ cells, cultured without GFs. 
Timecourse studies also demonstrated that any CML cells which were sensitive to 
TKI, were likely to be targeted within the first few hours of treatment. In an attempt 
to completely isolate and then characterise the CML cells which are not initially 
targeted by TKI treatment, the exposure time to dasatinib was increased. Figure 4-
5A demonstrates the cell counts as determined by trypan blue dye exclusion, 
following treatment ± 150nM dasatinib for 12 days. Every 3 days, cells were 
washed twice with PBS, cultured with fresh medium and re-drugged with 
dasatinib, to ensure no degradation of drug over the timecourse. As with previous 
data, untreated cells were able to expand despite being cultured without GFs, 
whereas, dasatinib-treated cells were significantly reduced in viable cell number to 
3.4x105  total cells by day 12 (<2% cells remaining relative to no drug control, 
p=0.01). Figure 4-5B shows the percentage viability, as compared to input cell 
number, for dasatinib-treated cells. At the end of the timecourse, residual viable 
cells represented <10% of the starting cell number.  
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Figure 4-5 Assessment of CML cell viability following treatment with 
dasatinib 
Panel A demonstrates the viable cell counts from CD34+ CML cells treated ± 
150nM dasatinib and cultured without exogenous GF support, as measured 
by trypan blue dye exclusion at each time-point. Panel B shows the 
percentage of surviving cells at each time-point, calculated based on 
starting cell number (100%). 
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4.2.2 D-FISH profiles of CML cells treated with dasatinib 
Previous studies have reported BCR-ABL amplification in primary cells from 
patients with advanced phase CML and that this may be a mechanism of acquired 
drug resistance (238). In order to determine whether the cells which survived 
dasatinib exposure showed evidence of oncogene amplification, D-FISH was 
performed. Only a single copy of the BCR-ABL gene was detected in each of the 
samples. Figure 4-6 demonstrates the D-FISH profile of one representative 
patient’s CML cells following 12 days treatment ± 150nM dasatinib. In each of the 
three patients samples kindly tested by Mrs Elaine Allan, >95% of the cells were 
shown to be BCR-ABL positive by D-FISH, both before and after dasatinib 
treatment. Although normal cells would not survive 12 days culture in SFM without 
GF support; these data definitively rule out both the presence of normal cells and 
oncogene amplification as explanations for resistance.  
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Figure 4-6 D-FISH profiles of CML cells treated with dasatinib 
Representative FISH profile from non CML CD34+ cells at baseline (A), 
untreated CD34+ CML cells following the 12 day timecourse (B) and 150nM 
dasatinib-treated CD34+ CML cells following the 12 day timecourse (C). 
Green signals represent BCR; red signals represent ABL and yellow signals 
represent the BCR-ABL fusion gene (denoted by the white arrows). 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
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4.2.3 Analysis of ABL-kinase domain mutations in CML cells treated with 
dasatinib 
IM resistance is most often attributed to the development of point mutations within 
the ABL-kinase domain. To investigate whether this was a potential mechanism 
for the cells to remain resistant to dasatinib, a mutation screen of the ABL-kinase 
domain of BCR-ABL was kindly performed by Dr Sandrine Hayette (Hôpital Lyon, 
Lyon, France) on RNA purified from CML cells, both before and after ± 12 days 
dasatinib exposure. No mutation was detected in any of the patients’ samples 
(n=3). Direct sequencing of the ABL-kinase domain has a sensitivity of about 10-
20% (244), therefore if a mutation was present, it would be in less than 20% of the 
surviving cells following dasatinib treatment. This then rules out mutation as a 
means of dasatinib resistance, in the majority of the cells which remained following 
prolonged dasatinib treatment. 
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4.2.4 Expression of BCR-ABL in CML cells following dasatinib treatment 
Previously, it has been demonstrated that patients treated with allogeneic 
transplantation had Ph+ cells detected by D-FISH, but remained BCR-ABL 
negative by RT-PCR. To determine whether the primitive CML cells from this 
study were transcriptionally silent, the expression of BCR-ABL was measured in 
the untreated and 150nM dasatinib-treated cells at day 12 of the timecourse by 
qRT-PCR and these levels were compared to the same patients’ cells at baseline. 
Figure 4-7 demonstrates that CML cells at baseline expressed 82.7% BCR-ABL 
as compared to total ABL. For 12 day untreated and 150nM dasatinib-treated cells 
BCR-ABL as compared to total ABL was 71 and 59%, respectively, with no 
significant differences observed between the conditions (p=0.427 for baseline 
versus no drug; p=0.109 for baseline versus 150nM dasatinib and p=0.215 for no 
drug versus 150nM dasatinib). These data suggest that although BCR-ABL kinase 
activity has been inhibited within these surviving CML cells, BCR-ABL is still 
expressed at the transcript level. 
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Figure 4-7 Expression of BCR-ABL in CML cells following dasatinib 
treatment 
BCR-ABL mRNA transcripts were measured by qRT-PCR in CD34+ CML cell 
samples (n=3) either at baseline or following treatment ± 150nM dasatinib for 
12 days. 
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4.2.5 Analysis of p-CrkL within normal cells and compared to CML cells 
Since the previous experiments ruled out the most common means of resistance 
in TKI-treated CML cells, the level of inhibition of BCR-ABL kinase activity was 
next investigated. As stated in the introduction, p-CrkL has been found to be an 
excellent marker for the measurement of BCR-ABL kinase activity in CML cells. 
However, in addition to its role in CML, CrkL is also implicated in signal 
transduction by integrins, B- and T-cell receptors, and cytokines such as 
erythropoietin, IL-3, SCF, and thrombopoietin (304-309). This, therefore, implies 
that some level of CrkL phosphorylation is evident in normal cells. In order to test 
this, non CML CD34+ cells (n=3) and CML CD34+ cells (n=3) were treated ± 
150nM dasatinib for 24 hours and p-CrkL levels were compared. The 24 hour 
time-point was chosen in order to reflect the early effects of TKI treatment. The 
percentage of p-CrkL present in each sample was then calculated based on the 
levels of p-CrkL detected in untreated CML CD34+ cells (n=3) (100%). Figure 4-8 
demonstrates that a level of 34 and 32.3% p-CrkL was observed in the non CML 
cells untreated and treated with dasatinib, respectively, as compared to 37% p-
CrkL in dasatinib-treated CML cells. No significant differences in p-CrkL levels 
were observed between the conditions (p=0.35 for dasatinib-treated CML cells 
versus untreated non CML cells; p=0.14 for dasatinib-treated CML cells versus 
dasatinib-treated non CML cells and p=0.28 for untreated non CML cells versus 
dasatinib-treated non CML cells).  
 
In all subsequent experiments, the level of p-CrkL present in normal cells was 
subtracted from the level present in CML cells treated ± dasatinib, in order to give 
a true measure of BCR-ABL inhibition.  
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Figure 4-8 Analysis of p-CrkL within normal cells and compared to CML cells 
Levels of p-CrkL were measured by flow cytometry in non CML (n=3) versus 
CML CD34+ cells (n=3) treated ± 150nM dasatinib for 24 hours.  
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4.2.6 Flow cytometric analysis of p-CrkL expression within a total population 
of CML cells treated with dasatinib 
In order to determine whether prolonged dasatinib exposure could completely 
inhibit BCR-ABL activity within the total CML cell population, flow cytometry was 
used to measure p-CrkL levels within the 12 day dasatinib-treated CML samples. 
Figure 4-9 demonstrates that within the bulk population of CML cells, dasatinib 
induced a maximal inhibition of p-CrkL by day 12 of treatment, with no significant 
difference observed between the time-points (p=0.54 for day 4 versus day 8; 
p=0.84 for day 4 versus day 12 and p=0.3 for day 8 versus day 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-9 Flow cytometric analysis of p-CrkL expression within a total 
population of CML cells treated with dasatinib 
CD34+ CML cells (n=3) were cultured in SFM minus GFs and treated ± 150nM 
dasatinib for 12 days. The levels of p-CrkL were then measured by flow 
cytometry at each indicated time-point. 
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4.2.7 Western blot analysis of p-CrkL expression within a total population of 
CML cells treated with dasatinib 
In order to confirm the results from the flow cytometric anaysis of p-CrkL within the 
bulk population of dasatinib-treated cells (as described in Figure 4-9), a Western 
blot for p-CrkL was performed on the cells remaining after 12 days treatment. 
Figure 4-10A shows that near complete inhibition of p-CrkL was achieved in 2 of 
the patients’ dasatinib-treated CML cells (CML 232 and 219) and that complete 
inhibition was reached in 1 patient’s CML cells (CML 235).  To determine the 
percentage of p-CrkL in each sample, densitometry was performed on the blots 
shown in Figure 4-10A, with correction on each arm for its corresponding pan-
actin loading control. Figure 4-10B demonstrates that 94.5% inhibition of p-CrkL 
was achieved in the total population of dasatinib-treated CML cells, as determined 
by Western blot (p=0.00014 for dasatinib-treated cells versus no drug control 
(100%)).  
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Figure 4-10 Western blot analysis of p-CrkL expression within a total 
population of CML cells treated with dasatinib 
Panel A shows p-CrkL profiles from 3 patients’ CD34+ CML cells treated ± 
150nM dasatinib for 12 days. Pan-actin was included in each experiment as a 
protein loading control. Panel B shows the mean percentage of p-CrkL 
expressed in the samples shown in panel A, as measured by densitometry. 
Each sample was corrected for its corresponding pan-actin control 
(p=0.00014 for dasatinib treatment versus no drug control (100%)). 
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4.2.8 Levels of p-CrkL within each cell division of CML cells treated with 
dasatinib 
It has previously been demonstrated by our own group (131) and others 
(300),(298), that BCR-ABL is over-expressed within very primitive populations of 
CML cells. Therefore, it is unclear whether the level of inhibition of p-CrkL 
following dasatinib treatment, as seen in the total population of CML cells (Figure 
4-10), is representative of all cells, or potentially 100% inhibition in the majority of 
cells and 0% inhibition in a smaller subpopulation. To determine whether 
prolonged dasatinib exposure could completely inhibit BCR-ABL activity, 
specifically within the undivided primitive CML cell population and also in each 
subsequent cell division, multi-colour flow cytometry was used. In the CML CD34+ 
cells described in Figure 4-10, intracellular p-CrkL measurement was combined 
with CFSE analysis by flow cytometry. Cells that retain maximal CFSE 
fluorescence (CFSEmax), as compared to a colcemid control, represent the 
primitive CD34+ cells that remain undivided. Figure 4-11A shows the levels of p-
CrkL within each cell division following 150nM dasatinib treatment, as calculated 
based on the levels of p-CrkL in each corresponding untreated control (100%).  
Statistical analysis revealed no difference in p-CrkL levels between the total CML 
cell population and each cell division at every time-point (Table 4-1). 
 
 Day 4 Day 8 Day 12 
Undivided population 0.152 0.578 0.377 
Division 1 0.312 0.457 0.645 
Division 2 0.748 0.391 0.805 
Division 3 0.061 0.743 0.776 
 
Table 4-1 p values for the total CML cell population versus each division of 
CML cells treated with 150nM dasatinib for 12 days 
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In order to determine whether this was the maximal amount of BCR-ABL inhibition 
achievable by dasatinib, CML CD34+ cells (n=3) were also treated with a much 
increased dose of dasatinib (1000nM; not achievable in patients). Figure 4-11B 
demonstrates that, using a higher concentration of dasatinib, no significant 
difference was observed between the total population and each cell division at 
every time-point (Table 4-2). Furthermore, no significant difference was observed 
between 150nM and 1000nM dasatinib treatment (Table 4-3). 
 
 Day 4 Day 8 Day 12 
Undivided population 0.787 0.382 0.455 
Division 1 0.529 0.441 0.940 
Division 2 0.319 0.984 0.273 
Division 3 0.616 0.185 0.191 
 
Table 4-2 p values for the total CML cell population versus each division of 
CML cells treated with 1000nM dasatinib for 12 days 
 
 Day 4 Day 8 Day 12 
Total population 0.827 0.718 0.768 
Undivided population 0.748 0.947 0.494 
Division 1 0.954 0.567 0.715 
Division 2 0.694 0.143 0.877 
Division 3 0.945 0.422 0.425 
 
Table 4-3 p values for the 12 day 150nM dasatinib-treated CML cells versus 
the 12 day 1000nM dasatinib-treated CML cells 
 
Although there looks to be a trend towards increased p-CrkL inhibition in later cell 
divisions as compared to earlier ones (specifically, division 3 versus undivided 
cells) in both 150 and 1000nM dasatinib-treated cells, the difference was not 
significant (Table 4-4).  
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 Day 4 Day 8 Day 12 
150nM dasatinib 0.174 0.409 0.357 
1000nM dasatinib 0.803 0.332 0.329 
 
Table 4-4 p values for the undivided population of cells versus cell division 3 
of both 12 day 150nM dasatinib-treated CML cells and 1000nM dasatinib-
treated CML cells 
 
These data indicate that maximal pharmacological inhibition of BCR-ABL is 
achieved with 150nM dasatinib and that every subpopulation of CML cells is 
inhibited equally. 
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Figure 4-11 Levels of p-CrkL within each cell division of CML cells treated 
with dasatinib 
CFSE-stained CML CD34+ cells (n=3) were treated with either 150nM 
dasatinib (A) or 1000nM dasatinib (B) for 12 days. Measurement of p-CrkL 
was performed by flow cytometry at the indicated time-points, within each 
cell division. The level of p-CrkL was calculated based on the relevant 
untreated control (100%). 
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4.2.9 Comparison of the phosphorylation levels of CrkL and STAT5 within 
dasatinib-treated CML cells 
Shah and colleagues have recently suggested that, since CrkL is physically 
associated to- and highly phosphorylated by- BCR-ABL, the detection of p-CrkL 
may not be sensitive enough to detect modest changes in BCR-ABL activity. The 
authors suggest that other endpoints should also be measured in order to make 
an accurate assessment of BCR-ABL inhibition (310). Therefore, in order to verify 
whether the measurement of p-CrkL gave an exact representation of the amount 
of BCR-ABL inhibition achieved, the phosphorylation of another downstream 
substrate, STAT5, was also measured. Figure 4-12 demonstrates the levels of p-
STAT5 within each cell division of CFSE-stained CML CD34+ cells, treated for 12 
days with 150nM dasatinib, as measured by flow cytometry. These data were then 
compared to the p-CrkL results at day 12 which were demonstrated in Figure 4-
11A. No significant differences were observed between the two methods for 
determining the inhibition of BCR-ABL kinase activity (p=0.4 for the total 
population; p=0.95 for the undivided population; p=0.83 for division 1; p=0.8 for 
division 2 and p=0.52 for division 3).  
 
It should be noted that, since non CML samples are relatively rare, it was not 
feasible to use one sample solely for the purpose of measuring the baseline levels 
of p-STAT5. Therefore, the levels of p-STAT5 and p-CrkL were compared within 
CD34+ CML cells only, without any non CML background correction. 
 
These data further confirmed the reliability of the p-CrkL flow cytometric method 
for the measurement of BCR-ABL activity. 
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Figure 4-12 Comparison of the phosphorylation levels of CrkL and STAT5 
levels in dasatinib-treated CML cells 
CFSE-stained CML CD34+ cells (n=3) were treated ± 150nM dasatinib for 12 
days. Measurement of p-STAT5 was performed by flow cytometry at day 12, 
within each cell division. The level of p-STAT5 was calculated based on the 
relevant untreated control (100%) and compared to the p-CrkL data 
described in Figure 4-11A. 
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4.2.10 Undivided CML cell recoveries as measured by CFSE-staining 
Previous studies by our lab have demonstrated the anti-proliferative effect of both 
IM (226) and dasatinib (131). Since the quiescent CML stem cell population 
resides within the CFSEmax population, it is important to measure the percentage 
of cells within this gate, in order to determine whether these cells have been 
targeted following TKI treatment. Therefore, CFSE staining was used to assess 
the most primitive CML cell recovery during the 12 day treatment timecourse of 
CML CD34+ cells (n=3) with 150nM dasatinib. Figure 4-13 demonstrates the 
percentage of CML cells which remain undivided at day 12 of treatment, as 
compared to the input cell number from the start of the timecourse. The 
percentage of dasatinib-treated CML cells which remained undivided was 
significantly increased as compared to untreated control (0.21% versus 0.07%; 
p=0.03). This corroborates previous data which showed an enrichment for the 
CFSEmax undivided population following TKI treatment (131, 226).  
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Figure 4-13 Undivided CML cell recoveries as measured by CFSE-staining 
CFSE-stained CML CD34+ cells (n=3) were treated ± 150nM dasatinib for 12 
days and measurement of CFSE was performed by flow cytometry. The 
percentage of undivided cells recovered at day 12 was calculated based on 
the input cell number at day 0.  
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4.2.11 CML cell recoveries within each division as measured by CFSE-
staining 
Next, a further analysis of the cell division status of the cells which remained 
following the 12 day timecourse was performed. Figure 4-14 demonstrates the 
percentage of cells within each cell division, recovered following 12 days treatment 
± 150nM dasatinib. Consistent with previous data, an anti-proliferative effect was 
observed with dasatinib treatment as compared to no drug control. The data 
described in Figure 4-13 showed enrichment for the undivided population of CML 
cells following TKI treatment. However, Figure 4-14 shows that it is not only the 
quiescent population of CML cells which is able to survive the prolonged dasatinib 
exposure. It would appear that a further resistant CML cell population, which is 
able to reach the earlier cell divisions, exists. CFSE analysis of the CML cells 
which survived the 12 days treatment with 150nM dasatinib revealed that the 
majority of recovered cells resided within cell division 2 (Table 4-5). 
 
 No drug (%) 150nM dasatinib (%) 
undivided population 0.55 3.01 
Division 1 0.483 40.05 
Division 2 14.81 48.71 
Division 3 43.52 7.99 
Division 4 26.53 0.23 
Division 5 9.26 0 
Division 6 4.84 0 
 
Table 4-5 Percentages of CML cells residing within each division, following 
12 days treatment ± 150nM dasatinib 
 
 
 
 177 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
Figure 4-14 CML cell recoveries within each cell division as measured by 
CFSE-staining 
CD34+ CML cells were first stained with CFSE, cultured in SFM minus GFs 
and treated ± 150nM dasatinib for 12 days. The percentages of cells residing 
within each cell division were then determined by CFSE-staining, as 
measured by flow cytometry. 
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4.2.12 CML cell cycle status as measured by Ki67 and 7AAD staining 
Although CFSE staining has proven to be a reliable technique for the identification 
of undivided cells, it should be noted that cell quiescence cannot be directly 
confirmed by this method, as it does not give any information on cell cycle status 
i.e. cells within the undivided gate may either be quiescent or in G1 arrest. In order 
to determine the cell cycle status of the CML cells which have been treated ± 
150nM dasatinib, Ki67/7AAD staining was carried out. Figure 4-15 shows 
representative patient’s CML cells left untreated (A) and treated with 150nM 
dasatinib (B); cultured with (right hand panel) and without (left hand panel) GFs at 
day 12 of treatment. Panel A shows that the majority of untreated CML cells, 
which have been cultured with exogenous GF support, are in division (G0: 26.5%; 
G1: 48.56%; S/G2/M: 24.47%). As expected, fewer cells had gone into division in 
the CML cells which were untreated and cultured without GFs (G0: 55.34%; G1: 
36.48%; S/G2/M: 7.24%). Panel B demonstrates the anti-proliferative effect of 
dasatinib, with the majority of cells residing within the G0 stage of cell cycle. Again, 
far fewer cells had gone into division in the CML cells which had been cultured 
without GFs versus the cells which had been cultured with GFs by day 12 of 
dasatinib treatment (G0: 86.49% and 51.23%; G1: 6.99% and 40.31%; S/G2/M: 
2.17% and 7.57%, respectively). This finding is consistent with previous data, 
whereby a detailed analysis of CML cells revealed very little/no detectable levels 
of Ki67 expression within the quiescent stem cell population (224). This would 
suggest that the dasatinib-treatment without GFs in the culture media has selected 
for a quiescent population of CML cells. However, since the CFSE data (described 
in Figure 4-14) shows that the majority of the cells have been able to divide to 
division 2, it may mean that the cells divided early in the timecourse and had 
stopped almost all cell division by the day 12 time-point.  
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It is also interesting to note that the percentage of cells in G0 was approximately 
equal in the untreated cells cultured without GFs and the dasatinib-treated cells 
cultured with GFs (G0: 55.34% versus 51.23%, respectively). This finding 
corroborates the data presented in Figure 4-1, where TKI treatment in the 
presence of GFs gave the same effect as removing the GF support from untreated 
control cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-15 CML cell cycle status as measured by Ki67 and 7AAD staining 
Representative Ki67/7AAD FACS profile from one patient’s CD34+ CML cells 
left either untreated (A) or treated with 150nM dasatinib (B) and cultured ± 
GFs for 12 days. 
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4.2.13 The effect of dasatinib treatment on the localisation of FoxO3a within 
CML cells 
The previous data demonstrated that dasatinib treatment exerted a potent anti-
proliferative effect on CML cells, consistent with other studies (131, 226). 
However, the mechanism by which dasatinib causes these anti-proliferative effects 
is still not fully understood. Since the nuclear localisation of FoxO3a and its 
subsequent transcriptional activity, has been shown to be important for the 
induction of cell cycle arrest (311); this was next investigated.  CML CD34+ cells 
were first cultured in SFM ± GF and treated with 150nM dasatinib for 12 days, 
before being fixed onto slides and stained with anti-FoxO3a antibody. Nuclei were 
counterstained with then DAPI and levels of FoxO3a were then visualised within 
these cells by IF. Figures 4-16A and B demonstrate a representative FoxO3a IF 
profile and corresponding surface plot profile (using ImageJ software) from one 
patient’s cells, respectively. In the untreated CML cells cultured with (top left 
panel) and without (top right panel) GFs, FoxO3a was found to be predominantly 
localised to the cytoplasm where it is transcriptionally inactive. The greatest 
amount of cytoplasmic FoxO3a-positive puncta was observed in the untreated 
cells cultured with GFs. Treatment of the CML cells with dasatinib in the presence 
of GFs (bottom left panel), resulted in a localisation of FoxO3a to both the nucleus 
and cytoplasm. However, treatment of the CML cells with dasatinib without 
exogenous GF support (botton right panel), resulted in FoxO3a to be 
predominantly localised to the nucleus and therefore, in a transcriptionally active 
state. Since FoxOs transcription factors are direct targets of activated Akt, it could 
be said that the activation of the PI3K/Akt pathway within CML cells, by BCR-ABL 
and/or GF stimulation, induces the cytoplasmic localisation and hence inhibition of 
FoxO3a, which is consistent with previous studies (312-314). Treatment of CML 
cells with dasatinib induces the nuclear localisation and hence activation of 
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FoxO3a transcriptional activity. However, this can be partially overcome by the 
addition of exogenous GF support. 
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Figure 4-16 The effect of dasatinib treatment on the localisation of FoxO3a 
within CML cells 
CD34+ CML cells were cultured in SFM ± 5GF and treated ± 150nM dasatinib 
for 12 days. Remaining CML cells were then fixed onto multi-spot slides and 
stained with anti-FoxO3a antibody. Nuclei were counterstained with DAPI. 
Representative IF profiles (A) and surface plots using ImageJ software (B) 
from one patient are shown. 
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4.2.14 Analysis of cyclin D1 expression in dasatinib-treated CML cells 
The cyclin D1 proto-oncogene is an important regulator of G1 to S phase transition 
in many different cell types and its expression is often disrupted in various 
cancers. It has been recently reported that BCR-ABL silencing by small interfering 
RNAs (siRNA) resulted in significantly reduced cyclin D1 mRNA and protein 
expression in K562 cells (315). Furthermore, the nuclear localisation of FoxOs (as 
demonstrated in Figure 4-16) results in the activation of their transcriptional activity 
which promotes cell cycle arrest through down-regulation of cyclin D (139). 
Therefore, the effect of BCR-ABL activity inhibition on cyclin D1 expression was 
next assessed in the primary CML cells remaining after dasatinib treatment. The 
relative mRNA expression of cyclin D1 was measured by qRT-PCR, following 12 
days treatment ± 150nM dasatinib and cultured in the absence of GFs. Figure 4-
17 demonstrates that inhibition of BCR-ABL by dasatinib caused approximately a 
3-fold reduction in cyclin D1 mRNA, relative to no drug control (p=0.016), 
consistent with previous studies (314). This also is in keeping with the Ki67/7AAD 
data presented in Figure 4-15, where the majority of cells resided within the G0 
phase of cell cycle.  
 
These data taken together indicate that the treatment of CD34+ CML cells with 
dasatinib leads to the nuclear localisation and subsequent activation of FoxO3a. 
This then contributes to the reduced transcription of the FoxO3a downstream 
target, cyclin D1, and maintenance of quiescence within these resistant CML cells.  
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Figure 4-17 Analysis of cyclin D1 expression in dasatinib-treated CML cells 
Expression of cyclin D1 mRNA transcripts as measured by qRT-PCR in 
CD34+ CML cell samples (n=3) following treatment ± 150nM dasatinib for 12 
days. 
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4.3 Analysis of functionality of the CML cells remaining following 
prolonged BCR-ABL kinase inhibtion 
 
4.3.1 Characterisation of 12 day dasatinib-treated CML cells following 
additional culture with GF support 
To investigate whether the dasatinib-resistant cells were still fully functional and 
able to proliferate when stimulated with cytokines, further analyses were carried 
out. First, the cells remaining following 12 days dasatinib treatment were washed 
with PBS to remove the drug and cultured in the presence of a potent 5GF cocktail 
for 7 days. A viable cell count using trypan blue dye exclusion was then performed 
at this time-point. Figure 4-18A demonstrates that the ± dasatinib-treated cells 
were found to expand 17- and 5-fold, respectively (p=0.086). The lower cell 
number within the dasatinib-treated arm may reflect the fact that this cell fraction 
contained more primitive CML cells, which were slow to proliferate as compared to 
the actively cycling untreated cells. The levels of p-CrkL, as a measure of BCR-
ABL activity, were also determined in the cytokine-cultured cells at this time-point. 
Figure 4-18B shows that the dasatinib-treated cells had a level of 98% p-CrkL as 
compared to untreated control (100%) (p=0.95). This therefore suggests that BCR-
ABL activity had been re-activated in these dasatinib-treated cells and that BCR-
ABL inhibition is survivable.  
Due to the fact that there was a trend towards lower viable cell counts in the 
dasatinib-treated CML cells as compared to the untreated cells at the day 7 time-
point (Figure 4-18A), it was hypothesised that at least a proportion of the 
dasatinib-treated cells may have undergone an irreversible growth arrest following 
drug treatment. In order to address this, Ki67/7AAD staining was also carried out 
on the cells following the 7 days culture with 5GF. Figure 4-18C demonstrates that 
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the majority of both the untreated and the dasatinib-treated cells were in cycle, 
following drug wash out and 7 days culture with cytokines (G0: 2.73 and 6.43%; 
G1: 66.15 and 70.91% and S/G2/M: 31 and 22.55%, for untreated and dasatinib-
treated cells, respectively). These data indicate that the dasatinib treatment did not 
cause irreversible growth arrest in the vast majority of these cells. As this 
Ki67/7AAD profile is only a reflection of what is happening at a particular time-
point, it is also possible that the remaining 6.43% of cells in G0 would also go into 
cycle in time, particularly since the dasatinib treated cells contained more primitive 
cells and as suggested above would likely take longer to enter cell division upon 
GF stimulation. A further possibility is that these cells represent a quiescent 
population which, consistent with previous studies (224), remain undivided even in 
the presence of high GFs. In order to verify the cell cycle data, CFSE staining was 
also carried out. Following 12 days dasatinib treatment, the cells were washed 
with PBS and stained with CFSE, before being cultured for 7 days in SFM+5GF. 
Figure 4-18D confirms the data from the cell cycle analysis (Figure 4-18C) as the 
majority of both the untreated and the dasatinib-treated cells were in a state of cell 
division, following drug wash out and 7 days culture with cytokines (undivided 
population: 1.95 and 4.51% for untreated and dasatinib-treated cells, respectively). 
Since the proportion of undivided cells remaining following 12 days of 150nM 
dasatinib treatment, was an average of 3.01% (range: 2.05, 2.4 and 4.58%) 
(Figure 4-14), it is possible that the undivided cell fraction remaining at day 7 of 
culture in SFM+5GF, represents a quiescent population of CML cells which was 
both unaffected by prolonged treatment with dasatinib and also remained 
undivided after exposure to high concentrations of cytokines. 
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Figure 4-18 Characterisation of 12 day dasatinib-treated CML cells following 
additional culture with GF support 
The 12 day ± 150nM dasatinib-treated cells were washed with PBS, stained 
with CFSE and cultured in 5GF for 7 days. At the 7-day time-point, viable cell 
counts were performed by trypan blue dye exclusion (A) and p-CrkL (B), 
Ki67/7AAD (C) and CFSE (D) were all measured by flow cytometry. 
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4.3.1.1 The effect of dasatinib removal and GF culture on the localisation of 
FoxO3a within CML cells 
As stated in Section 4.2.13, the nuclear localisation of FoxO3a and its subsequent 
transcriptional activity, has been shown to be important for the induction of cell 
cycle arrest (311). Since we demonstrated that the treatment of CML cells with 
dasatinib induces the nuclear localisation of FoxO3a, it was next investigated 
whether this could be reverted following the removal of dasatinib and the culture 
with GFs. First, the CML cells remaining following 12 days dasatinib treatment 
were washed with PBS and cultured in SFM+5GF for 7 days. An aliquot of the 
CML cells was then fixed onto slides and stained with anti-FoxO3a antibody. 
Nuclei were counterstained with then DAPI and levels of FoxO3a were then 
visualised within these cells by IF. Figure 4-19 demonstrates a representative 
FoxO3a IF profile from one patient’s cells. In both the untreated and dasatinib-
treated CML cells, FoxO3a was found to be predominantly localised to the 
cytoplasm and was therefore transcriptionally inactive. This suggests that the 
reactivation of the PI3K/Akt pathway, by BCR-ABL and GF stimulation, following 
the dasatinib wash-out within the CML cells, induced the cytoplasmic localisation 
and inhibition of FoxO3a, which would thereby allow the cells to continue to divide.  
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Figure 4-19 Detection of FoxO3a in dasatinib-treated CML cells following 
drug wash-out and additional culture with GFs 
The 12 day ± 150nM dasatinib-treated cells were washed with PBS and 
cultured in 5GF for 7 days. Aliquots of CML cells were then fixed onto multi-
spot slides and stained with anti-FoxO3a antibody. Nuclei were 
counterstained with DAPI.  
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4.3.2 Analysis of committed and primitive progenitor capacity in surviving 12 
day dasatinib-treated CML cells  
To determine whether the surviving CML cells had functional committed and 
primitive progenitor capacity, the ± dasatinib-treated cells were plated in CFC 
(committed progenitor) and LTC-IC (primitive progenitor) assays and compared to 
a baseline (CD34+ CML cells which had no prior culture or treatment.) The 
resulting colonies were picked and analysed for Ph+ cells by D-FISH. In each of 
the three patients’ samples kindly tested by Mrs Elaine Allan, >98% of the cells in 
each of the conditions were shown to be BCR-ABL positive by D-FISH. Figure 4-
20A demonstrates that the untreated arm was able to form 3 times the number of 
CFC as compared to the cells at baseline (100%), suggesting differentiation and 
expansion from stem cells, even in the absence of GFs. Dasatinib-treated cells 
were only able to form ~2% CFC as compared to baseline and were significantly 
reduced as compared to no drug control (p=0.0125). Next, the number of CML 
cells which were able to form a CFC colony, per 1000 surviving cells at day 12 
was calculated. The no drug control was then normalised to 1 and the dasatinib-
treated arm was calculated based on this. Figure 4-20B shows that there was a 
trend towards a reduction in the CFC colonies produced per 1000 cells at day 12 
in the dasatinib treatment arm, as compared to untreated control. However, there 
was no significant difference observed between the two conditions (p=0.25). 
These data indicate that dasatinib treatment effectively targeted the more mature 
committed progenitor CML cell population, based on the starting cell number. 
However, the ability to form a CFC colony within the cells which survived the 
dasatinib treatment did not significantly alter, as compared to untreated control 
cells. 
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Figure 4-20C shows that compared to baseline cells, the untreated cells formed 
50% less LTC-IC colonies, suggesting that half of these cells had proceeded 
towards terminal differentiation. Dasatinib-treated cells recovered a significantly 
reduced number of LTC-IC (~14%) as compared to both baseline and no drug 
control (p=0.01 and p=0.02, respectively). Next, the number of CML cells which 
were able to form a LTC-IC colony, per 1000 surviving cells at day 12 was 
calculated. Again, the no drug control was then normalised to 1 and the dasatinib-
treated arm was calculated based on this. Figure 4-20D shows that there was a 
21-fold increase in the LTC-IC colonies produced per 1000 cells at day 12 in the 
dasatinib treatment arm, as compared to untreated control (p=0.025). This mirrors 
the data described in Section 4.2.10, where the percentage of primitive undivided 
cells recovered at day 12 of dasatinib treatment was increased as compared to 
untreated control cells. 
 
Overall, these data suggest that following BCR-ABL inhibition by dasatinib, within 
a total CML cell population, the committed CML progenitor population is targeted, 
whereas, the primitive quiescent CML cells with LTC-IC potential remain relatively 
unaffected. However, in the population which survives drug treatment, the CML 
cells with CFC potential remain relatively unaffected, whereas the cells with    
LTC-IC potential are enriched. 
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Figure 4-20 Analysis of committed and primitive progenitor capacity in 
surviving 12 day dasatinib-treated CML cells 
Following the 150nM dasatinib treatment timecourse, the remaining CML 
cells (n=3) were washed with PBS to remove any drug and added to CFC (A 
and B) and LTC-IC (C and D) assays. 
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4.3.3 Analysis of murine engraftment of surviving CML cells following 
treatment ± 150nM dasatinib for 12 days 
To further investigate the functionality of the cells that survived the 12 day 150nM 
dasatinib treatment timecourse, the remaining CML cells (n=3) were also 
transplanted into NOD/SCID mice, to determine any reconstitution potential. The 
surviving cells were first washed twice with PBS and sent to the animal facility at 
the University of Bristol, where Dr Allison Blair kindly performed all murine 
engraftment experiments. Engraftment was determined by the flow cytometric 
measurement of human CD45 in the murine BM cells. Figure 4-21 demonstrates 
that insufficient engraftment was achieved in both the untreated control and the 
dasatinib-treatment arm; therefore no definitive conclusion could be drawn from 
this experiment. 
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Figure 4-21 Analysis of murine engraftment of surviving CML cells following 
treatment ± 150nM dasatinib for 12 days 
Following the treatment timecourse, the CML cells (n=3) were washed with 
PBS to remove any drug and transplanted into NOD/SCID mice. Three mice 
were transplanted per patient sample. Mice were sacrificed at 16 weeks post-
transplant. Engraftment levels were determined by flow cytometric analysis 
of human CD45 in the murine BM cells. 
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4.4 Summary 
The term “oncogene addiction” is used to describe the phenomenon by which 
some cancers acquire dependency on one or a few genes for the maintenance of 
the malignant phenotype and cell survival. The purpose of the work in this chapter 
was to determine whether CML stem cells are “addicted” to BCR-ABL kinase 
activity, by exposing CD34+ CML cells to TKI treatment and investigating whether 
the inhibition of BCR-ABL kinase correlated with cell death.  
In experiments designed to determine optimal treatment conditions, it was 
confirmed that CD34+ CML cells are able to survive and proliferate in the absence 
of cytokine support. Furthermore, the TKI treatment of CML cells in the presence 
of high GFs gave the same effect as leaving the CML cells untreated in the 
absence of GFs. This confirms work first published by Dorsey et al. whereby IL-3 
was found to protect IL-3 responsive, BCR-ABL-transformed haemopoietic 
progenitor cells from apoptosis caused by TKIs, including IM (303). This finding 
also has potential implications for the treatment of patients, in whom cytokines 
would be present at physiological concentrations. Studies which examined the 
effect of TKI exposure time and concentration also showed that each TKI exerted 
its effects very early in the timecourse (after 1 hour and possibly even earlier) and 
transient exposure was as effective as prolonged treatment, confirming the results 
from other investigators (310, 316). Furthermore, escalation up to clinically 
unachievable doses, did not give any increased cell kill over lower concentrations 
of the drug. 
 
During a 12 day timecourse, dasatinib treatment in the absence of GF support 
resulted in a reduction in CML cell number to <2% of no drug control and <10% of 
the starting cell number. Investigation of possible resistance mechanisms revealed 
no evidence of oncogene amplification by D-FISH and no ABL-kinase domain 
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mutation was detected in any of the patient samples. Both D-FISH and qRT-PCR 
confirmed the presence of BCR-ABL within the surviving cells, ruling out the 
presence of normal cells as an explanation of dasatinib resistance. 
 
Since the most primitive CML cell fraction has previously been shown to express 
increased levels of BCR-ABL transcripts and protein, there was some concern that 
any resistance may be caused by the fact that dasatinib was not able to effectively 
inhibit the increased levels of BCR-ABL activity within these primitive cell 
subpopulations. The experiments which measured p-CrkL levels within each CML 
cell division demonstrated that 150nM dasatinib treatment inhibited p-CrkL within 
each cell subpopulation to the same degree as the bulk population of CML CD34+ 
cells. This level of inhibition could not be increased on dose escalation to 1000nM 
dasatinib and was not significantly different to the level of inhibition achieved of 
another downstream target, p-STAT5. Furthermore, since dasatinib treatment 
inhibited the phosphorylation of CrkL to the same level as that seen in non CML 
CD34+ cells, it was concluded that the 12 day dasatinib treatment maximally 
inhibited BCR-ABL activity within each CML subpopulation.  
 
Analysis of the percentage recoveries within each cell division revealed that the 
most primitive undivided cell fraction was higher in the dasatinib-treated cells as 
compared to the untreated control. A further subpopulation of CML cells, which 
were able to reach the earlier cell divisions, also remained. Not surprisingly, cell 
cycle analysis revealed that the majority of surviving CML cells following dasatinib 
exposure had stopped all cell division and resided within the G0 stage of cell cycle 
by 12 days treatment. This was further confirmed by the observation of FoxO3a 
which was predominantly localised to the nucleus, with significantly reduced cyclin 
D1 expression in dasatinib-treated cells as compared to untreated control.  This 
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data corroborates the findings from previous studies, whereby nuclear FoxO3a 
and its subsequent transcriptional activity, was important for the maintenance of 
both CML LICs in a CML-like disease mouse model (317) and quiescent CML 
stem cells in vitro (314). Although it is highly likely that other cell cycle regulators 
are involved in the anti-proliferative effect induced by dasatinib or any other TKI 
treatment, the FoxO axis may represent an important stem cell quiescence 
mechanism for future investigation.  
 
The cells which survived the 12 day dasatinib treatment course were able to 
reactivate BCR-ABL activity (as measured by p-CrkL) to approximately the same 
level as that of untreated cells, had predominantly cytoplasmic, transcriptionally 
inactive FoxO3a and were also able to expand 5-fold when cultured in the 
presence of cytokines. Data from the CFC assay confirmed that dasatinib 
treatment was able to effectively target mature committed progenitor cells which 
were able to form colonies. However, LTC-IC data suggested that the effect of 
dasatinib does not target the very primitive quiescent cell population to the same 
extent. 
 
Overall, these data imply that since only 10% of CML cells remain following 
dasatinib treatment, 90% of CD34+ CML cells are “oncogene addicted” to BCR-
ABL kinase activity. Due to the fact that dasatinib is a dual SRC/ABL-kinase 
inhibitor, it is difficult to say whether cell death is exclusively due to BCR-ABL 
inhibition. However, the similarity in response for IM, nilotinib and dasatinib 
(Section 4.1.2) suggests that sensitivity is mainly based on the potency of BCR-
ABL inhibition. Since BCR-ABL kinase is fully inhibited within the surviving CML 
cells, it could be said that this population is BCR-ABL-kinase-independent. It was 
also observed that two sub-populations exist within the BCR-ABL-kinase-
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independent CML cell fraction: the very primitive quiescent CML population and a 
further population of cells which is able to divide to the early cell divisions. It is 
likely that the quiescent CML cell population evades dasatinib treatment simply by 
virtue of their quiescent state. However, since the second BCR-ABL independent 
population is still able to divide even without both exogenous GF support and 
BCR-ABL kinase activation, which would normally allow these cells to proliferate, it 
is probable that these cells use other survival pathways as a mechanism of 
resistance against dasatinib treatment.  
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5. RESULTS (III) Analysis of the effects of autophagy on 
CML stem cell survival 
  
Clinical IM resistance has consistently been associated with gene amplification 
and the detection of BCR-ABL kinase mutations. However, previous experiments 
performed by our own laboratory and demonstrated in the last results chapter, 
have shown that CML cells which survive IM or dasatinib exposure in vitro, do not 
show any evidence of amplification and do not contain any ABL-kinase domain 
mutations at levels that would explain their IM resistance (131). Furthermore, the 
previous chapter also demonstrated that BCR-ABL kinase activity was completely 
inhibited in the CML cells which survived prolonged dasatinib treatment. This 
suggests that resistance may be partly influenced by BCR-ABL independent 
factors or pathways, which co-operate with BCR-ABL transformation and 
compensate for BCR-ABL inactivation. 
 
Autophagy is a conserved catabolic membrane-trafficking process which degrades 
long-lived cellular components, providing the cell with essential stores of energy. 
In addition to important housekeeping functions, autophagy plays an important 
role in cell survival under conditions of nutrient and/or oxygen deprivation (164) 
and hence could be predicted to play a protective role in maintaining cancer cell 
survival (318). Therefore, the nutrient depletion and cellular stress caused by anti-
cancer agents may induce autophagy and compromise the efficacy of therapy. 
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To examine the role of autophagy as a BCR-ABL independent survival 
mechanism, experiments were designed to determine whether: 
 
1. autophagy is induced following the TKI treatment of CML cells 
2. targeting of autophagy potentiates the TKI-induced death of CML cells 
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5.1 Autophagy is induced following the TKI treatment of CML 
cells 
 
5.1.1 Analysis of key properties of cells undergoing autophagy 
In order to determine whether CML cells undergo autophagy following TKI 
treatment experiments were designed to study the cellular changes in CML cells 
induced by dasatinib treatment in more detail. CD34+ CML cells, which remained 
viable following culture with either SFM only (Figure 5-1A-C) or SFM ± 5GF 
(Figure 5-1D) and treatment ± 150nM dasatinib for 12 days, were analysed by flow 
cytometry (Figure 5-1A+B), light microscopy (Figure 5-1C) or EM (Figure 5-1D). 
Flow cytometry measuring the FSC-height (FSC-H) parameter, revealed that the 
dasatinib-treated CML cells were significantly smaller in size as compared to 
untreated cells, as shown by a representative histogram from one patient’s cells 
(Figure 5-1A) and mean FSC-H from 3 patients’ cells (p=0.02) (Figure 5-1B). This 
was also demonstrated by morphology analysis using conventional light 
microscopy (Figure 5-1C). Figure 5-1D (upper panel) demonstrates that GF 
deprivation of untreated CML cells (upper right) resulted in a reduction of 
cytoplasm and an increase of vacuoles, as compared to untreated cells cultured in 
the presence of GFs (upper left). This is consistent with previous studies, whereby 
the cytoplasm of haemopoietic cells became progressively replaced by vesicular 
structures, following GF withdrawal. These investigators found that the cells had 
induced autophagy in order to combat the GF starvation (164). Figure 5-1D (lower 
panel) also shows that treatment with dasatinib caused an increase in both the 
size and number of these cytoplasmic vacuoles within CML cells, cultured both in 
the presence (lower left) and absence (lower right) of GFs. Many electron-dense 
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inclusions within the vacuoles were also observed within the CML cells cultured 
without the presence of GFs (as denoted by the black arrows).  
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Figure 5-1 Analysis of key properties of cells undergoing autophagy 
CD34+ CML cells were either cultured in SFM only (A-C) or SFM ± 5GF (D) 
and treated ± 150nM dasatinib for 12 days. Cell size was measured using the 
FSC-H parameter by flow cytometry, with a representative histogram from 
one patient (A) and the mean from 3 patients (B) shown. Cell size was also 
analysed by light microscopy, with a representative morphology profile from 
one patient’s cells demonstrated (C). The remaining CML cells were then 
fixed, sectioned and examined unstained by EM (D). 
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5.1.2 Evaluation of autophagic structure formation by EM 
The autophagosome and autolysosome both contain cytoplasmic material at 
various stages of degradation. However, in this experiment, it was observed that 
many of the vesicles appeared to be empty (Figure 5-1D). Therefore, it was not 
possible to determine whether the electron lucent or empty vesicles were 
autophagic compartments or some other kind of vacuole. Since autophagy is a 
dynamic process, whereby an autophagosome is formed, the autophagic material 
is delivered to the lysosome and the material is then degraded within the 
lysosome, it is probable that by this time-point the majority of the autophagic 
material had already been degraded. Therefore in order to block this “autophagic 
flux”, the experiment was repeated using CD34+ CML cells cultured in SFM ± 5GF 
and treated ± 150nM dasatinib, both in the absence and presence of lysosomal 
protease inhibitors (pepstatin A and E-64d both at a 1:100 dilution) for 24 hours. 
The lysosomal protease inhibitors act by preventing the degradation of material 
within the autolysosome. Figures 5-2A-D confirm the previous EM data, whereby, 
in the absence of lysosomal protease inhibition, GF deprivation of untreated CML 
cells (Figure 5-2B) increased the number of cytoplasmic vacuoles as compared to 
untreated cells cultured with GF support (Figure 5-2A). Treatment with 150nM 
dasatinib increased the number of vacuoles both in the presence (Figure 5-2C) 
and absence (Figure 5-2D) of GFs. Addition of lysosomal protease inhibitors to the 
cells, had little or no effect on the untreated CML cells cultured in the presence of 
GFs (Figure 5-2E), however, protease inhibition increased the amount of vacuolar 
material (denoted by the black rings) in untreated cells cultured without GFs 
(Figure 5-2F) and in the dasatinib-treated cells cultured both in the presence 
(Figure 5-2G) and absence (Figure 5-2H) of GFs. Interestingly, the greatest 
accumulation of vacuolar material was observed in the dasatinib-treated cells 
cultured without GFs (Figure 5-2H).  
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Autophagosomes and autolysosomes can be defined as membrane-bound 
structures which contain cytoplasmic material and/or organelles. Furthermore, in 
conventional EM, the material within the autophagosome has the same 
morphology and electron density as the cytoplasm outside. Another feature of an 
autophagosome analysed by EM is a double limiting membrane, however this is 
not always the case, due to limitations in lipid preservation during sample 
preparation (319). Therefore, although it is difficult to determine the characteristic 
double membranes surrounding each vacuole within these EM images (Figures 5-
2F-H), it is highly likely that these vacuoles are autophagic structures. Hence, it 
could be said that autophagy was likely induced following both GF deprivation and 
dasatinib treatment of CML cells. 
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Figure 5-2 Evaluation of autophagic structure formation by EM 
CD34+ CML cells were cultured in SFM ± 5GF and treated ± 150nM dasatinib 
for 24 hours. The remaining CML cells were fixed, sectioned and examined 
unstained by EM (panels A-H). 
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5.1.3 Monitoring autophagy using LC3 
The protein LC3, a mammalian homologue of Atg8, was originally identified as 
microtubule-associated protein 1 light chain 3. To date, LC3 is the only known 
mammalian protein identified that stably associates with the autophagosome 
membranes (166) and therefore serves as a widely used marker for autophagy. 
There are three human isoforms of LC3 (LC3A, LC3B, and LC3C), where LC3B is 
the most widely studied (320). LC3 is first cleaved at the carboxy terminus by Atg4 
immediately following synthesis, to yield a cytosolic form LC3-I. During autophagy, 
LC3-I is conjugated with phosphatidylethanolamine (PE) to become LC3-II through 
lipidation by a ubiquitin-like system involving Atg7 and Atg3. Unlike the 
cytoplasmic LC3-I, LC3-II associates with the inner and outer membranes of the 
autophagosome. LC3-I can be detected on an immunoblot at a molecular mass of 
around 16-kDa and LC3-II at approximately 14-kDa. Following fusion with a 
lysosome, LC3 on the outer membrane is cleaved off by Atg4 and LC3 on the 
inner membrane is degraded by lysosomal enzymes resulting in low 
concentrations of LC3 within autolysosomes (166, 321). Therefore, the presence 
of endogenous LC3 as well as the conversion of LC3-I to the lower migrating form 
LC3-II serve as good indicators of autophagosome formation and hence, 
autophagy induction. 
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5.1.4 Formation of LC3-positive puncta in dasatinib-treated CML cells 
In order to verify the EM data described in Figure 5-2, LC3 was measured in 
dasatinib-treated CML cells as a more specific indicator of autophagy. CD34+ CML 
cells were cultured in SFM ± 5GF and treated ± 150nM dasatinib for 24 hours, 
before being fixed onto slides and stained with anti-LC3 antibody. Nuclei were 
counterstained with DAPI. Endogenous levels of LC3 were then visualised within 
these cells by fluorescence microscopy. Figures 5-3A and B demonstrate a 
representative LC3 IF profile from one patient’s cells and the average LC3-positive 
puncta per cell from 3 patients, respectively. A significant increase in LC3-positive 
puncta was observed in the GF deprived untreated cells as compared to untreated 
cells cultured with GF support (p=0.015) (Figure 5-3A upper panel and Figure 5-
3B). An even greater increase in LC3-positive puncta was observed following 
dasatinib treatment of cells cultured, both with and without exogenous GF support, 
as compared the relevant untreated control (p=0.0004 and p=0.0044 for untreated 
+GF versus dasatinib +GF and untreated  -GF versus dasatinib -GF, respectively) 
(Figure 5-3A lower panel and Figure 5-3B). As with previous data, the greatest 
increase in autophagy induction, as measured by LC3 puncta formation, was 
observed in CML cells cultured without GF support and treated with dasatinib 
(p=0.009 for dasatinib treatment +GF versus -GF).      
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Figure 5-3 Formation of LC3-positive puncta in dasatinib-treated CML cells 
CD34+ CML cells were cultured in SFM ± 5GF and treated ± 150nM dasatinib 
for 24 hours. Remaining CML cells were then fixed onto multi-spot slides 
and stained with anti-LC3 antibody. Nuclei were counterstained with DAPI 
and LC3-positive puncta were manually counted. 
A representative IF profile from one patient (A) and the average LC3-positive 
puncta per cell from 3 patients (B) are shown. 
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5.1.5 Accumulation of autophagosome-associated LC3-II in GF-starved cells 
In order to completely verify the previous results, the levels of autophagosome-
associated LC3-II were also measured. CD34+ CML cells were left untreated and 
cultured in SFM ± 5GF for 24 hours, before whole cell protein lysates were made 
from each sample. The levels of LC3-I and LC3-II were then determined by 
Western blot using an anti-LC3B antibody. Beta-tubulin levels were also measured 
as a protein loading control. Figure 5-4 demonstrates a clear increase in the levels 
of autophagosome-associated LC3-II within the GF-starved CML cells as 
compared to cells cultured with exogenous GF support. These data, thereby, 
confirm the finding that autophagy is induced upon GF deprivation of CML cells.  
 
 
 
 
 
 
 
 
Figure 5-4 Accumulation of autophagosome-associated LC3-II in GF-starved 
CML cells 
CD34+ CML cells were cultured in SFM ± 5GF for 24 hours and whole cell 
protein lysates were made at this time-point. Western blot determined the 
levels of LC3-I and LC3-II in each sample by LC3-antibody staining. Beta-
tubulin was also measured as a protein loading control. 
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5.1.6 Accumulation of autophagosome-associated LC3-II in dasatinib-treated 
CML cells 
Since previous data showed that autophagy appeared to be induced upon 
dasatinib treatment, LC3-II levels were also measured in dasatinib-treated CML 
cells. CD34+ CML cells were cultured in SFM only and treated with 150nM 
dasatinib for 24 hours, before whole cell protein lysates were made from each 
sample. As previously, the levels of LC3-I and LC3-II were then determined by 
Western blot using an anti-LC3B antibody. Levels of p-CrkL were determined as a 
measure of BCR-ABL activity and beta-tubulin levels were also measured as a 
protein loading control. Figure 5-5 demonstrates that upon dasatinib treatment of 
CML cells, p-CrkL and hence, BCR-ABL kinase activity is inhibited. This then 
results in an accumulation of autophagosome-associated LC3-II within the 
dasatinib-treated CML cells, as compared to untreated control. These data, 
thereby, confirm the finding that autophagy is induced upon dasatinib treatment of 
CML cells. 
 
Overall, these data suggest that autophagy is induced following GF deprivation of 
CML cells. Autophagy induction is then further increased within these cells, upon 
BCR-ABL inhibition following dasatinib treatment.  
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Figure 5-5 Accumulation of autophagosome-associated LC3-II in dasatinib-
treated CML cells 
CD34+ CML cells were cultured in SFM only, treated ± 150nM dasatinib for 24 
hours and whole cell protein lysates were made at this time-point. Western 
blot determined the levels of LC3-I and LC3-II in each sample by LC3-
antibody staining. BCR-ABL activity was determined by p-CrkL-antibody 
staining. Beta-tubulin was also measured as a protein loading control. 
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5.1.7 The PI3K-Akt-mTOR signalling pathway in CML cell survival 
The PI3K-Akt-mTOR axis is a cell survival pathway that is important for normal cell 
growth and proliferation (322). However, this pathway has also been implicated in 
the transformed phenotype of most cancer cells (323). Once activated by BCR-
ABL, GF-signalling or cross-talk from the Ras pathway (324), it plays an important 
role in cell growth, protein translation and hence, survival of CML cells. It has also 
been demonstrated that when PI3K-Akt signalling is activated, autophagic 
degradation is decreased (325).  The downstream effector of Akt, mTOR, has 
been shown to be a key negative regulator of autophagy, where it inhibits the 
autophagic process in the presence of abundant GFs and nutrients (326, 327). 
The mTOR kinase is present in two distinct protein complexes, mTORC1 and 
mTORC2, which have distinct mechanisms of action (328). As a central GF and 
nutrient sensor, mTORC1 plays a key role in the regulation of cell growth by 
activating protein synthesis and suppressing autophagy, through its two well 
characterised downstream substrates, S6K and 4EBP1. The phosphorylation 
levels of S6K and 4EBP1 are widely used as indicators of mTORC1 activity and 
decreased phosphorylation levels of these substrates are also used as markers for 
autophagy induction (329). It has previously been demonstrated that autophagy 
can be pharmacologically induced by inhibiting mTOR activity with rapamycin 
(163) which suppresses mTORC1-mediated S6K activation (Figure 5-6). 
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Figure 5-6 The PI3K-Akt-mTOR signaling pathway in CML cell survival 
The PI3K-Akt-mTOR signaling axis is central to the transformed phenotype 
of CML cells. Inhibtion of the autophagy inhibitor, mTORC1, by agents such 
as rapamycin results in the induction of autophagy. 
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5.1.8 Analysis of mTOR activity in dasatinib treated K562 cells 
In order to investigate the status of mTOR activity following TKI treatment of CML 
cells, further experiments were carried out. K562 (BCR-ABL+) cells were cultured 
in RPMI ± serum and treated ± either 150nM dasatinib or 20nM rapamycin for 8 
hours, before whole cell protein lysates were made. Western blot was then used to 
determined the levels of p-S6K within each sample. GAPDH was also measured 
as a protein loading control. Figure 5-7 shows that levels of p-S6K are reduced in 
serum-starved untreated K562 cells as compared to cells grown in the presence of 
serum-support (lane 1 versus lane 3). This is in keeping with the fact that mTOR 
acts as a nutrient sensor and promotes protein translation and cell growth, through 
phosphorylation of substrates such as S6K, in the abundance of GFs. Treatment 
with dasatinib caused an inhibition of p-S6K in both the absence and presence of 
serum (lanes 2 and 4). Treatment with the mTOR inhibitor, rapamycin, gave the 
same effect and also resulted in complete inhibition of p-S6K (lanes 5 and 6).  
 
These data may suggest that autophagy induction caused by dasatinib treatment 
is a result of the inhibition of mTOR activity. Furthermore, this suggests that within 
CML cells, autophagy may also be induced by agents which act downstream of 
BCR-ABL, such as Ras- or PI3K-Akt-pathway inhibitors. However, to completely 
verify that these hypotheses are the case, further investigations would be required. 
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Figure 5-7 Analysis of mTOR activity in dasatinib treated K562 cells 
K562 cells were cultured in RPMI ± serum and treated ± either 150nM 
dasatinib or 20nM rapamycin for 8 hours, before whole cell protein lysates 
were made. Western blot determined the levels of p-S6K. GAPDH was also 
measured as a protein loading control [UT: untreated; DAS: 150nM dasatinib 
and RAPA: rapamycin]. 
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5.2 Targeting of autophagy potentiates the TKI-induced cell death 
of CML cells 
 
5.2.1 Analysis of committed progenitor cell potential following TKI/FTI 
treatment in combination with autophagy inhibition of CP CML cells 
A number of investigations suggest that autophagy may act as a survival signal in 
tumour cells (164, 330) and that the inhibition of autophagy can lead to an 
increase in therapy-induced cell death (171, 331). Therefore, to determine whether 
autophagy acts as a protective mechanism in this system, it was thought to be 
critical to perform further experiments designed to modulate autophagic activity 
within TKI-treated CML cells. In order to inhibit autophagy, the pharmacological 
inhibitors, CQ and BAF were used. The lysosomotropic agent, CQ, is an inhibitor 
of lysosomal acidification, thus raises the pH within the lysosome. BAF acts by 
inhibiting the activity of the H+-ATPase responsible for the acidification of 
autolysosomes. Ultimately, both agents inhibit the autophagosome-lysosome 
fusion and thus, the final degradation of autophagic material within 
autolysosomes. First, the committed progenitor cell potential following TKI 
treatment of CML cells was tested. CD34+ CP CML cells (n=3) were sorted into 
primitive (CD34+38-) and more mature progenitor (CD34+38+) populations, were 
cultured in SFM+5GF and left untreated or pretreated for 48 hours with either TKIs 
(IM (0.5 and 2µM); dasatinib (10 and 150nM) or nilotinib (2µM)); the farnesyl 
transferase inhibitor (FTI), lonafarnib (10 µM) (note: lonafarnib inhibits the Ras-
pathway and was included to determine whether autophagy induction was specific 
to BCR-ABL inhibition) or autophagy inhibitors (CQ (10µM) or BAF (20nM)) alone 
or in the TKI/FTI/CQ/BAF combination. Following pre-treatment, aliquots of cells 
from each condition were taken for apoptosis measurement by annexin-V/viaprobe 
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staining determined by flow cytometry (CD34+38+ cells only) and the remaining 
cells were added to methycellulose for CFC analysis. The relevant drug 
combinations from the pre-treatment were also added to the methylcellulose. The 
number of CFCs obtained for each sample was then compared with a baseline - 
cells which had no prior culture or treatment (100%). Figure 5-8A shows that there 
was a trend towards an increase in apoptotic cells following combination treatment 
with TKI/FTI and autophagy inhibitors, as compared to both untreated control cells 
and TKI/FTI alone, with the greatest increase seen with 150nM dasatinib/CQ 
treatment (p=0.001 and 0.05 for 150nM dasatinib/CQ versus no drug and 150nM 
dasatinib alone, respectively). Figure 5-8B shows that within the CD34+38+ 
population, the untreated cells demonstrated a doubling of CFCs over the 48 
hours pre-treatment, consistent with stem/progenitor cell expansion in the culture 
medium. Neither CQ nor BAF alone had any effect on this expansion. However, 
consistent with previous studies (131, 226), the TKIs (IM, dasatinib (10nM) and 
nilotinib) all exhibited an anti-proliferative effect, which prevented any CFC 
expansion over baseline. Both dasatinib, at the highest clinically achievable 
concentration (150nM), and lonafarnib were able to reduce the number of CFCs to 
55 and 53% of baseline, respectively, suggesting some level of apoptosis was 
achieved by these agents alone. This effect was dramatically increased following 
TKI or FTI/autophagy inhibitor combination treatment, with 80-98% reduction in 
CFC formation versus baseline, and even more impressive as compared to the no 
drug control. Interestingly, lonafarnib treatment combined with autophagy inhibition 
gave the greatest effect, with a 98% reduction in CFC as compared to baseline. 
Since lonafarnib inhibits the Ras pathway, this finding indicates that BCR-ABL 
inhibition does not solely and directly induce autophagy within CML cells and 
thereby, corroborates the findings demonstrated in Figure 5-7. 
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Consistent with the CD34+38+ data, within the more primitive CD34+38- cell 
fraction (Figure 5-8C), the untreated cells demonstrated an increase in CFC 
number as compared to baseline and this remained unchanged following 
treatment with either CQ or BAF alone. TKI treatment alone also had a protective 
anti-proliferative effect on CFC expansion over baseline. However, for these 
primitive CML cells which are consistently resistant to TKI exposure, treatment 
with TKI/autophagy inhibitor was extremely effective, with only 2% CFCs 
remaining following 150nM dasatinib/CQ exposure.  
 
Notably, the combination treatment with TKI/BAF did not appear as effective as 
TKI/CQ treatment of these cells. Therefore it was decided that CQ should be used 
as an autophagy inhibitor for the subsequent primitive progenitor cell experiments. 
 
Overall, these data show that autophagy inhibition greatly potentiates the effect of 
either TKI or FTI treatment, on the reduction of committed progenitor cell potential 
of relatively mature CD34+38+ and primitive CD34+38- CML cell populations.  
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Figure 5-8 Analysis of committed progenitor cell potential following TKI/FTI 
treatment in combination with autophagy inhibition of CP CML cells 
CD34+ CP CML cells (n=3) were sorted into progenitor (CD34+38+) (A+B) and 
stem (CD34+38-) (C) cell populations. Cells cultured in SFM ± 5GF and left 
untreated or pretreated for 48 hours with IM (0.5 and 2µM), dasatinib (10 and 
150nM), nilotinib (2µM) (CD34+38+ cells only) or lonafarnib (10µM) (CD34+38+ 
cells only), either alone or in combination with CQ (10µM) or BAF (20nM). 
Aliquots of cells were taken for apoptosis measurement by annexin-V/ 
viaprobe staining (CD34+38+ cells only) (A) and the remaining cells were then 
plated in methylcellulose. Colonies were counted at 14 days and compared 
with those derived from cells at baseline (cells with no prior culture or 
treatment), which were taken as 100% (B:CD34+38+ and C:CD34+38-). 
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5.2.2 Analysis of committed progenitor cell potential following TKI/FTI 
treatment in combination with autophagy inhibition of AP CML cells 
Although TKI treatment has revolutionised the management of CP CML, it is less 
effective for the treatment of advanced phases of CML. ABL-kinase domain 
mutations are more common in the advanced phases of CML than in CP CML 
(332). Further, the acquisition of additional chromosomal abnormalities in the 
BCR-ABL clone, termed clonal evolution, is a criterion for the diagnosis of AP CML 
in the WHO guidelines for CML (333). These factors suggest that the advanced 
phase CML cells may develop BCR-ABL independent mechanisms of proliferation, 
which would thereby, render them TKI-resistant. The results in Figure 5-8 
demonstrated that lonafarnib in combination with autophagy inhibition was highly 
effective at eliminating the CP CML cells with committed progenitor cell potential. 
Therefore, since lonafarnib acts on the Ras pathway rather than BCR-ABL itself, it 
was predicted that the lonafarnib/autophagy inhibitor combination would also be 
effective at targeting AP CML cells. The previous experiment, as demonstrated in 
Figure 5-8, was repeated using CD34+ AP CML cells from one patient. Figure 5-
9A shows that the greatest increase in apoptotic cells was observed with both the 
lonafarnib alone and lonafarnib/CQ/BAF combination (28.2, 26.6 and 28.2%, 
respectively, as compared to 12.1% for no drug control). As expected, Figure 5-9B 
shows that TKI treatment, both alone and in combination with autophagy 
inhibitors, was relatively ineffective at targeting AP CML cells with committed 
progenitor cell potential, with little or no effect as compared to both baseline and 
untreated control cells. However, combination treatment with lonafarnib/CQ/BAF 
gave the greatest effect, with a 98 and 97% reduction in CFC as compared to 
baseline, for lonafarnib/CQ and BAF, respectively. 
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Although these experiments were performed on a single patient and therefore, no 
definitive conclusions can be drawn as yet, these data may be an early indicator 
that lonafarnib treatment in combination with autophagy inhibition is an effective 
therapy for patients with advanced phase CML. 
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Figure 5-9 Analysis of committed progenitor cell potential following TKI/FTI 
treatment in combination with autophagy inhibition of AP CML cells 
CD34+ AP CML cells (n=1) were cultured in SFM + 5GF and left untreated or 
pretreated for 48 hours with IM (0.5 and 2µM), dasatinib (10 and 150nM), 
nilotinib (2µM) or lonafarnib (10µM), either alone or in combination with CQ 
(10µM) BAF (20nM). Aliquots of cells were taken for apoptosis measurement 
by annexin-V/viaprobe staining (A) and the remaining cells were then plated 
in methylcellulose. Colonies were counted at 14 days and compared with 
those derived from cells at baseline (cells with no prior culture or treatment), 
which were taken as 100% (B). 
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5.2.3 Analysis of primitive progenitor cell potential following TKI treatment in 
combination with autophagy inhibition of CML cells 
Since the CFC assay measures a relatively mature, committed progenitor cell 
population, LTC-IC assays were also carried out to measure the effect of 
autophagy inhibition on the functionality of more primitive CML cells. As the 
presence of cytokines in the culture media may alter the requirement of autophagy 
for cell survival, the LTC-IC assays were carried out both in the presence and 
absence of a 5GF cocktail. CD34+ CML cells (n=3) were left untreated or 
pretreated for 6 days with either TKIs (2µM IM or 150nM dasatinib); CQ alone or 
the TKI/CQ combination. It was noted that the presence of the drug combinations 
in the methylcellulose for the CFC assays (Section 5.2.1) may have exerted an 
anti-proliferative effect rather than the elimination of functional CML progenitor 
cells. Therefore, following the pre-treatment, the cells were washed twice with 
PBS, to remove any drug, before being added to LTC-IC assays. As it was not 
known how long it would take for the inhibition of autophagy by CQ to have any 
effect on the cells, a pre-treatment time-point of 6 days was chosen as a median 
of the 12 day dasatinib treatment timecourse (described in Chapter 4). If primary 
cellular material had been more plentiful, it would have been useful to perform a 
TKI/CQ treatment timecourse, in order to determine the most effective treatment 
times for the drug combination.  
 
As with the CFC assay, the number of LTC-ICs obtained for each sample was 
then compared with a baseline. Figure 5-10A shows that in the presence of GFs, 
untreated and CQ-treated cells formed 67 and 47% fewer LTC-IC colonies than 
cells at baseline, respectively, suggesting that a large proportion of these cells had 
proceeded towards terminal differentiation. Consistent with the CFC data and 
previous studies (131), treatment with IM or dasatinib was anti-proliferative, even 
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in the presence of GFs, and therefore resulted in a protective effect on the number 
of LTC-ICs over baseline. Combination treatment with TKIs and autophagy 
inhibitors counteracted this protective effect and resulted in an impressive 
decrease in the number of LTC-ICs, with a significant reduction for treatments with 
IM/CQ and dasatinib/CQ combinations versus TKI alone (p= 0.04 and 0.008, 
respectively). Figure 5-10B shows that untreated and CQ-treated cells cultured 
without supplemental GFs also formed reduced numbers of colonies, as compared 
with baseline cells. The removal of GFs combined with TKI treatment had a 
dramatic effect on the number of LTC-IC colonies (6.5 and 4.1% for IM and 
dasatinib, respectively), suggesting that cytokines may play an important 
protective role for the survival of TKI-treated CML cells, consistent with the results 
of a previous study (235). Combination treatment with CQ resulted in an even 
greater decrease in LTC-IC colony numbers, as compared to TKI alone (1%; 
p=0.175 and 0.65%; p=0.04 for IM/CQ and dasatinib/CQ, respectively). 
 
Overall, these data show that autophagy inhibition greatly potentiates the effect of 
TKI treatment, on the reduction of primitive progenitor cell potential of CML cells. 
Furthermore, that TKI treatment combined with autophagy inhibition of GF-starved 
CML cells promotes the most effective elimination of primitive CML cells. 
 
 
 
 
 
 
 
 230 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ba
se
lin
e
No
 
dru
g CQ IM
Da
sa
tin
ib
IM
 
+ 
CQ
Da
sa
tin
ib 
+ 
CQ
0
25
50
75
100
125
%
 
LT
C-
IC
(as
 
co
m
pa
re
d 
to
 
ba
se
lin
e)
 231 
B 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-10 Analysis of primitive progenitor cell potential following TKI 
treatment in combination with autophagy inhibition of CML cells 
CD34+ CML cells (n=3) were cultured in SFM with (A) and without GF (B) and 
left untreated or pretreated for 6 days with TKIs (IM 2µM or dasatinib 150nM) 
or CQ (10µM) alone or the TKI/CQ combination, before being added to LTC-
IC stromal feeder layers. Resulting colonies were compared with those 
derived from cells at baseline (cells with no prior culture or treatment), 
which were taken as 100%. Note: (B) is presented on a logarithmic scale due 
to the great differences between baseline and TKI/combination-treated arms. 
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5.3 Summary 
The previous results chapter demonstrated that, despite culture without 
exogenous GF support and full inhibition of BCR-ABL kinase activity via prolonged 
dasatinib exposure, a small proportion CML cells survived. This indicated that 
resistance within these cells may be mediated by other survival signals and/or 
pathways. Autophagy has previously been shown to provide survival signals for 
cancer cells against chemotherapy. Therefore, the purpose of the work in this 
chapter was to investigate whether the biochemical changes within the cells which 
survived dasatinib treatment, were characteristic of the autophagic process and to 
determine whether these changes could be therapeutically exploited.  
 
Initial experiments found that CML cells were decreased in size following 
treatment with dasatinib, as compared to untreated control cells. This is a typical 
characteristic of cells undergoing autophagy, as the lysosomal degradation of 
cellular components by the progressive autophagic process usually results in cell 
shrinkage due to self-consumption (164, 330). Further analysis by EM, revealed 
an increase in cytoplasmic vacuoles following GF deprivation. These vesicular 
structures increased in size and number following treatment with dasatinib. Further 
treatment with lysosomal protease inhibitors, which prevent the degradation of 
autophagic material, resulted in an increase in electron-dense inclusions within the 
vacuoles, with the greatest increase observed in dasatinib-treated CML cells 
cultured without GFs. These morphological and intracellular changes served as 
early indicators that the autophagic process was occurring.  
 
Experiments designed to verify whether the initial intracellular changes observed 
were indeed due to the induction of autophagy, revealed further biochemical 
hallmarks of the autophagic process, following both GF-deprivation and dasatinib 
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treatment. These included, an increase in LC3-positive puncta and LC3-II 
accumulation, with the greatest increase observed, again, within the CML cells 
which were treated with dasatinib and cultured without GFs. Mechanistic studies 
also demonstrated that the induction of autophagy caused by dasatinib treatment 
may be due to the indirect inhibition of the PI3K/Akt/mTOR pathway.  
 
These data suggest that autophagy may act as a survival mechanism within CML 
cells. Therefore, it was also investigated whether autophagy inhibition would 
potentiate the TKI/FTI-induced cell death of CML cells. Remarkably, the inhibition 
of autophagy combined with TKI/FTI treatment caused a highly significant 
elimination of CML cells with both committed and primitive progenitor cell 
potential. Interestingly, lonafarnib treatment in combination with autophagy 
inhibition gave an impressive reduction in CFCs from both CP-CML and AP-CML 
cells. This could have important implications for the treatment of CML patients with 
advanced phase disease and/or TKI-resistant mutations, such as T315I. 
 
Overall, these data demonstrate that TKI/FTI treatment, results in the induction of 
the BCR-ABL independent survival mechanism, autophagy, in CML cells. 
Furthermore, the induction of autophagy could also explain the drug resistance 
demonstrated by the primitive CML cells treated with dasatinib (shown in Chapter 
4 of this thesis). Blocking of the autophagic process then enhances the TKI/FTI-
induced death of CML cells, including the inherently TKI-resistant primitive stem 
cell population (Figure 5-11).  
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Figure 5-11 Inhibition of autophagy potentiates cell death dasatinib-treated 
CML cells 
Following dasatinib treatment, the inhibition of BCR-ABL results in the 
programmed cell death of all BCR-ABL kinase-dependent CML cells. Within 
the surviving BCR-ABL kinase-independent CML cells, autophagy is induced 
as a survival mechanism. Therefore, treatment with autophagy inhibitors 
results in increased cell death of dasatinib-treated CML cells. 
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6. DISCUSSION 
 
There is no doubt that IM treatment has revolutionised the management of CML. 
The remarkable activity of IM was first demonstrated in the pivotal phase III IRIS 
trial, whereby IM treatment significantly improved responses and survival 
outcomes compared with the previous standard therapy of IFNα and Ara-C (221). 
At the 5 year follow-up, the estimated cumulative rates of CHR, MCR, and CCR 
for patients treated with standard dose IM were 98, 92 and 87%, respectively. 
Moreover, the estimated freedom from progression and event free survival rates 
were an impressive 93 and 83%, respectively (222). The efficacy and safety of IM 
therapy was further confirmed by a recent update of the IRIS trial after a median 
follow up of 7 years, with an estimated overall survival rate of 86% (334). As a 
result, IM is widely considered as standard front-line therapy for patients with 
CML. However, despite these unparalleled results, an obvious outcome from the 
follow-up analyses is that only a small group of patients achieves a CMR. Variable 
levels of BCR-ABL mRNA can still be detected by RT-PCR in most patients 
receiving IM therapy (222). Furthermore, responses to IM therapy in patients with 
advanced stage CML are rare and usually short-term (217). The elements which 
contribute to this phenomenon of IM resistance have been extensively studied and 
are briefly summarised in Figure 6-1. 
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Figure 6-1 Mechanisms of IM resistance 
 
Resistance to IM and other TKIs can be broadly subdivided into BCR-ABL-
dependent and -independent mechanisms. Acquired resistance in Ph+ leukaemias 
is usually BCR-ABL-dependent, with the most common form of TKI resistance 
attributed to the development of point mutations within the ABL-kinase domain of 
the BCR-ABL gene (238). These mutations confer structural changes whereby the 
ABL-kinase is unable to adopt the inactive conformation to which IM binds (206). 
This results in either a suboptimal response within the patient or in the worst case 
scenario, complete failure of therapy. The observation of IM resistance has led to 
the development of a second generation of TKIs such as nilotinib, a high-affinity 
ABL-kinase inhibitor and dasatinib, a dual SRC- and ABL-kinase inhibitor, which 
binds to the ABL-kinase in both its active and inactive conformations. These 
agents have become essential for the management of resistant and advanced-
phase CML (254, 263). Nevertheless, neither of these TKIs have significant 
clinical activity against the “gatekeeper” T315I mutation, which confers a tyrosine-
to-isoleucine substitution at position 315 and was detected in up to 15% of CML 
patients who failed IM therapy (335). However, the implication of BCR-ABL point 
mutations as the sole underlying reason for TKI resistance remains uncertain. 
Although, some investigators have detected mutations in CD34+ cells from CML 
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patients both before (336) and after IM treatment (337), others have not detected 
any ABL-kinase mutations within the TKI-resistant CML cell population in vitro 
(131). Furthermore, it is also worth noting that the presence of BCR-ABL 
mutations does not always explain clinical IM resistance (245) and in CD34+ cells 
resistance mutations have not been present at high enough levels to explain the 
resistance of this population. 
 
Although less frequent than ABL-kinase domain mutations, BCR-ABL amplification 
has also been described as a potential BCR-ABL dependent resistance 
mechanism. Upregulation of BCR-ABL mRNA and protein was first reported in IM-
resistant, BCR-ABL expressing cell lines, in the absence of ABL-kinase domain 
mutations (237). BCR-ABL amplification has also been documented in patients 
with advanced phase disease, who developed resistance to IM treatment (238). 
Further, prolonged IM exposure has also been demonstrated to enhance 
oncogene amplification (236). However, in a subsequent screening of IM-resistant 
CML patients, only 2 out of 66 had BCR-ABL gene amplification as determined by 
D-FISH (132). This suggests that the phenomenon of point mutations within the 
ABL-kinase domain is a far more common mechanism of IM resistance. That said, 
it has been shown that CD34+ CML cells expressing increased amounts of BCR-
ABL are less sensitive to IM and are prone to develop mutations faster than those 
that express low levels of BCR-ABL (338). Further, it has also been demonstrated 
that very primitive, resistant CD34+ CML cells have higher transcript levels, 
despite having just single copy BCR-ABL (131, 298). This suggests that the levels 
of protein are at least partially responsible for the rate at which IM-resistant clones 
emerge (338) and that this increased BCR-ABL protein level still plays an 
important role in the propagation of disease, but possibly not as a result of 
amplification of the gene.  
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Although these mechanisms have been well-documented by many groups, 
resistance cannot solely be explained by oncogene mutation or amplification, as 
IM therapy does not eradicate all of the CML cells, even in those who respond 
well. For example, in patients who had achieved undetectable levels of BCR-ABL 
during IM treatment, molecular relapses were demonstrated in 50% of all cases 
when IM therapy was stopped (339). On the basis of these observations, it is 
predicted that this constant MRD in IM-treated patients is the result of residual 
LSCs. These primitive, quiescent CML cells have been shown to be resistant to 
IM, even at concentrations 10 fold higher than those achievable in vivo (224, 226). 
Furthermore, subsequent in vitro investigations have shown that this population 
persists in the face of treatment with the more potent TKI, nilotinib (256) and 
although dasatinib therapy appears to target a population of CML cells which 
resides deeper within the stem cell compartment, the most primitive, quiescent 
cells still remain (131). This rare population of quiescent CML cells, which 
represent approximately 0.5% of the total CD34+ cells (340), may be refractory to 
TKI treatment simply by virtue of their dormant status. However, quiescent 
primitive CML stem cells may also demonstrate other mechanisms of resistance. 
A variety of hypotheses have been suggested as the molecular basis for this TKI 
refractoriness. For example, optimal TKI plasma and intracellular concentrations 
within the cell are necessary for therapy to succeed. Therefore, it has been 
suggested that drug resistance may be induced by suboptimal intracellular TKI 
concentration. It has been hypothesised that TKI resistance in CML stem cells is 
as a result of reduced drug-influx and increased drug-efflux compared with more 
mature cells. Primitive CML CD34+38- stem cells apparently exhibit high level 
expression or activity of drug efflux proteins, such as MDR-1, and reduced 
expression or activity of drug influx proteins, such as the organic cation 
transporter-1, as compared with more mature cells (298).  Therefore, such 
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mechanisms could possibly confer resistance against TKIs and other apoptosis-
inducing drugs. However, this notion remains controversial as more recent work in 
the field has shown that at least the MDR-1 (249) and ABCG2 (250) transporters 
are unlikely players in IM resistance. 
 
As stated previously, one important finding is that BCR-ABL is over-expressed 
within the quiescent CML stem cell population. Copland et al. showed that the IM-
resistant CML CD34+38- cells expressed significantly increased BCR-ABL 
transcripts and BCR-ABL protein kinase than more mature CML cells. Additionally, 
phosphorylation of the direct downstream target, CrkL, was increased in the most 
primitive CML CD34+38- cells, as compared to the total CD34+ fraction (131). 
These discoveries alone may explain why this population is so resistant to TKI 
treatment and suggest that BCR-ABL is still a relevant target for the treatment of 
CML. Following on from this, it is then necessary to ask the question: “why are the 
mature, proliferating CML cells targeted by TKI treatment, whereas the primitive 
quiescent CML cells are not?” It is suggested that oncogenic fusion TK-
transformed cells are able to proliferate due to persistent survival signalling which 
counteracts any pro-apoptotic signals (341). The apparent dependence of a 
tumour cell on a single mutationally activated oncoprotein or oncoprotein-mediated 
signalling pathway(s) for their proliferation and/or survival has been described as 
“oncogene addiction” (271). Sharma et al. proposed a hypothesis to explain the 
oncogene addiction phenomenon. In the context of a tumour cell, the balance 
between pro-survival and pro-apoptotic signals derived from the activated 
oncoprotein favour a survival state. However, on acute inactivation of the 
oncoprotein, the pro-survival signals are decreased very rapidly as compared to 
the pro-apoptotic signals. This creates a temporal window, whereby the pro-
apoptotic signalling predominates, which lasts long enough for the cell to commit 
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to apoptotic death (342). With regards to the fact that the primitive quiescent 
population is not targeted by TKI treatment, it is still currently unclear why they 
should be so insensitive. One could predict that they are not oncogene addicted to 
BCR-ABL TK activity. Studies, which have used transgenic mouse models for the 
inducible expression of BCR-ABL, have shown that multiple rounds of induction 
and reversion are possible. This thereby, indicates that the LSC population is able 
to persist long-term, even following BCR-ABL reversion (75, 275). Further support 
for this hypothesis comes from investigations which demonstrated that despite 
inactivation of p190BCR-ABL in a murine model of ALL,  there was a failure to rescue 
the malignant phenotype, thereby suggesting that p190BCR-ABL is not required for 
the maintenance of disease in mice (343). However, this notion still remains 
controversial in primary CML cells, as one critical question which remains to be 
answered is whether BCR-ABL activity is completely inhibited by TKI within this 
rare primitive population of LSCs. If BCR-ABL was found to be incompletely 
inhibited within the stem cell population, then this would suggest that BCR-ABL is 
still a critical drug target for the management of CML. Therefore, efforts should be 
made to develop and use more potent TKIs, or manipulate drug transporters in 
order to increase the intracellular TKI concentrations within the CML stem cell 
population and effectively inhibit BCR-ABL TK activity. However, if BCR-ABL was 
found to be completely inhibited within the resistant pool of CML stem cells, then 
one could definitively say that this cell population is not oncogene addicted to 
BCR-ABL TK activity. This would also then suggest that these resistant primitive 
CML cells are perhaps reliant on other non BCR-ABL TK-related mechanisms for 
their proliferation and/or survival. This thesis concentrated on determining whether 
primitive CML stem cells are dependent on BCR-ABL TK activity for their 
proliferation and/or survival, with the further aim of characterising the resistant 
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population of CML cells and investigating any other potential cell survival 
mechanisms. 
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6.1 Is BCR-ABL relevant for the survival of cancer stem cells in 
CML? 
 
Previous studies have measured BCR-ABL TK activity as an indication of TKI 
response of CML cells, in a number of ways: total p-Tyr by FACS (291), p-CrkL 
measurement by Western blot (130, 131, 290, 294), p-CrkL by flow cytometry 
(130, 131). Here we aimed to provide an alternative technique for the 
measurement of BCR-ABL TK activity, by developing a novel ELISA method 
designed for the high throughput of samples. Although this technique was reliable 
against the other methods, it proved too costly in terms of cell numbers required to 
give an accurate read-out for stem cell work. Therefore, for the purposes of this 
thesis, where the quantity of samples and the cell number within each sample was 
low, we decided to use flow cytometry using a method developed in house (130) 
and other conventional methods. Nevertheless, the ELISA would perhaps prove to 
be more useful in a more clinical screening setting, where the sample numbers 
would be higher and material less limited. Even though Western blot has proven to 
be an extremely reliable technique for the assessment of kinase activity, it is not 
feasible when working with such rare populations of CML cells. Therefore, in order 
to accurately assess and characterise the CML cells which are undergoing drug 
treatment, the only reasonable option was found to be flow cytometry. One major 
advantage of flow cytometry over the other methods is the ability to measure 
multiple parameters simultaneously, within samples containing relatively low cell 
numbers. This was absolutely necessary for determining BCR-ABL TK activity 
within specific subpopulations of CML stem cells. 
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Following the initial TKI timecourse studies, it was found that transient exposure to 
intermediate concentrations of TKI was as effective as continuous treatment with 
increased concentrations, which are clinically unachievable. This challenges the 
assumptions based on early studies with IM (205, 207, 215), where it was 
concluded that it was necessary for TKIs to achieve continuous BCR-ABL 
inhibition in order for CML cells to commit irreversibly to apoptosis. However, the 
results of this study are in keeping with more recent investigations (310, 316, 344), 
which have demonstrated that transient, potent inhibition of BCR-ABL TK activity 
is sufficient to commit both CML cell lines (310, 316) and primary CD34+ CML 
cells (316, 344) irreversibly to apoptosis. This supports the “oncogenic shock” 
model, described previously, in which it is suggested that kinase inhibitors are 
effective against oncogene-addicted tumour cells because of the more rapid 
reduction of oncogene-mediated pro-survival versus pro-apoptotic signals 
following inactivation of the oncoprotein’s TK activity. Here, these data suggest 
that once a specific threshold of kinase inhibition is exceeded within TKI-sensitive 
CML cells, following potent TKI exposure of up to only one hour, these cells will 
commit irreversibly to apoptosis. However, within the TKI-resistant CML cells, 
neither dose escalation of TKI to concentrations which are clinically unachievable, 
nor an increase in the drug exposure time from 1 to 72 hours led to an 
enhancement of cell death. This suggested that the cells which survived the 
treatment were intrinsically resistant to BCR-ABL TK inhibition. The fact that drug-
sensitive CML cells commit to apoptosis following potent BCR-ABL inhibition 
induced by transient TKI exposure also has important implications for the 
treatment of CML. This has particular significance for the clinical application of 
more potent TKIs such as, dasatinib, whereby pulse-dosing may reduce any 
associated toxicities. Indeed, data from a very recent trial suggests that potent and 
transient kinase inhibition of BCR-ABL with dasatinib (100mg/day) achieves rapid 
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and durable cytogenetic responses, which are indistinguishable from those 
achieved with more continuous kinase inhibition, in CP CML patients with 
resistance, suboptimal response or intolerance to IM (345). 
 
An interesting finding from these studies was the fact that exogenous GF support 
gave a protective effect over the treatment of CML cells with TKI. In fact, treatment 
of CML cells with TKI in the presence of a high concentration of GFs gave the 
same effect as removing GFs from untreated control cells. This is perhaps, logical 
as the pathways which are constitutively activated by BCR-ABL 
autophosphorylation are also activated by GF stimulation. Therefore, in this 
setting, the addition of exogenous GFs then negates the CML cells’ requirement 
for BCR-ABL. Previous studies have shown that CML cells exhibit BCR-ABL-
independent IM and nilotinib resistance, through activation of the anti-apoptotic 
JAK2/STAT5 pathway, as a result of adaptive autocrine and paracrine secretion of 
GM-CSF (235). Konig and colleagues also demonstrated that MAPK, Akt and 
STAT5 phosphorylation was inhibited in CML CD34+ cells by nilotinib (346) and 
dasatinib (347) only in the absence, but not the presence of GFs. Jiang et al. 
showed that the deregulated growth of CD34+ CML cells caused by BCR-ABL 
was, at least partially, dependent on the autocrine  production of IL-3 and G-CSF 
and a stimulation of STAT5 phosphorylation. Similarly, BCR-ABL was shown to 
require the IL-3 receptor and subsequent downstream JAK2/STAT5-signalling for 
the oncogenic transformation of BCR-ABL-expressing fibroblasts (348). A very 
recent study by the group led by Tim Hughes also confirms these findings, where 
CML cells remained viable in culture with additional cytokines following short-term 
exposure to dasatinib. Treatment with dasatinib in combination with JAK activity 
inhibition then re-sensitised these cells to BCR-ABL TK inhibition, despite the 
presence of exogenous cytokine support. It was also observed that short-term 
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intense BCR-ABL TK inhibition commits CD34+ CML cells to death only in the 
absence of GFs (344), further confirming the results of our study.  
 
Overall, these data highlight the importance of GF signalling in the survival of CML 
cells treated with TKI. Further, it suggests that primitive CML progenitor cells may 
not be entirely dependent on BCR-ABL for proliferation and/or survival in the 
presence of GFs, due to the activation of cytokine-mediated signalling cascades, 
such as, JAK2/STAT5. This could have implications for the TKI treatment of CML 
patients, where cytokines would, of course, be present at physiological 
concentrations. Studies have demonstrated that the IL-3 receptor, CD123, is 
highly expressed on CD34+38- LSCs in AML (349) and CML (350, 351) and has 
been shown to be an effective therapeutic target in pre-clinical AML models (352, 
353). Groups have now begun to investigate the therapeutic potential of 
recombinant IL-3-diphtheria toxin (DT) conjugates which target CD123, both in in 
vitro and in vivo CML models (354) and in Ph+ ALL (355), whereby the co-
treatment with TKI and DT conjugate was more effective at eliminating Ph+ 
progenitor cells than either agent alone. Furthermore, a Phase I study 
investigating the effects of an anti-CD123 monoclonal antibody (CSL360) in AML 
is currently ongoing (356). Therefore, targeting of cytokine signalling in 
combination with BCR-ABL TK inhibition may represent an exciting new concept 
for therapeutic intervention in patients with CML and Ph+ ALL.  
 
In this study, following a prolonged treatment timecourse of 12 days with 150nM 
dasatinib in the absence of exogenous cytokine support, 10% of the starting 
CD34+ CML cells survived. Since no GFs were present in the culture media, the 
phenomenon of cytokine-mediated mechanisms of BCR-ABL-independent 
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resistance could be ruled out. Similarly, the other most common means of TKI 
resistance in CML cells (i.e. oncogene amplification and ABL-kinase domain 
mutations) were also found to be irrelevant in this TKI-resistant CML cell 
population. BCR-ABL TK inhibition was next measured by assessment of both p-
CrkL and p-STAT5. Previous studies which have used TKI to inhibit BCR-ABL TK 
activity have demonstrated incomplete levels of inhibition (131). To address the 
question of whether a CML stem cell is oncogene addicted, BCR-ABL TK activity 
must be fully inhibited and the cells tracked for survival. Here, it was concluded 
that maximal pharmalogical inhibition of BCR-ABL TK activity was achieved in the 
surviving dasatinib-treated CML cells, both in the bulk population of cells and the 
more problematic primitive stem cell population. As with previous studies (131), 
those cells which survived the dasatinib treatment were primitive, residing mainly 
in the undivided cell fraction and the very early cell divisions. Since these BCR-
ABL TK-inhibited, resistant cells were also able to grow when re-cultured in 
cytokines and form LTC-IC colonies, these data suggest that ~10% of primitive 
CD34+ CML cells are not addicted to BCR-ABL TK activity for their survival. 
However, it would be presumptuous to say that these CML cells are not addicted 
to the BCR-ABL oncoprotein itself, since components in BCR-ABL, other than the 
kinase domain, could mediate resistance. Recent studies have identified Alox5 as 
a key gene that regulates the functions of LSCs, but not normal HSCs, in mice. It 
was demonstrated that Alox5 deficiency or inhibition prevented CML development 
initiated by BCR-ABL (357). Furthermore, Alox5 was also found to be regulated by 
BCR-ABL oncoprotein, but was unaffected by TKI treatment (358). Therefore, 
Alox5 represents a potential BCR-ABL dependent, but BCR-ABL TK independent, 
target. Previous investigations have used si- and short hairpin (sh)RNA designed 
to target BCR-ABL itself, both in Ph+ cell lines and primary CD34+ CML cells (359-
361). Such a strategy should block all BCR-ABL activity and not just kinase 
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activity. Although in certain cases, BCR-ABL knockdown was associated with 
increased apoptosis, the level of down-regulation was often transient and/or 
incomplete. Studies performed by our own lab used shRNA against BCR-ABL, 
delivered by either electroporation or more stable lentiviral transduction, in 
combination with dasatinib treatment of CML cells. It was demonstrated that BCR-
ABL oncoprotein knockdown and inhibition of kinase activity resulted in a 
synergistic induction of activated caspase-3, expression of annexin-V and 
dramatic reduction in viable K562 cells (362).  However, since K562 are a BC 
CML cell line, they may prove to be more dependent on BCR-ABL expression for 
their survival. Therefore, further work is currently underway in this laboratory to 
use TKI to inhibit BCR-ABL TK activity, in combination with lentiviral shRNA to 
stably target BCR-ABL itself within the most primitive compartment of CML cells. If 
the CML cells survive both complete inhibition of BCR-ABL TK activity and 
complete loss of the BCR-ABL oncoprotein, then it could be definitively said that 
this resistant population of CML cells are truly independent of BCR-ABL for their 
survival. 
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6.2 Analysis of the effects of autophagy on CML stem cell 
survival 
 
During the experiments which used dasatinib to inhibit BCR-ABL TK activity within 
CD34+ CML cells, CFSE-staining revealed that within the CML cells which 
survived the prolonged treatment timecourse, two populations existed; one which 
remained undivided and another which was able to divide up to 3 times. This 
suggested that these primitive, resistant CML cells appeared to survive and 
proliferate by BCR-ABL-independent mechanisms. Therefore, the next 
experiments were then designed to investigate autophagy as a potential means of 
primitive CML cell survival. Autophagy has previously been shown to be an 
important event for the megakaryocytic differentiation of the CML cell line, K562 
(363). Furthermore, since the induction of autophagy has previously been 
demonstrated to provide tumour cells with a protective mechanism to survive in 
the face of irradiation (364), alkylating agents (365) or arsenic trioxide (366), it was 
hypothesised that resistant CML cells could also be employing such a mechanism 
to survive following dasatinib treatment, especially under conditions of GF 
deprivation. In this study, analysis of the cellular properties of CD34+ CML cells, 
which remained viable following the 12 days, revealed that the dasatinib-treated 
cells were significantly smaller in size as compared with control cells – a property 
of cells which are undergoing autophagy. EM also showed that both GF 
deprivation of untreated CML cells and dasatinib treatment of CML cells induced 
the formation of cytoplasmic autophagic structures. Significantly increased LC3-
positive puncta and the autophagosome-asociated LC3-II were also observed in 
the CML cells treated with dasatinib, particularly in the cells cultured without GFs. 
Overall, these data suggested that autophagy is induced following GF deprivation 
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of CML cells and is significantly increased within these cells, upon BCR-ABL 
inhibition following dasatinib treatment. It was next hypothesised that autophagy 
was responsible for a condition by which primitive CML cells rely upon a state of 
metabolic inactivity, in order to survive following TKI treatment. Therefore, in order 
to test this hypothesis, it was assessed whether TKI-induced CML cell death could 
be enhanced by the chemical inhibition of autophagy by CQ or BAF. These agents 
act by blocking the last step of the autophagy process (i.e. the degradation of 
autophagosomes following fusion with lysosomes). Remarkably, it was found that 
the inhibition of autophagy greatly potentiates the effect of TKI treatment on the 
reduction of primitive CML progenitor cells, in terms of the effective eradication of 
functionally defined CFCs and LTC-ICs. Although CQ and BAF are relatively non-
specific for the autophagy process, genetic inhibition of autophagy by RNA 
interference-mediated knockdown of either ATG5 or ATG7 yielded comparable 
effects in CML cell lines (172). These data thereby demonstrate that the effects of 
CQ and BAF depend largely on the inhibition of autophagy. However, further work 
is currently underway in this laboratory to investigate ATG5 and ATG7 knockdown 
within human primary CML cells, in order to completely verify that the 
enhancement of TKI-induced cell death caused by CQ or BAF treatment is a direct 
result of autophagy inhibition. Recent studies have also confirmed the importance 
of autophagy in CML cells, as inhibition of the autophagic process increased the 
effect of both the histone deacetylase inhibitor, SAHA (171), and the TKI, INNO-
406 (170), for the eradication of drug-resistant CML cells.  
 
Overall, the results of this study have provided a powerful rationale for the design 
and implementation of a Medical Research Council TSCRC 
(www.mrc.ac.uk/Fundingopportunities/Grants/TSCRC/index.htm) randomised 
phase II clinical called CHlOroquine Imatinib Combination to Eliminate Stem cells 
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(CHOICES). The trial compares IM treatment versus HCQ in combination with IM, 
for patients with CML who have been on IM for 1-3 years and have achieved a 
MCR, with residual disease detectable by qRT-PCR (Figure 6-2).  
 
 
 
 
 
 
 
 
 
 
Figure 6-2 Schematic diagram of the protocol for the CHOICES trial 
 
 
Although the preliminary in vitro data have shown the effectiveness of TKI 
treatment in combination with CQ for the eradication of primitive CML cells, CQ 
has been shown to be responsible for significant retinal toxicity in a number of 
patients (367). Therefore, for this trial it was replaced by HCQ, which has been 
used extensively in rheumatology and is well tolerated (368). Furthermore, 
preliminary in-house in vitro data indicated that HCQ was approximately 
equipotent to CQ when combined with TKI treatment in terms of reduction of 
functional CFCs from CD34+ CML cells.  
 
The primary end-points of the study are to provide preliminary evidence that HCQ 
given in combination with IM is more effective than IM alone in terms of BCR-ABL 
levels in CML patients who are in MCR with residual BCR-ABL+ cells after at least 
one year of IM treatment and to determine the safety and tolerability of HCQ given 
CML Start IM MCR Randomisation
Standard arm:
IM 400mg/day
Experimental arm:
HCQ 800mg/day
plus IM 400mg/day
Year 1 Year 2
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in combination with IM in these patients. The success criteria for the trial is defined 
as patients who have >0.5 log reductions in their 12 month PCR level of BCR-ABL 
transcripts from baseline. Secondary end-points are to determine whether the 
introduction of HCQ influences IM plasma levels and to confirm that whole blood 
HCQ levels achieved on a continuous 800mg/day dose in combination with IM are 
in the expected range. Correlative end-points are to confirm that HCQ at 
800mg/day inhibits autophagy in vivo and to study the effect of HCQ given in 
combination with IM on residual BCR/ABL+ primitive progenitors. 
 
Recruitment for the trial started in April of this year, with 33 patients to be 
randomised to each treatment, making a total of 66 patients recruited in 3 UK 
centres. 
 
In conclusion, the findings from this study clearly demonstrate that autophagy 
provides a BCR-ABL independent survival mechanism for primitive primary CML 
cells which have been treated with TKIs. In-house micro-array data also further 
backs up this notion, as the autophagy genes ATG5 and ATG4 were found to be 
upregulated in dasatinib-treated CD34+ CML cells as compared to control cells. 
Likewise, the genes which transcribe cathepsins B and L (hydrolases which are 
thought to be important for the degradation of autophagic material within 
autolysosomes) are also increased in dasatinib-treated cells. We have also shown 
that the inhibition of autophagy can greatly potentiate TKI-induced CML cell death, 
which ultimately resulted in the initiation of a UK-wide clinical trial to investigate 
the benefits of the use of autophagy inhibitors in combination with TKI. Most 
importantly, we have demonstrated that the combination of autophagy inhibition 
combined with TKI is able to target the TKI-resistant CML stem cell population. 
Previously, it was shown that dasatinib is a much more potent inhibitor of BCR-
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ABL TK activity than IM and is able to target BCR-ABL+ cells deeper into the stem 
cell compartment (131). Here, we have shown that the combination of autophagy 
inhibition and BCR-ABL TK inhibition by TKI is able to target CML cells from even 
deeper within the stem cell compartment than dasatinib alone, as measured by the 
dramatic reduction in functional LTC-IC (Figure 6-3). Whether the truly quiescent 
CML stem cell population is targeted still remains to be seen. However, this 
strategy may represent a novel approach for the improvement of responses in 
patients with CP CML by the more effective eradication of TKI-resistant CML cells. 
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Figure 6-3 Schematic diagram to show the effects of either TKI treatment 
alone or in combination with autophagy inhibition on the different CML cell 
subpopulations 
(A) More mature haemopoietic cells and the majority of progenitor cells are 
sensitive to both IM and dasatinib. (B) More primitive progenitor cells are 
resistant to IM but targeted by dasatinib. (C)The CML stem cell compartment 
is resistant to both IM and dasatinib, but targeted by a combination of TKI 
plus autophagy inhibition. It is not yet known whether the truly quiescent 
LSC population is affected by treatment with TKI and autophagy inhibition. 
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6.3 Summary and future directions 
 
Overall, these findings suggest for the first time, that BCR-ABL targeting by TKI 
should no longer be the only focus of treatment for CML. Despite the success of 
both IM and the more potent second generation TKIs, such as dasatinib, in the 
treatment of CML, it is clear that quiescent stem cells still remain (131, 226). It was 
hypothesised that these resistant CML cells persist due to incomplete inhibition of 
BCR-ABL TK activity. However, here we have shown that despite maximal BCR-
ABL TK inhibition, these cells are still able to survive. To attain the ultimate 
eradication of all CML cells, it is clear that combination therapies involving TKI and 
agents/therapies with activity specifically towards the cancer stem cell 
compartment will be required. In previous years, there were less well defined 
mechanisms for quiescent stem cell resistance to pro-apoptotic agents and 
therefore, no obvious molecular targets for therapeutic intervention. This prompted 
investigators to attempt to improve the effectiveness of TKI treatment by “waking 
up” the quiescent stem cell population, using cytokines to force them into cycle. It 
was demonstrated that a significant reduction of CML cells was observed following 
intermittent exposure to G-CSF compared to continuous treatment of IM alone, 
which was further enhanced when the cells were treated with a combination of IM 
and intermittent G-CSF (369). These impressive in vitro results led to a multi-
centre clinical trial that further investigated the potential clinical use of cytokines in 
combination with IM to improve the management of CP CML. However, no 
significant difference was observed in patients treated with the combination as 
compared to continuous IM alone, indicating no further benefit compared to 
standard IM therapy (370). The group led by Andreas Trumpp has also used this 
approach in a mouse model. Here they first primed the quiescent stem cells into 
cycle with IFNα, which greatly sensitised these cells to the anti-proliferative agent 
 255 
5-FU (371). However, since this was not a CML model, these data may have no 
relevance for the clearance of human primary CML cells. 
 
In recent years, significant progress has been made in the objective for specific 
LSC-targeting in CML. A number of novel strategies for cancer stem cell therapy in 
CML are currently being investigated, with a few nearing the clinic and are briefly 
summarised in Table 6-1.  
 
 
Strategy Treatment 
 
Reference 
 
 
PP2A activation via SET 
inhibition 
 
FTY720 (372) 
 
Self-renewal pathway 
(Smoothened) inhibition 
 
TKI and cyclopamine (373),(374) 
 
PML protein degradation 
 
AraC and As2O3 (375) 
 
BCR-ABL and autophagy 
inhibition 
 
TKI and HCQ (172) 
BCR-ABL and histone 
deacetylase inhibition TKI and LBH589 (376) 
 
 
Table 6-1 Notable examples of LSC-targeted therapy in CML 
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In this study we have now shown that autophagy may also play a major role in the 
survival of LSCs following inhibition of critical oncogenic pathways. Little is known 
about the precise mechanism by which the autophagic process is induced by TKI 
in CML stem cells, therefore this remains to be elucidated by future investigations. 
Indeed, it is still not known why the primitive stem cell compartment is specifically 
able to survive through autophagy during conditions of stress. However, clues may 
come from the microenvironment in which they reside. The BM niche is a hypoxic 
tissue (377) and additionally, LSCs are more hypoxic than normal HSC in the BM, 
due to overcrowding from accelerated growth (378). It has also been 
demonstrated that CD34+ human primary leukaemic cells populated the most 
hypoxic region of the BM (the epiphysis), when inoculated into immunodeficient 
mice (379). Recently, one study has suggested that a hypoxic microenvironment is 
important for the maintenance of CML stem cell quiescence (380). Therefore, it is 
likely that the quiescent CML stem cell population predominantly resides and 
thrives in a hypoxic BM environment. Since one of the processes which activate 
autophagy is prolonged hypoxia (381), it is perhaps possible that the most 
primitive CML cells, in particular, are already primed to use the autophagic 
process for survival. Therefore, understanding the hypoxic nature of LSCs and the 
importance for them to reside in such a microenvironment may be a further 
interesting avenue for future investigation. 
 
In 1999, Holyoake et al. highlighted the importance of quiescent LSCs for the 
propagation of CML (224) and this population was subsequently found to persist in 
the face of TKI treatment (226). Significant progress has been made since then in 
terms of the development of agents which are able to specifically target this 
resistant cell population. However, little is known about why these primitive CML 
cells should remain quiescent? Here, we have shown that targeting autophagy is 
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highly effective in the eradication of primitive CML cells. Yet, it is still not clear as 
to whether the truly quiescent cells are targeted by this strategy and whether this 
population would rely on autophagy for its survival at all? One interesting finding 
comes from in-house microarray data in which it was observed that the essential 
autophagy genes, ATG12, ATG2, ATG3 and the autolysosomal hydrolases - 
cathepsins L and D, were all decreased in dividing CML cells as compared to 
quiescent CML cells in the G0 phase of cell cycle. Another important finding which 
may provide the connection between quiescence, the cell cycle arrest observed 
following TKI treatment and the induction of autophagy, was the observation that 
the dasatinib-treated cells demonstrated predominantly nuclear FoxO3a, as 
compared to untreated control cells. Activation of the PI3K/Akt pathway, results in 
FoxO inactivation which leads to enhanced cell survival and proliferation. In the 
absence of GF or insulin-signalling, or in the presence of stress stimuli, FoxO 
members reside within the nucleus, where they are active as transcription factors 
involved in cellular processes such as, apoptosis, cell-cycle arrest and stress 
resistance (382). In the normal HSC compartment, FoxOs reside within the 
nucleus where they are thought to play a role in cellular quiescence through their 
transcriptional activation of cell cycle regulators, such as p21, p27, p130 and 
down-regulation of cyclin D (311). FoxOs are also thought to play an important 
role in protecting quiescent HSCs from oxidative stress. In FoxO-deficient stem 
cells, there is a marked increase in reactive oxygen species which leads to an 
increase in the number of cycling HSCs and eventual HSC exhaustion (383). 
Recently, it was demonstrated that BCR-ABL inactivated the transcriptional activity 
of FoxOs in untreated CD34+ CML cells. Furthermore, the TKI-mediated G1 arrest 
seen in CML cells was found to be induced by the reactivation of FoxOs. Finally, 
and most importantly, primitive CML stem cells retained sustained activation of 
FoxOs (314) which presumably regulated their quiescence. Other studies have 
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also shown that FoxO3a was important for the maintenance of CML LSCs in a 
murine model (317). Therefore, within this study it is highly likely that the activation 
of FoxO3a played some part in the cell cycle arrest of the resistant dasatinib-
treated CML cells.  
 
Interestingly, as another cellular regulation mechanism, it has been demonstrated 
that stimulation of the energy sensor pathway, which is activated by an increased 
adenosine monophosphate (AMP)/ATP ratio, results in the AMP-activated protein 
kinase (AMPK)-mediated activation of FoxO3a (384).  AMPK is a central metabolic 
switch which responds to low energy. It is found in all eukaryotes and governs 
glucose and lipid metabolism in response to changes in nutrients and intracellular 
energy levels. Furthermore, AMPK has been shown to be a direct downstream 
effector of the LKB1 tumour suppressor kinase and is involved in a mechanism 
representing the connection between energy metabolism and cell growth control 
(385). Recently, it has been reported that the conserved AMPK/FoxO3a energy 
sensor pathway is inducible in human tumour cells in response to metabolic 
stress. In colorectal and ovarian cancer cells, decreased glycolysis caused by 
inhibition of the p38α/HIF1α pathway, led to the nuclear accumulation of FoxO3a 
and the subsequent transcriptional activation of target genes whose protein 
products promote the autophagic process, such as, ATG6, ATG7 and ATG12 
(386-388). In response to the acute energy demand that induced the autophagy 
process, the cells also exited the cell cycle and accumulated in the G1 phase, 
which also mirrors what we observed in the dasatinib-treated CML cells tested in 
this study. Taken together these data indicate that there may be an important link 
between the cell cycle arrest induced by the nuclear accumulation of FoxO3a and 
the apparent reliance on autophagy for survival in TKI-resistant primitive CML 
stem cells.  
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Thus, it could be speculated that in response to acute energy depletion, caused by 
either GF deprivation or BCR-ABL TK inhibition, AMPK induces FoxO3a to 
accumulate in the nucleus of TKI-treated CML cells and triggers the transcription 
of target genes involved in both autophagy and cell cycle arrest. The cells would 
then induce autophagy and exit the cell cycle, arresting in G0/G1 in an attempt to 
retain energy for survival. The PI3K/Akt activation of mTOR has been shown to be 
an important negative regulator of autophagy. The known pathway by which Akt 
activates mTOR is via direct phosphorylation and inhibition of TSC2, which is a 
negative regulator of mTOR. It has also been demonstrated that Akt is a negative 
regulator of AMPK, which is an activator of TSC2 (389). Therefore, it seems 
logical that activated AMPK would have an important role in the ultimate induction 
of autophagy. Interestingly, it was also shown that hypoxia induced autophagy in 
tumour cell lines via AMPK activity (390). Thus, this could be another indicator that 
the very quiescent CML stem cells rely on autophagy for survival within the 
hypoxic conditions of the BM niche. This may also mean that the AMPK/FoxO3a 
axis could represent a potential approach for therapeutic intervention in CML. Of 
course, the link between the observation of nuclear FoxO3a, with subsequent 
downregulation of cyclin D1 in dasatinib-treated primitive CML cells and the high 
level of autophagy induction within this resistant cell population is still a little 
tenuous. Therefore, further work should be carried out to prove that this 
hypothesis is actually the case. However, this preliminary data may be an exciting 
early indicator of future insights in CML which are still to come. 
 
In 1990, George Daley and colleagues used murine models to establish BCR-ABL 
as an oncogene to induce CML, whereby retroviral transduction of BCR-ABL 
cDNA into the BM of recipient mice was sufficient to induce a CML-like 
myeloproliferative disease (74). In the subsequent years great efforts have been 
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made to try to further understand the key signalling pathways and molecular 
drivers of malignant transformation of CML stem cells. This has yielded a wealth of 
preliminary data from novel agents which have demonstrated impressive results 
both in vitro and in Phase I-III clinical trials. Many efforts have been made to direct 
therapy towards the kinase activity of BCR-ABL. However, this thesis has shown 
for the first time that the most resistant primitive CML cells are likely to be 
independent of BCR-ABL TK activity for their survival. Furthermore, we have 
shown that these resistant CML stem cells rely on the BCR-ABL independent, 
autophagy process for survival in response to stressful conditions, such as, TKI 
treatment. This highlights the importance for further work directed towards the 
understanding of the complex biology of cancer stem cells and why they remain 
quiescent, both in CML and other haematological malignancies. Since the majority 
of CP CML cells appear to be dependent on BCR-ABL TK activity for their 
survival; the use of TKI to remove the burden of the CML tumour load, combined 
with BCR-ABL independent therapies, targeted specifically towards the quiescent 
LSC compartment should provide more effective future approaches for the 
ultimate eradication of CML. 
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